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GENERAL INTRODUCTION, AIM AND OUTLINE OF THE THESIS
Steroid synthesis in the adrenal gland
The adrenal glands, though small, are essential for life. They are located on top of 
the kidneys and are composed of a cortex and a medulla. Steroid synthesis takes 
place in the adrenal cortex. The adrenal cortex consists of three anatomically 
distinct zones, where several steroid hormones are synthesized from the common 
precursor cholesterol: aldosterone in the outer zona glomerulosa, cortisol in the 
central zona fasciculata, and adrenal androgens in the inner zona reticularis. [1] 
Multiple enzymatic steps are required for adrenal steroid synthesis (figure 1).  
Cortisol, a glucocorticoid hormone, is also known as a stress hormone. It regulates 
cardiovascular, metabolic and immune homeostasis. The production of cortisol is 
regulated through the hypothalamic – pituitary – adrenal (HPA) axis. The hypothalamus 
produces corticotrophin releasing hormone (CRH), which stimulates the release of 
adrenocorticotropic hormone (ACTH) by the anterior pituitary gland. ACTH promotes 
the conversion of cholesterol to cortisol in the adrenal cortex. The secretion of 
CRH and ACTH is controlled by three mechanisms: a negative feedback mechanism 
by cortisol, a circadian rhythm and stress-responsiveness of the HPA-axis. [1]
Aldosterone, a mineralocorticoid hormone, is involved in the water and salt 
homeo stasis and primarily regulates blood volume. Aldosterone promotes the 
sodium reabsorption and potassium excretion in the kidneys. With the reabsorption 
of sodium, water is also retained. The secretion of aldosterone is mainly regulated 
through the renin – angiotensin – aldosterone system. 
Adrenal androgens have weak androgenic activity and are peripherally converted to 
the more potent androgens testosterone and dihydrotestosterone. In adult men, 
most androgens are derived from the testes. However, in both males and females 
adrenal androgens are involved in pubertal development, and in females adrenal 
androgens contribute substantially to total androgen production and effect. 
Amongst other effects, androgens promote bone maturation and skeletal growth, 
and are necessary for adequate bone health. [2]
Congenital adrenal hyperplasia
Enzyme deficiency
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders 
of the adrenal cortex in which a deficiency of one of the enzymes involved in 
steroid synthesis results in disturbed steroidogenesis. The most common form, 
12
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accounting for 95% of the cases, is 21-hydroxylase deficiency, caused by mutations 
in the CYP21A2 gene. [3, 4] The incidence is approximately 1:12,000 in the 
Netherlands and other European countries. [5] The second most frequent type of 
CAH in European populations is 11-hydroxylase deficiency. Less common forms are 
deficiencies of StAR, P450scc, 3β-hydroxysteroid dehydrogenase, 17α-hydroxylase 
and POR. [6, 7] This thesis will mainly focus on 21-hydroxylase deficiency. 
In 21-hydroxylase deficiency, the conversion of 17-hydroxyprogesterone (17OHP) 
and progesterone to 11-deoxycortisol and 11-deoxycorticosterone respectively is 
impaired (figure 2). This results in a deficiency of cortisol and – in the most severe 
form – also of aldosterone. Due to the lack of negative feedback from cortisol to 
the hypothalamus and the pituitary gland, ACTH secretion is increased. The excess 
ACTH stimulation results in adrenal hyperplasia and accumulation of the steroid 
precursors proximal to the enzymatic block, mainly 17OHP and progesterone. 
These precursors are shunted into the androgen-synthesis pathway that does not 
require 21-hydroxylation, increasing the production of adrenal androgens. [3] 
Additionally, 17OHP is converted by alternative pathways. 11-hydroxylation of 
17OHP results in the formation of 21-deoxycortisol. Also, through the so-called 
‘back-door pathway’ dihydrotestosterone is formed from 17OHP without andro-
stenedione or testosterone as intermediate steroids. [8]
Subtypes of CAH
Conventionally, CAH due to 21-hydroxylase deficiency is divided in subtypes 
depending on the remaining enzyme activity: a classic form usually diagnosed in 
the neonatal period, consisting of a salt wasting (SW) and a simple virilizing (SV) 
subtype, and a late onset or nonclassic (NC) form. [3]
SW-CAH is the most severe form of 21-hydroxylase deficient CAH, with a remaining 
enzyme activity of <1% resulting in deficiencies of both cortisol and aldosterone. 
The aldosterone deficiency leads to severe salt loss after the first week of life, which 
can result in life-threatening hyponatremia, hyperkalemia and dehydration. The cortisol 
deficiency can lead to adrenal crises, with vomiting, hypoglycemia, hypotension, and 
decreased consciousness. The androgen overproduction is already present 
antenatally and can result in various degrees of virilization of the external genitalia 
in females. In boys, external genital development is normal apart from occasionally 
hyperpigmentation. [3]
In SV-CAH, the residual enzyme activity is 1-5%. Cortisol synthesis is deficient, but 
aldosterone production is sufficient to prevent salt wasting crises. Androgen 
overproduction is present as in SW-CAH, resulting in antenatal virilization of female 
14
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GENERAL INTRODUCTION, AIM AND OUTLINE OF THE THESIS
external genitalia and signs of androgen excess such as precocious pseudopuberty 
occurring in male patients in the first years of life. [7] 
The NC form of CAH is less severe with an enzyme activity of 20-50%. Aldosterone 
production is sufficient. Baseline cortisol levels are not reduced, although ACTH 
stimulated cortisol levels may be decreased. [9, 10] Androgens are slightly elevated. 
Clinical signs and symptoms of androgen overproduction can occur later in life, for 
example precocious pseudopuberty in childhood; acne, hirsutism and menstrual 
disturbances in adolescence and adulthood; and subfertility in adulthood. However, 
not all individuals with genotypes consistent with NC-CAH develop clinical signs 
and symptoms. [3, 9, 11, 12] 
Nowadays, CAH is considered to be a spectrum of disease, depending on the 
severity of the underlying CYP21A2 mutation and the residual activity of 21-
hydroxylase. In clinical practice the distinction between the conventional subtypes 
is not always clear. 
Genetics
The CYP21A2 gene is located at chromosome 6p21.3 and lies in close proximity to 
a highly homologous pseudogene CYP21A1P. Over 200 mutations in the CYP21A2 
gene have been described, however approximately ten mutations account for most 
affected alleles (figure 3)  (www.pharmvar.org/gene/CYP21A2). [13] Most mutations 
result from non-homologous recombination or gene conversion events with the 
pesudogene. [14]  
The CYP21A2 mutations have been categorized in mutation groups based on their 
in vitro 21-hydroxylase activity, in analogy with the clinical subtypes. [15] In mutation 
group null, there is no residual enzyme activity. In groups A, B and C the residual 
enzyme activity is 0-1%, 1-5% and 20-50% respectively. Groups null and A are usually 
associated with a SW phenotype, group B with a SV phenotype and group C with a 
NC phenotype. Most CAH patients are compound heterozygotes with different 
mutations on each allele. The phenotype is usually determined by the least severe 
mutation of the two affected alleles. [7, 11] The genotype-phenotype correlation is 
generally good, however exceptions have been found and some mutations can 
result in various different phenotypes. [3, 14] 
Diagnosis
The diagnosis of CAH can be made biochemically, by determining the levels of 
adrenal steroid precursors (in 21-hydroxylase deficiency most importantly 17OHP) 
by immunoassays and – preferably – mass spectrometry methods, because of 
16
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the risk of cross reactivity with other steroid metabolites in immunoassays. ACTH 
stimulation tests can be required. The diagnosis can be confirmed by mutation 
analysis.  [3, 4, 11] 
Historically, CAH was diagnosed after the occurrence of clinical signs and symptoms 
such as ambiguous genitalia at birth and/or salt wasting crises in the neonatal 
period. Since the year 2002, CAH is included in the neonatal screening program in 
the Netherlands. In a dried filter paper blood spot collected within 72-96 hours after 
birth, the level of 17OHP is determined. When it is above the cut-off values for 
gestational age, the patient is immediately referred to a pediatric endocrinology 
centre for a further diagnostic work-up. This ensures early diagnosis and aims to 
prevent the occurrence of severe salt wasting crises especially in males, in whom 
no signs of excess androgen exposure are apparent at birth. Evaluation of the 
screening program has shown that more than 30% of CAH girls are also primarily 
diagnosed through the neonatal screening program, as virilization of the external 
genitalia can be overlooked. [5] Both SW-CAH and SV-CAH are detected in the 
neonatal screening program, while NC-CAH is normally not diagnosed since the 
17OHP concentration is generally below the cut-off level in this mild form of CAH. 
Figure 3  The location of the CYP21A2 gene on the short arm of chromosome 6. 
The blue boxes represent the exons of the CYP21A2 gene. The most frequently encountered mutations in 
21-hydroxylase deficiency – other than large deletions – are depicted. The I2 splice mutation is located in 
an intron.   
17
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Treatment and treatment goals
The treatment of classic CAH consists of chronic glucocorticoid and if necessary 
also mineralocorticoid therapy. The aim of the treatment is not only to replace the 
deficient hormones, but also to suppress the excess production of adrenal androgens. 
Through the treatment with glucocorticoids, the negative feedback to the hypothalamus 
and pituitary is restored. The ACTH secretion is suppressed, resulting in less stimulation 
of the adrenal cortex and less production of adrenal androgens. [3] 
Specific treatment goals differ according to the patient’s age. In childhood and 
adolescence, main goals are to ensure normal linear growth and skeletal maturation, 
to prevent early pubertal development and to prevent symptoms of hyperandro-
genism. In adult patients, maintaining fertility is an important objective. In all 
patients, ensuring optimal quality of life and avoiding the long-term consequences 
of chronic glucocorticoid use are main issues. [11, 16, 17] 
To reach these treatment goals, the balance between over- and undertreatment 
needs to be found. To adequately suppress adrenal androgens, often supraphysio-
logical doses of glucocorticoids are necessary. [4, 11] Failure to suppress adrenal 
androgens can lead to increased growth velocity, but also premature epiphyseal 
maturation ultimately resulting in a decreased final height. Also, during puberty and 
adulthood gonadal function can be impaired since elevated androgens, which are 
converted to estrogens, can suppress gonadotropin secretion by the pituitary 
gland. [4, 9] However, chronic use of supraphysiological doses of glucocorticoids 
can result in side effects such as hypertension, insulin resistance, obesity and a 
decreased bone mineral density. It can also result in a decreased final height, due 
to direct effects on the growth plate and impaired growth hormone secretion and 
action. [3, 4, 7, 9, 18] Therefore, adequate linear growth and final height can serve 
as long-term outcome parameters of the treatment of CAH in children.  
To ensure adequate treatment of this complex disorder, patients should be 
monitored closely throughout their lives using both clinical and laboratory 
parameters. In childhood and adolescence, regular measurements of height, 
weight, blood pressure, bone age, adrenal steroid precursor levels (usually 17OHP 
and androstenedione) and renin levels should be performed. [4, 17] During 
treatment, the glucocorticoid dose needs to be increased in situations of stress 
such as significant illness, trauma and surgery to prevent the occurrence of adrenal 
crises. Parenteral administration of glucocorticoids may be necessary in these 
situations. An important part of the care of CAH patients is appropriate education 
of the patients and their parents on when and how to apply stress-dosing and this 
education should be repeated during follow-up. [19] 
18
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For NC-CAH patients, treatment should focus on the patient’s symptoms, not 
merely on normalizing abnormal steroid hormone levels. It is advised to reserve 
chronic glucocorticoid treatment for patients with clinically significant signs of 
 hyperandrogenism. [3, 4, 7, 9, 11, 12, 17] There is still debate on the need for 
stress-dosing in NC-CAH patients who are not on chronic glucocorticoid therapy. 
Although ACTH stimulated cortisol levels may be decreased, clinical manifestations 
of adrenal insufficiency seem uncommon in NC-CAH patients. [10] Routine stress 
dosing is currently not recommended, but it may be advisable during serious illness 
or major surgery in patients with an inadequate cortisol response after ACTH 
administration. [7, 9, 10, 12, 17]  
Aim and outline of the thesis
Despite the increasing understanding of CAH, many questions remain unanswered. 
This thesis aims to gain more insight in the pathophysiological processes related to 
elevated adrenal steroid precursors, both from a clinical and from a biochemical 
perspective.  
The first part of the thesis contains clinical studies, focusing on growth patterns and 
adrenal steroid levels in CAH patients. These are important elements of the clinical 
evaluation of CAH patients, both in diagnosis and in long term follow-up. In chapter 2, 
we describe the patterns of linear growth and bone maturation of untreated children 
with NC-CAH. In chapter 3, we focus on the salivary levels of 17OHP and andro-
stenedione in treated children with classic CAH, before and during puberty. Chapter 4 
describes the long term follow-up of classic CAH children, combining their patterns 
of linear growth and bone maturation with longitudinal measurements of their 
salivary steroid measurements and glucocorticoid use. 
In the second part of this thesis the glucocorticoid and mineralocorticoid potency 
of adrenal steroid precursors is examined. The starting point is the description of an 
untreated SW-CAH patient in chapter 5, who showed no clear signs of cortisol 
deficiency. Combined with other clinical observations, this has led to the hypothesis 
that the accumulating adrenal steroid precursors may have glucocorticoid properties. 
In chapter 6 we evaluate the in vitro binding and transactivation of the human 
glucocorticoid receptor (hGR) by the adrenal steroid precursors 21-deoxycortisol, 
17OHP, progesterone and androstenedione. In chapter 7, we expanded the in vitro 
transactivation studies of the hGR with additional adrenal steroid precursors. 
Additionally, in this chapter we describe a unique cohort of untreated classic CAH 
patients with clinical data on episodes of severe stress they survived without 
19
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glucocorticoid treatment, and with biochemical data on adrenal steroid levels. 
Chapter 8 focuses on the in vitro binding and transactivation of adrenal steroid 
precursors to the mineralocorticoid receptor.
In the concluding part of this thesis, chapter 9, the results and conclusions of the 
thesis are discussed in relation to the existing literature. Future perspectives are 
explored. Chapter 10 consists of a summary of the studies included in this thesis. 
The addendum contains the Dutch summary as well as a list of abbreviations, list of 
publications, acknowledgements and curriculum vitae. 
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Patterns of growth and 
salivary steroid levels in congenital 
adrenal hyperplasia patients

Chapter 2
Absence of clinically relevant 
growth acceleration in  
untreated children with nonclassic 
congenital adrenal hyperplasia
Pijnenburg-Kleizen KJ, Borm GF, Otten BJ, Schott DA,  
van den Akker EL, Stokvis-Brantsma WH, Voorhoeve PG, Bakker B,  
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Abstract
Background/Aims In classic congenital adrenal hyperplasia (CAH) elevation of adrenal 
androgens leads to accelerated growth and bone maturation with compromised 
adult height. In untreated children with nonclassic CAH (NC-CAH), in which adrenal 
androgens are generally only slightly increased, growth velocity may not be significantly 
elevated. 
Methods 24 patients were included and divided in a symptomatic and an asymptomatic 
group. Height was expressed as height standard deviation score (HSDS) and 
corrected for target height (HSDS-THSDS). Bone maturation was expressed as bone 
age acceleration (BAc= bone age - calendar age). Linear mixed models with random 
factor patient were used for the analysis of growth and bone age. 
Results In symptomatic patients (n=17) HSDS-THSDS only slightly increased with 
0.06 SDS per year (95% CI 0.02 – 0.10). Mean BAc  was 2.21 years (SDS 0.66, p< 0.0001). 
In asymptomatic patients (n=7) no significant growth acceleration or BAc was found. 
Conclusions In untreated NC-CAH children growth acceleration is small and generally 
not visible in their growth charts. BAc is more pronounced. Therefore, the absence 
of an increase in growth velocity does not exclude the diagnosis NC-CAH. When 
considering this diagnosis, bone age acceleration should also be taken into account. 
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GROWTH PATTERNS IN NONCLASSIC CAH
Introduction
Congenital adrenal hyperplasia (CAH) is one of the most common autosomal 
recessive endocrine disorders. It is characterized by specific enzymatic defects in 
the steroid biosynthesis. In most cases the deficient enzyme is 21-hydroxylase 
(21OHD) leading to impaired production of cortisol and in classic salt wasting (SW) 
cases also of aldosterone. As a consequence of impaired cortisol synthesis the 
secretion of ACTH by the pituitary gland is increased, leading to hyperplasia of the 
adrenal cortex. Steroid precursors immediately proximal to the defective step 
accumulate and are shunted into the androgen pathway, resulting in excessive 
production of adrenal androgens. 
Three forms of 21OHD CAH can be distinguished by clinical, hormonal and molecular 
genetic criteria: the classic SW, classic simple virilising (SV), and nonclassic (NC) form.
 In the most severe, SW form, which has an incidence of 1:20.000 [1], the residual 
enzymatic activity is less than 1% leading to cortisol deficiency as well as decreased 
aldosterone synthesis. Female patients are virilised prenatally due to adrenal androgen 
excess and neonates of both sexes can suffer from life-threatening SW. In classic 
SV-CAH, with an incidence of 1:60.000 [1], the residual enzymatic activity is 1-5%. 
Aldosterone synthesis is usually intact, but cortisol synthesis is impaired. Affected 
females present with genital ambiguity. 
 The mildest, NC form of CAH, or late onset type, is more common: the incidence 
is 1:1000 [1], It is characterized by a residual enzymatic activity of 20-50% with 
generally normal cortisol and aldosterone production but with mild androgen excess 
leading to variable signs of hyperandrogenism that can manifest at any age. [2-5] 
The main  symptoms in childhood and adolescence include premature pubarche, 
cystic acne, hirsutism, and menstrual disorders. [1-8]
In patients with classic CAH androgen excess leads to a progressive increase in 
growth velocity and bone maturation after the first year of life. [9] Therefore, 
adequate suppression of adrenal androgens is important to prevent early epiphyseal 
fusion and compromised adult height. In children with NC-CAH adrenal androgens 
are only slightly elevated. Whether growth is accelerated in childhood and adult 
height is compromised in NC-CAH is not yet agreed upon. [1,2,6,7,10-12] A study 
describing the phenotypic profile of parents of CAH children, who were identified 
by family genetic studies as having NC-CAH, showed adult heights in the normal 
range. However, these parents were either asymptomatic or developed symptoms 
in adulthood. Therefore, their growth pattern might have been different from the 
growth pattern of children who are already symptomatic. [13] 
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Based on our personal clinical observations, we hypothesize that in children with 
NC-CAH growth velocity may not be significantly elevated at the time of diagnosis. 
We therefore retrospectively evaluated a group of children with NC-CAH to define 
their growth pattern prior to treatment. Furthermore, we evaluated the age of onset 
of symptoms, the presenting symptoms and the bone maturation.
Patients and Methods
Patients
We collected the data of NC-CAH children treated or followed at the Radboud 
University Nijmegen Medical Center from 1980 until 2009, and of patients currently 
under treatment or follow-up in five other Dutch hospitals (3 University Hospitals). 
The diagnosis of NC-CAH was based on clinical and biochemical criteria and was 
confirmed by mutation analysis. 
 Age at diagnosis, clinical symptoms at presentation, bone age and growth data 
from birth until initiation of treatment were obtained from the patient’s medical 
records. In most cases adult heights were not available. Those that were available 
were not collected, since they could be affected by treatment and therefore do not 
only represent the effect of androgen excess on growth in this population. Height 
was expressed as height standard deviation scores (HSDS) according to the national 
references [14] and corrected for target height, defined as corrected midparental 
height (HSDS-THSDS). [9] Bone maturation (bone age, BA) was determined according to 
Greulich and Pyle and expressed as advance in bone age (BAc= BA – chronological age).
Statistical analysis
Data were analysed using Statistical Package for Social Sciences (SPSS) for Windows 
(version 16.0). The growth and bone age were analyzed for the entire patient group 
and for two subgroups separately. The first subgroup (symptomatic group) consists 
of patients diagnosed after the onset of signs or symptoms of increased androgens; 
the second subgroup (asymptomatic group) concerns children, who did not show 
signs or symptoms but were detected by family screening or the neonatal screening 
program. This division was made because of the fact that the latter group may not 
develop signs of androgen overproduction until adulthood and their growth patterns 
may be different from those of the patients who become symptomatic in childhood. 
 Since in the first years of life growth patterns can be different from later years 
due to target seeking, and in the initial analysis the growth data of symptomatic 
patients showed a different pattern before and after the age of three years, separate 
analyses were done for the age groups 0-3 years and  >3 years. Linear mixed 
models with random factor patient were used for the analysis of the growth and the 
bone age. Ninety-five percent confidence intervals (CI) were calculated. 
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Results
Clinical presentation
24 NC-CAH patients were included, 14 females and 10 males (Table 1). 17 patients 
were included in the symptomatic group; their mean age at presentation was 
7.1 years (range 2.4 – 9.3 years). The main presenting symptom was precocious 
Table 1   Clinical presentation and BAc at presentation, and mutation analysis 
in 24 patients with NC-CAH.
Patient
No.
Sex Age at 
presentation 
(yrs)
Symptoms at 
presentationa
BAcb at 
presentation 
(yrs)
Mutation analysis
Allele 1 Allele 2
Symptomatic patients
1 F 2.4 3 -0.1 656A/C>G P453S
2 F 3.0 1 - V281L V281L
3 F 4.6 1,3 - R356W 902C>A
4 M 7.3 1 3.5 V281L Del-Conv
5 F 8.7 1,3 2.3 V281L 8BP-DEL
6 F 6.3 1 - V281L R408C
7 M 7.8 1 4.7 V281L 656A/C>G
8 F 7.4 1,2 1.3 V281L  V281L
9 M 8.5 1 -0.1 V281L Del/Conv
10 F 9.3 1 2.2 V281L R356W
11 F 8.3 1,3 1.9 V281L P30L
12 M 7.4 1 2.7 V281L 656A/C>G
13 F 7.0 1,2 3.0 V281L V281L
14 F 7.0 1 3.1 V281L 656A/C>G
15 F 9.0 1,2 1.0 Del-Conv P432L
16 F 8.0 1 1.7 I172N 1177C>T
17 M 8.3 1 3.2 P453S Del-Conv
Asymptomatic patients
18 M 0.0 4 0.6 V281L I172N
19 M 8.3 4 -0.5 V281L V281L
20 F 4.5 4 1.0 V281L R356W
21 F 6.2 4 0.6 V281L Del-Conv
22 M 0.0 4 -0.2 V281L Del-Conv
23 M 3.0 4 0.5 V281L 656A/C>G
24 M 6.0 4 1.3 P453S Del-Conv
a Symptoms at presentation. 1, pubic hair; 2, axillary hair; 3, clitoromegaly; 4, asymptomatic
 b BAc Bone age – Chronological age
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pubarche. Treatment was started in all but one 7-year-old female patient, presenting 
recently with precocious pubarche. Mean age at initiation of treatment was 8.1 years 
(range 2.5 – 12.3 years), mean 0.9 years after first presentation (range 0.1 – 2.0 years).
 7 patients were included in the asymptomatic subgroup. They were diagnosed 
because of an affected sibling (n=6) or because of a positive CAH screening in the 
national screening programme (n=1). Their mean age at presentation was 4.0 years 
(range 0.0 – 8.3 years). All patients were followed in outpatient clinics to monitor 
them for signs and symptoms of androgen excess. In two initially asymptomatic 
patients treatment was started at the age of 7.5 and 8.1 years, because of an 
increasing advance in bone age, respectively 1.3 and 8.1 years after diagnosis. 
Growth analysis
In the entire patient group HSDS-THSDS increased with 0.06 SDS per year (95% 
CI 0.03 – 0.09, p = 0.003) (Figure 1).  
In the symptomatic group growth data were available from 0 to 12.3 years of age. 
The mean number of measurements per patient was 8.4 (range 3 – 16). In the first 
three years of life HSDS-THSDS increased with 0.33 SDS per year (95% CI 0.08 - 
Figure 1  Growth expressed as HSDS-THSDS for chronological age in 24 NC-CAH 
patients (14 symptomatic patients, 7 asymptomatic patients).
The thick line represents the regression coefficient (0.06 SDS per year, 95% CI 0.03 – 0.09, p = 0.003).
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0.59, p = 0.01), with a large variation in growth velocity. After the age of three years 
there was a small increase in HSDS-THSDS of 0.06 SDS per year (95% CI 0.02 – 0.10, 
p = 0.002).
In the asymptomatic group, growth data were available from 0 to 9.0 years of age. 
The mean number of measurements per patient was 10.6 (range 5 – 15). No growth 
acceleration was seen in this patient group, with a mean HSDS-THSDS of -0.07 (SDS 
0.74, p = 0.80). 
Bone age analysis
In 19 patients bone age was determined at presentation. In 11 patients bone age 
determination was repeated once or twice during follow-up. BAc increased with 
0.11 years per year (95% CI -0.01 – 0.24, p=0.08) (Figure 2). Measurements at a 
younger age (0-7 years) were almost exclusively of the asymptomatic patients, 
measurements at an age of 7 years and older were mainly of symptomatic patients. 
In symptomatic patients mean BAc was 2.21 years (SDS 0.66, p < 0.0001). Analysis 
of BAc of asymptomatic patients showed a - not statistically significant - mean 
advance of 0.45 years (SDS 0.66, p = 0.15) Because of the limited number of 
measurements and the relatively small time intervals it could not be determined 
whether there is an increase in BAc over the course of time in the two subgroups. 
Figure 2  Advance in bone maturation expressed as Bone age – Chronological age 
(BAc) in years in 13 symptomatic NC-CAH patients (closed dots) and in 6 asymptomatic 
NC-CAH patients (open dots).
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Discussion
To our best knowledge this is the first report describing the growth pattern and 
bone maturation of symptomatic and  asymptomatic untreated children with 
NC-CAH. In our study group the growth acceleration was very small even in 
symptomatic children (0.06 SDS per year), most likely not clinically recognizable in 
the growth charts. Despite this absence of relevant growth acceleration we found 
an increase in BAc over time and a significant BAc at the age of 7-11 years in the 
symptomatic patient group. 
Increased growth velocity is viewed as one of the most prominent symptoms of 
androgen excess in childhood. In prepubertal classic CAH patients overproduction 
of adrenal androgens leads to accelerated growth velocity and bone maturation 
with compromised adult height. [9,12,15-17] Treatment with glucocorticoids aims 
to suppress the androgen secretion, and to restore normal growth and maturation. 
However, oversuppression can lead to Cushing syndrome and growth retardation. 
[1,11,12,15-18] A recent meta-analysis describing the adult height of classic CAH 
patients who started glucocorticoid treatment in the first 5 years of life, showed 
that the final height is still decreased, though in the normal range: -1,38 SDS. [19] 
Factors that positively influence the final height are a young age at diagnosis and 
good compliance with therapy. [12]
Skeletal growth and maturation is a complicated process depending not only on 
androgens but also on estrogens and other growth factors. Testosterone can 
stimulate growth directly through the androgen receptor in osteoblasts, osteoclasts, 
osteocytes and growth plate chondrocytes. [20] However, evidence of recent years 
indicates that the growth promoting effects of testosterone are mainly mediated 
through aromatization to estrogens. In male patients suffering from either an estrogen 
deficiency or estrogen resistance skeletal development is significantly delayed, 
suggesting a dominant role of estrogens in bone maturation. [20-22] Besides their 
direct effect on skeletal growth, androgens and estrogens may also influence the 
growth hormone – insulin-like growth factor I axis. [20,21] 
 The sensitivity to androgens seems to differ in different age groups. In an earlier 
study describing the growth patterns of untreated children with the classic SV form 
of CAH we showed that growth velocity and bone maturation are not increased in 
the first year of life [9], suggesting a relative resistance to androgen excess at this 
age, due to a reduced amount of receptors or to post-receptor effects. Thereafter, 
androgen excess leads to a progressive increase in growth velocity and bone 
maturation in strong relation to the duration of androgen exposure. [9] Therefore, 
after the age of 1 year growth velocity and bone maturation are valuable and well 
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known markers for the diagnosis and follow up of children with significant androgen 
excess syndromes.  
 Our results suggest that the response to androgens is not only age-dependent 
but also dose-dependent: in untreated NC-CAH children with generally only mild 
androgen excess, growth acceleration is small even in symptomatic patients. 
However, as shown in our study bone age advancement can still occur. Therefore, 
in childhood slightly elevated androgens may have a stronger effect on bone maturation 
than on growth velocity. 
 The same effect has been observed in classic CAH children with suboptimal 
hormonal control and consequently slightly elevated androgens. Hargitai et al 
described a large cohort of CAH patients with an increased acceleration in bone 
maturation during the prepubertal years without an increase in growth velocity. [23] 
This resulted in an advance in bone age at the start of puberty, which was the main 
reason for the reduced peak growth velocity and reduction in adult height. 
In our study group we observed a larger variation in growth acceleration below 
the age of 3 yrs. This is probably not a result of androgen exposure, but of target 
seeking, since there is a clear movement towards the 0 SD, the height as expected 
based on the target height. 
There are some limitations to our retrospective study. The number of available 
growth data per patient was variable. Furthermore, because of the limited data on 
bone age of the individual patients we could not determine whether there is a 
continuous increase of bone age acceleration over time or whether the significant 
increase of  BAc over time is a result of differences in bone age development in 
symptomatic and asymptomatic patients. Further prospective studies are necessary 
to analyze bone age advancement over time in this patient category in more detail. 
Our findings have important implications for both diagnosis and follow-up of children 
with NC-CAH, but also of patients with other conditions of androgen excess: 
1. In patients presenting with signs of precocious pubarche in the absence of 
increased growth velocity, the diagnosis of NC-CAH cannot be excluded 
without further appropriate diagnostic studies such as bone age evaluation and 
biochemical analysis. 
2. In asymptomatic, untreated NC-CAH patients regular measurements of growth 
velocity should be combined with bone age assessment at regular intervals, 
e.g. yearly. Treatment with glucocorticoids should be considered when signs 
and symptoms of androgen excess become manifest and/or when bone age 
advancement becomes pronounced. [1,17,18]
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3. Monitoring of both classic and non classic CAH children who are treated with 
glucocorticoids should include evaluation of growth velocity as well as bone 
age determination at regular intervals to determine the effect of both subtle 
androgen excess and of glucocorticoid treatment.  
Conclusion
In untreated NC-CAH children growth acceleration is small and generally not 
recognizable in their growth charts. BAc is more pronounced. Therefore, the 
absence of an increase in growth velocity does not exclude the diagnosis NC-CAH. 
When considering the diagnosis and when monitoring NC-CAH patients over time, 
the emphasis should be on both BAc as well as on growth acceleration.   
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Abstract
Background Treatment of congenital adrenal hyperplasia due to 21-hydroxylase 
deficiency can be monitored by salivary androstenedione (A) and 17-hydroxypro-
gesterone (17OHP) levels. There are no objective criteria for setting relevant target 
values or data on changes of 17OHP and A during monitoring.   
Methods We evaluated A and 17OHP levels in nearly 2000 salivary samples collected 
during long-term treatment of 84 pediatric patients with classic 21-hydroxylase 
deficiency. 
Results A and 17OHP levels and its ratio 17OHP/A remained constant from 4 to 11 
years with no sex-related differences. During puberty, A and 17OHP levels both 
increased, starting at earlier age in girls than in boys. The ratio 17OHP/A declined. 
Normalized A concomitant with elevated 17OHP [1.43 nmol/l (0.46 – 4.41) during 
prepuberty; 2.36 nmol/l (0.63 – 8.89) for boys and 1.99 nmol/l (0.32 – 6.98) for girls 
during puberty] could be obtained with overall median glucocorticoid doses of 11 
– 15 mg/m2/day. A levels above the upper reference limit (URL), suggesting 
undertreatment, coincided with 17OHP levels ≥10 times the URL. The percentage 
of A levels above the URL was 16% at ages 4 – 8 years, but increased to 31% for girls 
at 16 years and 46% for boys at 17 years. 
Conclusions Normalized A consistent with 17OHP three times the URL during 
prepuberty and normalized A consistent with 4 – 6 times the URL during puberty 
could be obtained by moderate glucocorticoid dosages. A constant 17OHP/A ratio 
during prepuberty suggested absence of adrenarche. During puberty, a higher 
percentage of samples met the criteria for undertreatment, especially in boys.
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Introduction
Congenital adrenal hyperplasia (CAH) is a group of inherited disorders caused by 
deficiency of one of the enzymes involved in the biosynthesis of adrenal steroids. 
The most frequent cause of CAH is deficiency of the enzyme 21-hydroxylase due 
to a mutation in the CYP21A2 gene, which accounts for approximately 90% – 95% 
of the cases of CAH.
 21-Hydroxylase deficiency results in impairment of the production of cortisol 
and, depending on the residual enzymatic activity, also of aldosterone. Due to lack 
of a negative feedback of cortisol to the pituitary gland, adrenocorticotrophic 
hormone (ACTH) concentration increases. ACTH stimulates the adrenal gland to 
produce cortisol. However, because of the 21-hydroxylase block, conversion of 
17-hydroxyprogesterone (17OHP) to 11-deoxycortisol is impaired. 17OHP 
accumulates and subsequently converts into androstenedione (A) and testosterone. 
These androgens are responsible for virilization of female external genitalia, 
precocious puberty in both sexes and irregular menstruation in adolescence and 
adulthood.  [1 – 4] 
 Variability in severity of the mutation results in various degrees of residual 
enzymatic activity of 21-hydroxylase and different clinical and biochemical 
presentations. [1, 3, 4] Therefore, 21-hydroxylase deficiency is divided into classic 
and non classic forms. The classic forms are the salt wasting (SW) and non-salt 
wasting, simple virilizing (SV) types. Residual enzymatic activity is 0% in SW and 1% 
– 2% in SV. In both classic forms there is insufficient cortisol production and excess 
androgen production. Additionally, aldosterone production is impaired in SW. In the 
non classic, late onset form of 21-hydroxylase deficiency residual enzymatic activity 
is 20% – 50%. Both cortisol and aldosterone production are generally sufficient, 
while adrenal androgen production is still slightly increased. [1, 3, 4] 
 The purpose of treatment of classic CAH is to overcome glucocorticoid and 
mineralocorticoid deficiency and suppress elevated levels of adrenal androgens. 
Glucocorticoid substitution results in lowering of ACTH secretion by restoring the 
negative feedback to the pituitary gland, thereby also lowering adrenal androgen 
production. Unfortunately, often supraphysiological doses of glucocorticoids are 
necessary to suppress adrenal androgen production with the potential risk of poor 
growth, hypertension and cushingoid features. In contrast, undertreatment might 
lead to persistently elevated androgens with premature epiphyseal maturation and 
loss of growth potential. Therefore, monitoring of glucocorticoid treatment is 
important. [2, 5 – 8]
 Monitoring of glucocorticoid therapy may be accomplished by measuring 
early morning serum 17OHP and A concentrations. [2, 5, 6, 9] However, a venipuncture 
is inconvenient for children. Venipuncture causes stress, which may activate the 
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ACTH-adrenal axis and influence the actual levels of steroids. Saliva has been found 
to be an excellent alternative and collection is almost stress free. [10 – 12] Collection 
can be done at home before the morning glucocorticoid dose, reflecting the 
endogenous production of androgens and the ACTH pressure on the adrenal 
gland. Salivary 17OHP and A levels have been found to correlate well with serum 
values. [10 – 12]
 There are no objective criteria for setting relevant target values for A and 17OHP 
in CAH patients. According to clinical guidelines A levels should be normalized, but 
17OHP levels within the normal range indicate overtreatment. [5, 6] Furthermore, 
no data on changes of A and 17OHP levels during long-term treatment are available. 
Charmandari et al.  [13]  indicated that puberty imposes increased difficulty in 
attaining adrenocortical suppression despite optimal substitution therapy and 
adherence to medical treatment.
 The objective of the present study was to retrospectively evaluate the morning 
levels of A and 17OHP measured in nearly 2000 salivary samples during long-term 
glucocorticoid treatment of a large cohort of pediatric patients with 21-hydroxylase 
deficiency. We determined androgen changes during childhood and puberty and 
estimated the extent of androgen control.  
Patients and methods
Patients
The data of 84 patients with classic 21-hydroxylase deficiency, treated by paediatric 
endocrinologists at the Radboud University Medical Center Nijmegen in the period 
1981 – 2010, were collected in a local database and analyzed anonymously. All collected 
data were part of the routine follow-up within patient care. The retrospective 
analysis was approved by the local Ethical Committee. No informed consent was 
asked because of the historical and anonymous evaluation of the data.
 Sixty-five patients were classified as having the SW form (32 females, 33 males) 
and 19 patients as having the SV form (9 females, 10 males) of CAH. Classifications 
were based on DNA mutation analysis, clinical presentation (genital ambiguity in 
females, SW crisis) and/or biochemical measurements (serum/plasma ACTH, 
cortisol, androgens, renin and aldosterone at diagnosis).
 Therapeutic follow-up within our center was started at 0.3 years of age 
(median; 75% of patients <4.0 years, 25% between 4.0 and 16.2 years) in SW and 4.0 
years of age (median; 75% <5.2 years, 25% between 5.2 and 10.2 years) in SV 
patients. Some patients were referred to our clinic after initial treatment in another 
center. Median duration of follow-up was 12.8  years (range 3.2 – 19.0) in SW and 
11.9 years (range 6.1 – 18.6) in SV patients.
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Patients were treated with hydrocortisone, divided into three daily doses or with 
dexamethasone in one or two daily doses in some postpubertal patients. In case of 
mineralocorticoid requirement, fludrocortisone acetate was given. Glucocorticoid 
doses were related to the body surface area, expressed in milligrams per square 
meter. For comparability, all glucocorticoid formulations were transformed into 
equivalent doses of hydrocortisone using dosage equivalents based on growth 
retarding and androgen suppressing effects, i.e., 10 mg hydrocortisone = 0.125 mg 
dexamethasone. [14, 15] The surface area (SA) of the total body was calculated as: 
ln(SA) =  –3.751 + 0.422* ln(H) + 0.515*ln(W), in which ln is the natural logarithm, 
SA is surface area in square meters, H is height in centimeters, and W is weight in 
kilograms. [16]
 During follow-up, the therapy was monitored as described earlier [15] every 
3 – 6 months by evaluating clinical symptoms, length and weight, bone age once 
a year and biochemical monitoring (see below). Patient numbers, duration of 
follow-up and medication are summarized in Table 1.
Biochemical monitoring
Saliva was obtained from children older than 3  years of age (for younger children 
salivary collection is hard to apply). Samples were collected four times a year before 
routine visits to the outpatient clinic of our hospital. Saliva samples were taken 
before administration of the glucocorticoid dose between 07.00 and 09.00 a.m. 
by asking the patient to salivate in a polypropylene tube (Greiner Bio-one). Clear 
instruction was given to prevent blood contamination in the samples. After collection, 
samples were sent to the laboratory and frozen at –20°C until analysis.
 Three milliliters of saliva were extracted by diethyl ether and purified by paper 
chromatography as previously described. [10, 17, 18] A and 17OHP levels in the 
elutes were measured by in-house radioactive immunoassays. [10] In the immuno - 
assays antibodies raised in sheep against androstenedione-19-carboxymethylether 
and against 11-deoxylcortisol-21-hemisuccinate, conjugated to BSA (ICN Biomedicals 
Inc.) were used. In the time period that is covered by this study (almost 30 years), 
this laboratory method remained unchanged. Long-term quality was assessed by 
control material, consisting of serum and saliva pools. The limit of detection of 
both A and 17OHP in saliva was 0.02 nmol/l. Intra- and inter-assay coefficients of 
variation were <8% for A and <9% for 17OHP.
 Upper reference limits (URL) of morning A and 17OHP levels were 0.24 and 
0.45 nmol/l, respectively, for children ≤ 11 years of age, independent of sex. [10] URL 
of morning A and 17OHP levels were 1.10 and 0.32 nmol/l, respectively for female 
adolescents/adults and 0.96 and 0.61 nmol/l, respectively for male adolescents/
adults (URL was determined by logarithmic transformation of the data of previous 
studies [10, 19]) and subsequently, calculation of the 95% reference interval).  
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Data analysis
For descriptive and statistical analyses the data were categorized in intervals of 
years or by pubertal stage of the patients. Data collected between 3 and 19 years of 
age were analyzed. Data obtained between ages 3 and 4 were categorized as 
4 years, between ages 4 and 5 as 5  years and so on. Pubertal stage was categorized 
as prepubertal or pubertal. Prepubertal stage was defined as Tanner stage <2. 
Pubertal stage was defined as Tanner stage ≥2. Tanner stage 2 was reached at 
breast stage M2 for girls and at a testicular volume ≥ 4 ml for boys. [20] 
 As the distribution of steroid concentrations was skewed in several groups, results 
are expressed as medians and ranges. Ranges are defined as minimal to maximal value, 
when outliers are excluded. Outliers are defined as values >1.5 times the interquartile 
range from the edge of the box in the box plot (Tukey’s Hinges) as calculated from 
SPSS. One way Kruskal-Wallis analysis was used to analyze overall differences 
between groups. Mann-Whitney U-test was used as a post hoc test to consider 
differences between two groups. Overall, p-values <0.05 were considered statistically 
significant. When post hoc tests (for various age differences) were performed, a p-value 
<0.01 was considered significant because of repeated testing. The ratio 17OHP/A was 
calculated for A levels >0.05 nmol/l as very small A values may influence the ratio 
disproportionally. SPSS version 20 was used to perform statistical analysis.   
Results
Glucocorticoid medication
Glucocorticoid doses are shown in Table 1. Median glucocorticoid doses were 
between 11 and 15 mg/m2/day for the various subgroups. Glucocorticoid doses 
were significantly higher in SV than in SW patients in all subgroups and higher in 
boys than in girls (except for SW patients of 4 – 11 years). In the subgroups SW male 
and SV female slightly higher doses were given at 12 – 19 than at 4 – 11 years, while 
in the subgroup SW female lower doses were given at 12 – 19 than 4 – 11 years. The 
wide range of doses was due to incidental adjustment of individual daily dosages 
using hormonal and linear growth data.  
Salivary A and 17OHP levels during glucocorticoid treatment
Figure 1 and Table 2 present the morning salivary A and 17OHP levels and the ratio 
17OHP/A. In Figure 1 the levels are plotted against age and in Table 2 the data are 
categorized by pubertal stage.
 The total number of results was 1892 for A, 1913 for 17OHP and 1462 for the 
ratios of 17OHP/A. The number of results categorised by age varied from 18 to 169 
and by pubertal stage from 311 to 500.  
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Prepuberty
Median A levels remained constant from 4 years (0.10 nmol/l, range <0.02 – 0.28) 
to 11 years (0.11 nmol/l, range <0.02 – 0.64). Median 17OHP levels also remained 
constant during the age period of 4 – 11 years (1.06 nmol/l, range <0.02 – 6.83). 
The median 17OHP/A ratio was about 11 (range 0.17 – 33.21) during this period.  
Puberty
In the overall group, median A concentration significantly increased at the age of 13 
years (0.29 nmol/l; range <0.02 – 1.21; p <0.01) when compared to the previous 
years. The maximal value was reached at the age of 16  years (median 0.72 nmol/l; 
range <0.02 – 2.71) and gradually, but not significantly, declined to 0.45 nmol/l 
(range 0.07 – 1.30) at 19 years of age (Figure 1).
 Similar to A, 17OHP levels started to increase significantly at the age of 13 years 
(median 1.79 nmol/l; range <0.02 – 10.81; p <0.01). A maximum of 17OHP was 
reached at 15 years (median 3.40 nmol/l; range <0.02 – 11.70), remained at this 
level until 17 years and slightly, but not significantly, decreased at 18 and 19 years of 
age. The ratio 17OHP/A was 7.09 (range 0.20 – 22.67) at 12 years of age and 
significantly (p <0.01) decreased to 2.81 at 19 years of age (range 0.28 – 7.10).
Table 1   Patient numbers, follow-up and medication.
Total  
CAH 
Salt wasting  
CAH
Simple virilizing 
CAH
Number of patients
     Male
     Female
84
43
41
65
33
32
19
10
9
Start follow-up, age in years 1.2 (0.0-16.2) 0.3 (0.0-16.2) 4.0 (0.0-10.2)
Duration of follow-up, years 12.8 (3.2-19.0) 12.8 (3.2-19.0) 11.9 (6.1-18.6)
Glucocorticoid dose, mg/m2/day
     4-11 years
     Male
     Female
     12-19 years
     Male
     Female
12.2 (4.6-22.8)
12.5 (4.6-23.3)
11.9 (4.8-22.2)c
12.6 (4.2-23.0)
13.3 (6.6-23.1)a
11.9 (4.2-22.9)c
11.7 (4.6-21.1)b
11.9 (4.6-20.4)b
11.5 (4.8-21.7)b
11.6 (4.2-22.2)b
12.3 (6.6-22.2)a,b
10.9 (4.2-22.2)a,b,c
14.2 (4.9-23.5)
14.8 (6.1-24.1)
12.8 (4.9-21.1)c
14.6 (8.0-23.8)a
14.9 (8.0-27.1)
13.7 (8.1-21.1)a,c
All data are given as medians and ranges. CAH, congenital adrenal hyperplasia. Glucocorticoid dose 
expressed as hydrocortisone equivalents [14 – 16].  a Significant difference in glucocorticoid dose between 
4 – 11 vs. 12– 19 years of age; p<0.05;  b Significant difference in glucocorticoid dose between SW and SV 
patients; p<0.05;  c Significant difference in glucocorticoid dose between male and female; p<0.05.
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Figure 1  Morning salivary A (A) and 17OHP (B) levels (nmol/l) and the ratio 17OHP/A 
(C) of CAH patients, categorised by age in years. Patients were treated with gluco-
corticoids. 
Results are expressed as medians and ranges (logarithmic scale). A, androstenedione; 17OHP, 17OH 
progesterone. Points which extend more than 1.5 times the interquartile length from the edge of the box 
are illustrated by  ‘o’  and more than 3.0 times the interquartile length from the edge of the box are 
illustrated by ‘*’.
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When patients were categorized by Tanner stage (Table 2), the median salivary A 
level was 4.7 times higher, while median 17OHP was about two times higher in 
pubertal compared to prepubertal children. Correspondingly, the ratio 17OHP/A 
was significantly lower in pubertal than in prepubertal children (p <0.05).
Table 2   Morning salivary A and 17OHP levels (nmol/l) and the ratio 17OHP/A 
at prepuberty (Tanner stage <2) and puberty (Tanner stage ≥2) of 
patients with classic 21-hydroxylase deficiency, who are treated with 
glucocorticoids.
N Median Range
Androstenedione
Prepuberty
     Male
     Female
     Total
Puberty
     Male
     Female
     Total
500
311
811
465
470
935
0.09
0.09
0.09
0.41b
0.42b
0.42b
<0.02-0.52
<0.02-0.45
<0.02-0.51
<0.02-2.12
<0.02-1.65
<0.02-1.80
17OHP
Prepuberty
     Male
     Female
     Total
Puberty
     Male
     Female
     Total
508
314
822
470
473
943
0.96
1.00
0.99
2.31a.b
1.72b
1.93b
<0.02-6.91
<0.02-6.12
<0.02-6.60
<0.02-14.47
<0.02-8.89
<0.02-11.14
17OHP/androstenedione
Prepuberty
     Male
     Female
     Total
Puberty
     Male
     Female
     Total
319
199
518
424
417
841
10.47
11.01
10.81
5.40a.b
4.02b
4.76b
0.17-31.96
0.20-35.29
0.17-34.12
0.03-17.18
0.03-12.73
0.03-15.00
All data are given as medians and ranges. A, androstenedione; 17OHP, 17OH progesterone.  a Significant 
difference between male and female; p <0.05;  b Significant difference between prepubertal and pubertal; 
p <0.05.
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Gender
There were no significant differences in A concentrations between prepubertal 
boys and girls. A levels were twice as high in girls as in boys at 12 and 13 years, i.e., 
0.29 (range <0.02 – 0.93) vs. 0.13 (range <0.02 – 0.46) nmol/l, respectively at 12 
years (p <0.05) and 0.41 (range <0.02 – 1.57) vs. 0.24 (range <0.02 – 0.91) nmol/l, 
respectively at 13 years (p <0.05). At 14, 15 and 16 years of age, there were no 
significant differences between the sexes. At 17 years of age, A levels were 
significantly lower in girls than in boys, i.e., 0.56 (<0.02 – 1.71) vs. 0.83 (0.08 – 5.00) 
nmol/l, respectively (p <0.05). When patients were categorised by Tanner stage 
there were no significant differences in A between boys and girls.
 17OHP levels were significantly higher in girls than in boys at the age of 6 years, 
i.e., 1.48 (<0.02 – 7.90) vs. 0.39 (<0.02 – 5.60) nmol/l, but were about two times 
lower in girls than in boys during the pubertal period (significant at 11, 15, 16 and 17 
years; p <0.05). When categorised by pubertal stage, the difference in 17OHP levels 
between boys and girls was still present.  
Salivary androgen levels suggesting optimal versus undertreatment
In Table 3 the salivary data are divided in three subgroups, i.e., 1) A below URL and 
17OHP above URL suggesting optimal treatment; 2) A and 17OHP below URL 
suggesting overtreatment; 3) A and 17OHP above URL suggesting undertreatment.
In the group representing optimal treatment median A levels were 0.4 –0.5 times 
the URL, i.e., 0.11 (<0.02 – 0.24) nmol/l for children of 4 – 11 years of age, 0.37 (0.02 
– 0.96) nmol/l for boys and 0.50 (<0.02 – 1.10) nmol/l for girls of 12 – 19  years of 
age. Median 17OHP was 1.43 (0.46 – 4.41) nmol/l for the age group 4 – 11 years, 
which corresponds with three times the URL. Median 17OHP was 2.36 (0.63 – 8.89) 
nmol/l for boys and 1.99 (0.32 – 6.98) nmol/l for girls of 12 – 19 years of age, 
corresponding with four and six times URL, respectively.
 A and 17OHP levels suggesting undertreatment were 2 and 10 times URL, 
respectively for the age group 4 – 11 years. For the age group 12 – 19 years median 
A levels were also up to 2 times URL, while 17OHP levels were 16 – 18 times URL for 
girls and boys. When categorized by age, about 16% of the androgen concentrations 
met the criteria for undertreatment at 4 – 8 years of age, which substantially 
increased to 31% for girls at 16  years and 46% for boys at 17 years of age.   
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Discussion
We retrospectively evaluated morning salivary A and 17OHP concentrations in 
nearly 2000 samples of a large pediatric cohort of classic CAH patients (21-
hydroxylase deficiency). The patients were treated with glucocorticoids and 
monitored in our outpatient clinic from childhood to adulthood. We described 
changes of salivary A and 17OHP during childhood and puberty. In addition, we 
evaluated the levels in light of optimal treatment and undertreatment by a 
combination of A and 17OHP. To the best of our knowledge no published data on 
salivary A and 17OHP levels during long-term treatment of CAH patients are 
Table 3   Morning salivary A and 17OHP levels (nmol/l) in patients with classic 
21-hydroxylase deficiency, divided in 3 subgroups: 1) A below URL  
and 17OHP above URL suggesting optimal treatment; 2) A and 17OHP 
below URL suggesting overtreatment; 3) A and 17OHP above URL 
 suggesting undertreatment.
N Androstenedione 17OHP
4-11 years
Total 1024 0.10 (<0.02-0.55) 1.07 (<0.02-6.83)
1. Optimal 429 0.11 (<0.02-0.24) 1.43 (0.46-4.41)
2. Overtreated 342 0.02 (<0.02-0.09) 0.12 (<0.02-0.45)
3. Undertreated 252 0.40 (0.24-1.02) 4.70 (0.49-14.50)
12-19 years
Total
     Male
     Female
868
485
383
0.44 (<0.02-1.97)
0.41 (<0.02-2.20)
0.47 (<0.02-1.71)
2.02 (<0.02-11.51)
2.32 (<0.02-15.04)a
1.78 (<0.02-8.50)
1. Optimal
     Male
     Female
464
238
226
0.45 (<0.02-1.10)
0.37 (0.02-0.96)a
0.50 (<0.02-1.10)
2.21 (0.32-7.70)
2.36 (0.63-8.89)a
1.99 (0.32-6.98)
2. Overtreated
     Male
     Female
211
121
90
0.10 (<0.02-0.45)
0.10 (<0.02-0.41)
0.10 (<0.02-0.52)
0.15 (<0.02-0.60)
0.24 (<0.02-0.60)a
0.07 (<0.02-0.38)
3. Undertreated
     Male
     Female
193
126
67
1.53 (0.96-3.73)
1.60 (0.96-4.60)
1.47 (1.11-2.32)
7.64 (1.48-25.00)
9.52 (1.55-27.11)a
5.69 (1.48-17.00)
Results are expressed as medians and ranges. A, androstenedione; 17OHP, 17OH progesterone; URL, 
upper reference limit. a Significant difference between male and female; p <0.05.
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available. The present analysis is based on the same, accurate and validated steroid 
hormone assays throughout the observation period of about 30 years. This method 
employs preliminary solvent extraction and chromatography prior to the 
immunoassay, preventing interference from cross reacting steroids. [10, 17, 18]
 Moderate median glucocorticoid dosages of 11 – 15 mg/m2/day were used, 
which is in line with current international guidelines. [5, 6] Our data show that 
slightly higher dosages of hydrocortisone were needed in boys than in girls and in 
SV than in SW patients to suppress adrenal androgens. Probably, in these patients 
higher hydrocortisone dosages were necessary to normalize the chronically activated 
pituitary adrenal axis. Bonfig et al.  [21]  advised not to exceed the hydrocortisone 
dosage above 17 mg/m2/day during puberty as supraphysiological dosages of 
 glucocorticoids may have adverse effects on pubertal growth and final height. 
The balance between overtreatment and undertreatment is still a clinical challenge.
 During prepuberty A and 17OHP levels remained constant with no sex-related 
differences. In healthy children adrenarche starts around 6 years of age, initiated by 
an increase in CYP17 activity within the adrenal cortex. Especially the 17,20-lyase 
component of the CYP17 enzyme is enhanced due to increase in cytochrome B5 
activity that serves as a co-factor for 17,20-lyase. Consequently, adrenal androgen 
production [DHEA(S), and A] increases with a decrease in 17OHP/A ratio during 
childhood. Our data showed no change of the 17OHP/A ratio, suggesting no increase 
in CYP17 activity and therefore absence of clear adrenarche in CAH patients, 
corresponding to other studies. [22, 23] Chronic hydrocortisone treatment may 
suppress the zona reticularis activation with consequently absence of adrenarche.
 Significant increases of salivary A and 17OHP levels were observed during 
puberty indicating gonadal activity and steroid production within the testes or 
ovaries. The pattern of A and 17OHP changes in CAH patients should be compared 
with a reference population of healthy children, categorised by sex and age or 
Tanner stage. Our reference values were not detailed in this respect. In the literature 
few reports are available on serum and even less on saliva reference values. [9, 24 
– 26] Additionally, there is a lack of international standardisation of A and 17OHP 
assays, cross-reactivity in immunoassays causing overestimation, and use of different 
techniques (i.e., immunoassay vs. LC-MS/MS), complicating comparison of studies.
 Kushnir et al. [25] studied morning serum A levels in more than 2500 healthy 
children. Concentrations of A increased during puberty reaching a maximum at the 
age of 20 – 30  years and gradually declining afterwards. In smaller studies (n = 132 
– 337) comparable changes of A and 17OHP in serum or saliva were found during 
puberty versus childhood. [9, 24, 26] Kushnir et al. [25]  observed that serum A levels 
reached adult values at Tanner stage 3 for girls and at Tanner stage 4 – 5 for boys. 
Our results in CAH patients correspond with the findings of Kushnir et al. [25] that A 
levels increase sooner in girls reflecting earlier gonadal maturation. [27] This 
51
3
SALIVARY STEROID LEVELS IN CLASSIC CAH
suggests that reference values of A and 17OHP based on Tanner stage rather than 
age should be used for the monitoring of glucocorticoid therapy in CAH patients.
 In the literature, serum A levels are about 2 – 3 times higher in healthy females 
than in males during the age period of 12 – 19 years. [9, 25, 26] In our CAH patients 
no sex-related differences in A levels were visible when categorized by pubertal 
stage. This may be explained by the contribution of elevated A levels representing 
undertreatment in the overall group. Accordingly, we found gender-related 
differences in the levels of 17OHP during puberty with higher 17OHP in boys than 
in girls, whereas no gender-related differences of 17OHP were described in healthy 
pubertal subjects. [9, 24 – 26] When only the subgroup with levels suggesting 
optimal treatment was considered, A levels were higher in girls than in boys during 
puberty corresponding to the literature. [9, 25, 26] The sex-related difference of 
17OHP levels, though, was still present.
 According to clinical guidelines A levels should be normalized by treatment, 
but 17OHP levels within the normal range indicate overtreatment. [5, 6] We found 
normalized A levels associated with 17OHP levels three times URL during prepuberty 
and 4 – 6 times URL during puberty. A levels suggesting undertreatment were up to 
two times URL in combination with 17OHP levels ≥10 times URL during prepuberty 
and puberty. The percentage of A levels representing undertreatment was 16% 
during the age interval of 4 – 8 years and increased to 31% for girls at 16 years and 
46% for boys at 17 years of age, suggesting less adrenal suppression during puberty. 
[13, 27] Several studies indicated that the cortisol clearance rate increases during 
puberty due to either inhibition of the activity of 11β hydroxysteroid dehydrogenase 
type 1 or 5α-reductase activity. [13, 27, 28] In CAH patients these changes may 
result in decrease of cortisol concentrations, subsequently inadequate suppression 
of the adrenal gland and increased production of 17OHP and A. Lack of compliance 
may further contribute to increases in adrenal androgen levels. During puberty, 
adherence to medical therapy is more difficult due to psychosocial factors. 
Hirsutism and acne may be important drives for girls to better adhere to medical 
therapy than boys. Moreover, the presence of testicular adrenal rest tumours in 
boys may contribute to enhanced production of 17OHP.  [29] Further studies are 
necessary to investigate this hypothesis.
 It is important to note that in the clinical laboratory liquid chromatography- 
tandem mass spectrometric methods (LC-MS/MS) are replacing immunoassays for 
steroid analysis. Various LC-MS/MS methods on serum A and 17OHP are described 
[9, 25, 26, 30], but only very few reports on salivary A or 17OHP are available. [31, 
32] High sensitivity is needed as concentrations in saliva are low. Future research is 
needed to extrapolate our results to LC-MS/MS methods.
 In summary, the ratio 17OHP/A remained constant during prepuberty suggesting 
the absence of adrenarche. During puberty, A and 17OHP levels increased at an 
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earlier age in girls than in boys, suggesting that reference values of A and 17OHP 
based on Tanner stage rather than age should be used for the monitoring of 
glucocorticoid therapy in pediatric CAH patients. Normalized A levels in combination 
with 17OHP three times URL during prepuberty and normalized A levels in 
combination with 17OHP 4 – 6 times URL during puberty could be obtained with 
moderate glucocorticoid dosages of 11 – 15 mg/m2/day. A levels suggesting 
undertreatment were up to two times URL, while 17OHP levels were ≥ 10 times URL 
during prepuberty and puberty. During puberty the highest percentage of androgen 
levels consistent with undertreatment was found in boys of 17 years of age.
53
3
SALIVARY STEROID LEVELS IN CLASSIC CAH
References
1.  Huynh T, McGown I, Cowley D, Nyunt O, Leong GM, Harris M, et al. The clinical and biochemical 
spectrum of congenital adrenal hyperplasia secondary to 21-hydroxylase deficiency. Clin Biochem Rev 
2009;30:75 – 86.
2. Dauber A, Kellogg M, Majzoub JA. Monitoring of therapy in congenital adrenal hyperplasia. Clin Chem 
2010;56:1245 – 51.  
3.  Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005;365:2125 – 36.
4.  Kim MS, Ryabets-Lienhard A, Geffner ME. Management of congenital adrenal hyperplasia in infancy. 
Curr Opin Endocrinol Diabetes Obes 2012;19:483 –8.
5.  Clayton PE, Miller WL, Oberfield SE, Ritzen EM, Sippell WG, Speiser PW. CAH working group. Consensus 
statement on 21-hydroxylase deficiency from the European Society for pediatric endocrinology and 
the Lawson Wilkins Pediatric Endocrine Society. Horm Res 2002;58:188 – 95.
6.  Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia 
due to steroid 21 hydroxylase deficiency. An Endocrine Society clinical practice guideline. J Clin 
Endocrinol Metab 2010;95:4133 – 60.  
7.  Merke DP, Bornstein SR, Avila NA, Chrousos GP. NIH conference. Future directions in the study and 
management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Int Med 
2002;136:320 – 34.
8.  Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003;349:776 – 88.
9.  Rauh M, Gröschl M, Rascher W, Dörr HG. Automated, fast and sensitive quantification of 17α -hydroxy-
progesterone, androstenedione and testosterone by tandem mass spectrometry with on-line 
extraction. Steroids 2006;71:450 – 8.
10.  Otten BJ, Wellen JJ, Rijken JC, Stoelinga GB, Benraad Th J. Salivary and plasma androstenedione and 
17-hydroxyprogesterone levels in congenital adrenal hyperplasia. J Clin Endocrinol Metab 1983;57:1150 – 4.
11.  Lewis JG. Steroid analysis in saliva: an overview. Clin Biochem Rev 2006;27:39 – 46.
12.  Wood P. Salivary steroid assays  –  research or routine ?  Ann Clin Biochem 2009;46:183 – 96.
13.  Charmandari E, Brook CG, Hindmarsh PC. Why is management of patients with classical congenital 
adrenal hyperplasia more difficult at puberty ?  Arch Dis Child 2002;86:266 – 9.
14.  Miller WL. Clinical review 54: genetics, diagnosis, and management of 21-hydroxylase deficiency. J Clin 
Endocrinol Metab 1994;78:241 – 6. 
15.  Claahsen-van der Grinten HL, Stikkelbroeck NM, Otten BJ, Hermus AR. Congenital adrenal hyperplasia 
–  pharmacologic interventions from the prenatal phase to adulthood. Pharmacol Therapeut 2011;132:1 – 14. 
16.  Bailey BJ, Briars GL. Estimating the surface area of the human body. Stat Med 1996;15:1325 – 32.   
17.  Smals AG, Kloppenborg PW, Pieters GF, Losekoot DC, Benraad TJ. Basal and human chorionic 
gonadotropin stimulated 17α-hydroxyprogesterone and testosterone levels in Klinefelter’s syndrome. J 
Clin Endocrinol Metab 1978;47:1144 – 7.  
18.  Wellen JJ, Smals AG, Rijken JC, Kloppenborg PW, Benraad TJ. Testosterone and delta4-androstenedi-
one in the saliva of patients with Klinefelter’s syndrome. Clin Endocrinol (Oxf) 1983;18:51 – 9.
19.  Stikkelbroeck NM, Sweep CG, Braat DD, Hermus AR, Otten BJ. Monitoring of menstrual cycles, 
ovulation, and adrenal suppression by saliva sampling in female patients with 21-hydroxylase deficiency. 
Fertil Steril 2003;80:1030 – 6.
20.  Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight 
velocity, and stages of puberty. Arch Dis Child 1976;51:170 – 9.  
21.  Bonfig W, Bechtold Dalla Pozza S, Schmidt H, Pagel P, Knorr D, Schwarz HP. Hydrocortisone dosing 
during puberty in patients with classical congenital adrenal hyperplasia: an evidence based 
recommendation. J Clin Endocrinol Metab 2009;94:3882 – 8.
22.  Brunellli VL, Chiumello G, David M, Forest MG. Adrenarche does not occur in treated patients with 
congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 
1995;42:461 – 6.
23.  Völkl TM, Öhl L, Rauh M, Schöfl C, Dörr HG. Adrenarche and puberty in children with classic congenital 
adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res Paediatr 2011;76:400 – 10.
54
CHAPTER 3
24.  Dressendorfer RA, Strasburger CJ, Bidlingmaier F, Klug I, Kistner A, Siebler T, et al. Development of a 
highly sensitive non-isotopic immunoassay for the determination of salivary 17-hydroxyprogesterone: 
reference ranges throughout childhood and adolescence. Pediatric Res 1998;44:650 – 5.  
25.  Kushnir MM, Blamires T, Rockwood AL, Roberts WL, Yue B, Erdogan E, et al. Liquid chromatography- 
tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone 
with pediatric and adult reference intervals. Clin Chem 2010;56:1138 – 47.
26.  Kyriakopoulou L, Yazdanpanah M, Colantonio DA, Chan MK, Daly CH, Adeli K. A sensitive and rapid 
mass spectrometric method for the simultaneous measurement of eight steroid hormones and 
CALIPER pediatric reference intervals. Clin Biochem 2013;46:642 – 51.
27.  Charmandari E, Brook CG, Hindmarsh PC. Classic congenital hyperplasia and puberty. Eur J Endocrinol 
2004;151:U77 – 82.
28.  Wudy SA, Hartmann MF, Remer T. Sexual dimorphism in cortisol secretion starts after age 10 in healthy 
children: urinary cortisol metabolite excretion rates during growth. Am J Physiol Endocrinol Metab 
2007;293:E970 – 6.
29.  Claahsen-van der Grinten HL, Hermus AR, Otten BJ. Testicular adrenal rest tumours in congenital 
adrenal hyperplasia. Int J Pediatr Endocrinol 2009;624823.  
30.  Fanelli F, Belluomo I, Di Lallo VD, Cuomo G, De Iasio R, Baccini M, et al. Serum steroid profiling by 
isotopic dilution-liquid chromatography-mass spectrometry: comparison with current immunoassays 
and reference intervals in healthy adults. Steroids 2011;76:244 – 53.
31.  Turpeinen U, Hämäläinen E, Haanpää  M, Dunkel L. Determination of salivary testosterone and andro-
stenedione by liquid chromatography-tandem mass spectrometry. Clin Chim Acta 2012;41:594 – 9.
32.  Shibayama Y, Higashi T, Shimada K, Kashimada K, Onishi T, Ono M, et al. Liquid chromatography- 
tandem mass spectrometric method for determination of salivary 17alpha-hydroxyprogesterone: 
a noninvasive tool for evaluating efficacy of hormone replacement therapy in congenital adrenal 
hyperplasia. J Chromatogr B Analyt Technol Biomed Life Sci 2009;967:48 – 56.
55
3
SALIVARY STEROID LEVELS IN CLASSIC CAH

Chapter 4
Long term follow-up of 
children with classic congenital  
adrenal hyperplasia: time for more 
age-specific treatment strategies?
Pijnenburg-Kleizen KJ, Thomas CM, Otten BJ, Roeleveld N, 
Claahsen-van der Grinten HL. Submitted.
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Abstract
Background In congenital adrenal hyperplasia (CAH), achieving the balance 
between overtreatment and undertreatment remains challenging. Final height (FH) 
serves as a long term outcome measure. We aimed to identify age-specific factors 
that contribute to FH. 
Methods We retrospectively evaluated longitudinal data of 39 pediatric CAH patients. 
We analyzed height and bone age at diagnosis or 4 years of age, at the start of 
puberty, and at FH. Height data were corrected for parental height and secular 
trend. Hydrocortisone use and salivary steroid levels were studied longitudinally 
throughout childhood and puberty. 
Results Median FHSDS corrected for target height SDS (THSDS) was -1.63. In simple 
virilizing CAH, median height SDS corrected for THSDS (HSDS-THSDS) decreased 
from -0.1 SD (females) and +2.7 SD (males) at diagnosis to -1.93 SD (females) and 
-1.92 SD (males) at FH. In salt-wasting CAH, HSDS-THSDS decreased from -0.04 SD 
(females) and -0.78 SD (males) at 4 years of age to -0.79 SD (females) and -1.27 SD 
(males) at FH. However, when height was corrected for bone age, no height loss 
occurred from diagnosis or age 4 years to FH in any of the subgroups. Hydrocortisone 
dose and FH were negatively associated throughout childhood and puberty, as well 
as androstenedione levels and FH in childhood, but not in puberty. 
Conclusions In CAH, loss of growth potential already occurs in early childhood. In 
prepubertal children, exposure to elevated androgens is associated with decreased 
FH. In puberty, the growth suppressing effects of HC outweigh the negative effects 
of elevated androgens. Therefore, we suggest different treatment approaches in 
prepubertal and pubertal patients.
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Introduction 
Congenital adrenal hyperplasia (CAH) is caused by a deficiency of one of the 
enzymes involved in adrenal steroid synthesis, in most cases 21-hydroxylase. This 
results in impaired synthesis of cortisol. Due to reduced negative feedback to the 
hypothalamus and pituitary gland, the pituitary secretion of ACTH is increased. 
Consequently, steroid hormone precursors prior to the enzymatic block accumulate 
and are shunted into the androgen-synthesis pathway. [1] CAH represents a continuum 
of disease, depending on the severity of the enzyme deficiency. The severe, classic 
form can be subdivided into a salt wasting (SW) and a simple virilising (SV) subtype, 
both with severe cortisol deficiency. Patients with SW-CAH have a residual enzyme 
activity of <1% leading to additional aldosterone deficiency. A residual enzyme 
activity of 1-2% ensures sufficient aldosterone production to prevent severe salt 
loss, and results in SV-CAH. The non classic form (NC-CAH) is milder, with a residual 
enzyme activity of 20-50%. In NC-CAH, basal cortisol and aldosterone levels are 
usually normal.  Androgens are still slightly elevated which may lead to clinical 
signs, such as premature pubarche, hirsutism and menstrual disturbances. [1] 
The treatment of classic CAH consists of lifelong use of glucocorticoids and if necessary 
also mineralocorticoids to prevent adrenal and salt wasting crises. The glucocorticoids 
suppress the secretion of adrenal androgens due to decreased ACTH release. 
However, supraphysiological doses are usually necessary to suppress ACTH and 
consequently androgen production. [2] Since both over- and undertreatment may 
influence patient outcomes negatively, glucocorticoid treatment in CAH is a 
balancing act. Undertreatment results in chronically elevated adrenal androgens 
leading to premature epiphyseal maturation and a reduced final height. [3] 
Overtreatment may result in cushingoid features, hypertension, and osteoporosis. 
It may also reduce final height due to a reduction of growth hormone secretion 
and action, by a disturbance of calcium metabolism and by direct effects on the 
growth plate. [2, 4, 5] In clinical practice, both over- and undertreatment are 
common. [6] Despite the increasing understanding of pathophysiological 
mechanisms and the development of guidelines for clinical practice, [2] questions 
remain on how to optimize the care of CAH children, and monitoring and treatment 
strategies differ between treatment centers. [2, 4] 
Careful monitoring of treatment is an important aspect of the care of children with 
21-hydroxylase deficient CAH. The levels of the adrenal steroid precursors 
 17-hydroxyprogesterone (17OHP) and androstenedione (A) are used as markers for 
long term follow-up. These precursors can be measured in blood, urine, saliva, or 
dried filter paper blood samples. [4] In our center, we introduced salivary 17OHP 
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and A measurements as a routine monitoring tool for CAH patients more than 
30 years ago. Saliva collection is non-invasive and less stressful than taking blood 
samples, especially in pediatric patients. Samples can be collected at home several 
times per day reflecting the diurnal rhythm of steroid levels. Previous research showed 
that salivary levels of 17OHP and A reflect plasma steroid levels reliably. [7-9]  
In this study, we retrospectively evaluated the monitoring and treatment strategy in 
our pediatric CAH population over the past 30 years. We evaluated longitudinal 
data from diagnosis to final height regarding corticosteroid use, salivary steroid 
levels and growth. We aimed to determine age-specific characteristics and define 
treatment recommendations, to improve long term clinical outcome. 
Patients and methods
Patients
For this retrospective evaluation, we used the longitudinal Radboudumc CAH 
database. Longitudinal data have been collected for all CAH patients treated at the 
department of pediatric endocrinology of the Radboud university medical center, 
Nijmegen, the Netherlands, born from 1957 onwards (216 patients in total). 
The database contains data on mutation analysis and parental height, longitudinal 
data on height, weight, Tanner stages and doses of glucocorticoid and mineralo-
corticoid medication (nearly 6000 visits to the outpatient clinic), bone age 
(approximately 1500 occasions), and salivary steroid profiles (17OHP and A) at 
nearly 4000 occasions. 
 Patients were included in this study if they were diagnosed with classic CAH 
due to 21-hydroxylase deficiency, were born between 1980 and 1997, and were 
treated in our hospital from early childhood onwards with at least annual visits to 
our outpatient clinic. We limited the inclusion to patients born between 1980 and 
1997 because salivary steroid measurements were introduced in the early 1980’s 
and the method for analysis did not change during this time period.
 In this historical cohort, the patients were not diagnosed by neonatal screening 
since the Dutch CAH screening program was not implemented until the year 2002. 
The diagnosis of SW-CAH or SV-CAH was based on clinical and biochemical data 
and confirmed by mutation analysis. The CYP21A2 mutations were categorized into 
different mutation groups based on in vitro 21-hydroxylase activity: groups null (0%), 
A (0-1%), B (1-5%), and C (20-50%). [10] Mutations in groups null and A are associated 
with SW-CAH, group B with SV-CAH, and group C with NC-CAH. The phenotype is 
usually determined by the least severe mutation. In case of discrepancy between 
phenotype and genotype, patients were classified according to their phenotype. 
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Patients with NC-CAH were excluded because of the variation in treatment 
strategies in these patients. Patients with co-morbidity or using additional medication 
that might influence final height were also excluded. No informed consent was 
obtained because of the retrospective analysis of de-personalized data. 
The Radboudumc pediatric CAH treatment and monitoring protocol
All patients are treated with hydrocortisone (HC), generally below 15 mg/m2/day, 
divided in three daily doses with the highest dose in the evening. The patients visit 
the outpatient clinic every 3-4 months. Before each visit, patients collect saliva 
samples at home, three times during one day before taking their HC. The saliva is 
purified by paper chromatography and 17OHP and A are measured by in-house 
radioactive immunoassays as previously described. [11] Based on the results we 
adjust the HC dose, with the aim to decrease the A levels to within age- and sex- 
appropriate reference ranges without completely suppressing 17OHP levels to 
avoid overtreatment. [2] During each visit, height, weight, and blood pressure 
are recorded. Bone age (BA) assessment is performed yearly until final height 
is reached.
Data collection and definition
From the Radboudumc CAH database the following data were collected:
- Gender
- Mutation analysis and clinical data
- Age, height, and BA at diagnosis in SV-CAH patients, at the age of 4 years in 
SW-CAH patients, and at the start of puberty in all patients. The start of puberty 
was defined as Tanner stage M2 in girls and a testicular volume of ≥ 4 ml in boys. 
Height SDS (HSDS) was calculated using the 1997 Dutch growth study reference 
values. [12] Furthermore, HSDS was corrected for BA. BA was corrected for 
calendar age (BA-CA). 
- Final height (FH), defined by less than 0.5 cm growth in the previous 12 months 
or by a BA >17 years. Final height SDS (FHSDS) was calculated using the 1997 growth 
study reference values. The formulas used were FHSDS = (final height in cm – 
184)/7.1 for males, and FHSDS = (final height in cm – 170.6)/6.5 for females. [12]
- Parental height, used to calculate target height (TH) with the 1997 growth study 
formulas, which also account for secular trend. For males: TH in cm = (paternal 
height in cm + maternal height in cm + 13)/2 + 4.5. For females: TH in cm = 
(paternal height in cm + maternal height in cm - 13)/2 + 4.5. [12] Target height 
SDS (THSDS) was calculated using the same formulas as used for FHSDS. In the 
analyses, all height data were corrected for target height: HSDS-THSDS and 
FHSDS-THSDS. 
- Weight at FH. Body mass index (BMI) was calculated as weight(kg)/height(m)2. 
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- Glucocorticoid doses. HC doses were recorded from the age of four years until 
the patient reached FH. They were expressed as mg/m2/day. Mineralocorticoid 
use was not recorded because of the expected limited effects on our treatment 
outcome measures. 
- Salivary steroid measurements. All morning measurements of 17OHP and A were 
recorded from the age of four years until the patient reached FH. For SV-CAH 
patients, the salivary steroid measurements in the first three months after 
diagnosis were not used for analysis since the levels in this stage are more likely 
to represent disease activity than treatment effect. SD scores for 17OHP (17OHP 
SDS) and A (A SDS) levels were calculated for each patient to reflect variability in 
hormonal control. 
Statistical analysis
Descriptive analyses were performed to check the age and growth data for normal 
distributions. Because of the small numbers in the subgroups by gender and CAH 
subtype, all of these data were presented as medians plus ranges. Kruskal-Wallis 
and Mann-Whitney U tests were used to test differences among the groups, with 
p-values <0.05 being considered statistically significant. To take full advantage of 
the continuously recorded HC doses and the many salivary steroid measurements, 
while accounting for differences in the numbers of measurements among patients, 
we performed linear mixed model analyses to estimate the mean daily HC doses 
and the mean steroid levels with 95% confidence intervals (CI) for all patients, as 
well as separately by gender, subtype, and time period (childhood vs. puberty). 
Linear regression analyses, weighted for the square root of the number of 
measurements, were used to assess the effects of individual mean HC dose and 
steroid levels as well as their variability on final height (FHDSD-THSDS). If needed, 
the regression models were adjusted for the covariables HC dose, gender, CAH 
subtype, age at start puberty, and triptorelin use. All statistical analyses were 
performed using SPSS for Windows version 22 (IBM SPSS Inc., Chicago, IL, USA). 
Results
Patient characteristics
The data of 77 CAH patients born between 1980 and 1997 were recorded in the 
Radboudumc CAH database. 8 patients were excluded because of a different 
enzymatic defect than 21-hydroxylase (11β hydroxylase- (n=5) and 3β hydroxysteroid 
dehydrogenase deficiency (n=3)) and 17 patients because of NC-CAH. Of the 52 
patients with classic 21-hydroxylase deficiency, 2 patients were excluded because 
of relevant co-morbidity (severe spasticity and anorexia nervosa) and 10 patients 
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because of limited data and possible different treatment strategies in the first years 
of life, as they were diagnosed and treated elsewhere up to 8 years of age or older. 
In one additional patient, there was a lack of salivary steroid measurements due to 
non-compliance. This resulted in 39 CAH patients being eligible for inclusion in our 
study: 18 female and 21 male patients. 25 patients were classified as SW (12 female, 
13 male) and 14 patients were classified as SV (6 female, 8 male) based on their 
genotype and phenotype (Supplemental Table 1). In one patient, marker analysis was 
performed prenatally and DNA analysis was not performed after birth. The clinical 
picture in this patient was consistent with SW-CAH. In 3 patients, genotype and 
phenotype were not consistent. They were classified according to their phenotype 
(2 SV, 1 SW). 
Age, height, and bone age at diagnosis and at the age of 4 years
Of the 25 SW-CAH patients, 24 were diagnosed neonatally because of ambiguous 
genitalia and/or salt wasting crises. One boy with SW-CAH was diagnosed at the 
age of two years. Neonatally he was diagnosed with posterior urethral valves and 
his salt wasting was initially attributed to secondary pseudohypoaldosteronism. The 
clinical course in this patient was described in more detail elsewhere. [13] In the 
SW-CAH patients, at the age of 4 years the HSDS-THSDS was -0.04 in girls (range 
-2.82 – 0.94) and -0.78 in boys (range -1.59 – 2.03) (Figure 1a, Table 1). However, 
HSDS corrected for BA and THSDS was -1.30 in girls (range -4.07 – 1.70) and -1.01 
in boys (range -3.39 – 1.82) (Figure 1b, Table 1).
 Female SV-CAH patients were diagnosed earlier than male SV-CAH patients, at 
a median age of 2.3 years (range 0-4.0 years) compared to a median of 4.4 years 
(range 2.5-6.3 years). Bone age advancement was more pronounced in SV-CAH 
boys (+5.8 years). Median HSDS-THSDS at diagnosis in SV-CAH patients was -0.08 
in girls (range -1.41 – +3.30) and +2.69 in boys (range +1.88 – +4.90) (Figure 1a, 
Table 1). However, HSDS corrected for BA and THSDS was -1.97 (range -3.93 - -1.05) 
in females and -3.52 (range -4.56 - -1.63) in males (Figure 1b, Table 1).
Age, height, and bone age at start of puberty 
Puberty started at a median age of 9.6 years (range 7.8-13.2 years) in females and 
11.3 years (range 7.3-13.8 years) in males. Eleven patients (28%) were treated with 
triptorelin to delay puberty in an attempt to improve final height. The median 
HSDS-THSDS at start of puberty showed clear differences between boys and girls 
(p=0.01), but not between CAH subtypes (p=0.63) (Figure 1a, Table 1). Median 
BA-CA was most advanced in male SV-CAH patients (+2.6 years).  Median HSDS 
corrected for BA and THSDS was less favorable for SV-CAH patients compared to 
SW-CAH patients, although the HSDS for the SV patients improved compared to 
those at diagnosis (Figure 1b, Table 1). 
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Final height
Median FHSDS-THSDS was -1.63 (range -2.85 - -0.21) for the entire cohort, with 
clear differences between the CAH subtypes (p=0.01) (Figure 1, Table 1). The female 
SW-CAH patients reached a FHSDS-THSDS closest to their genetic potential, 
median -0.79 SDS, while the median FHSDS-THSDS in male SW-CAH patients was 
-1.27 SDS.  The median FHSDS-THSDS was almost -2 SDS in both male and female 
SV patients. 
BMI
The median BMI at FH was 21.5 kg/m2 (range 18.7-31.6 kg/m2). No differences were 
observed between males and females and between subtypes. Associations 
between BMI and FH, HC dose, 17OHP level, and A level were not observed (data 
not shown). 
Hydrocortisone use
The median number of HC doses recorded per patient was 39 with a range of 
18-51. From the mixed model analysis, the mean daily HC dose for the entire group 
of patients was estimated to be 12.7 mg/m2/day (95% CI 11.7-13.7) (Table 2). SV-CAH 
patients were treated with higher doses of hydrocortisone than SW-CAH patients 
(14.8 vs. 11.5 mg/m2/day; p=0.001). No clear differences were seen between male 
and female CAH patients (13.3 vs. 12.0 mg/m2/day; p=0.21) or between doses 
received in childhood and puberty (12.7 vs. 12.9 mg/m2/day; p=0.18). 
Salivary steroid measurements
For both 17OHP and A, a median of 31 (range 14-50) measurements were available 
per patient. The mean salivary 17OHP levels were lower in childhood than in 
puberty (p=0.000) without clear differences between males and females (p=0.20) 
and between CAH subtypes (p=0.11). The levels of 17OHP varied between 3 and 13 
times the upper limit of the age- and gender-appropriate reference ranges (Table 2). 
The salivary A levels were also lower in childhood than in puberty (p=0.000), and 
did not differ between gender and subtypes. The mean A levels were within age- 
and gender-appropriate reference ranges, except for male pubertal patients. In these 
patients, the A levels were slightly above the upper limit of the reference ranges. 
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Figure 1b  Height SDS corrected for bone age (BA) and target height SDS at diagnosis 
(SV-CAH) or at 4 years of age (SW-CAH), at Tanner stage 2 and at final height.
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Figure 1a  Height SDS corrected for target height SDS at diagnosis (SV-CAH) or at 
4 years of age (SW-CAH), at Tanner stage 2, and at final height.
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Associations between hydrocortisone doses, salivary steroid levels, 
and final height
Both in childhood and in puberty, each additional mg/m2/day of HC (averaged over 
the time period) was associated with a reduction in final height of -0.13 SDS (Table 3). 
Other variables included in the statistical model (gender, CAH subtype, age at start 
puberty and triptorelin use) did not influence the results (data not shown). 
 Small but statistically significant negative associations were seen between daily 
HC doses and salivary 17OHP and A levels in childhood (-0.16, p=0.00 and -0.01, 
p=0.00, respectively), whereas these associations were positive in puberty (for 
17OHP +0.24, p=0.01 and for A +0.03, p=0.05). 
 In childhood, negative associations were observed between both 17OHP levels and 
17OHP variability (17OHP SDS) and FHSDS-THSDS (-0.30, p=0.01 and -0.16, p=0.05). 
However, when HC dose was included in the statistical model, the association 
disappeared and only the associations with HC dose were statistically significant 
(Table 3). In puberty, the associations between FHSDS-THSDS and 17OHP levels 
and 17OHP variability were less strong and also disappeared completely when the 
results were adjusted for HC dose. For A, strong negative associations with FHSDS- 
THSDS were seen in childhood for both A levels and A variability, which were only 
slightly reduced by adjustment for HC dose, CAH subtype, and age at start of 
puberty. The initial slight associations between FHSDS-THSDS and A levels and 
A variability in puberty disappeared after adjustment for covariables. 
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Table 3   Associations of daily hydrocortisone dose (HC) and salivary steroid levels 
(17OHP and androstenedione, A) and the amount of variability in these 
levels (17OHP SDS and A SDS) with final height (FHSDS-THSDS).
FHSDS-THSDS p
Childhood
HC dose - 0.13 0.00
17OHP level -0.30 0.01
       Adjusted model:
       17OHP level
       HC dose 
-0.14
-0.11
0.22
0.01
17OHP SDS -0.16 0.05
       Adjusted model:
       17OHP SDS
      HC dose
-0.04
-0.12
0.57
0.00
A level -3.58 0.00
      Adjusted model:
      A level
      HC dose
-2.88 *
-0.07
0.03
0.12
A SDS -3.75 0.01
      Adjusted model:
      A SDS
      HC dose
-2.99 *
-0.07
0.01
0.12
Puberty
HC dose - 0.13 0.00
17OHP level -0.08 0.05
      Adjusted model:
      17OHP level
      HC dose 
-0.03
-0.10
0.42
0.01
17OHP SDS -0.07 0.08
      Adjusted model:
      17OHP SDS
      HC dose
-0.02
-0.011
0.66
0.01
A level -0.27 0.07
      Adjusted model:
      A level
      HC dose
-0.17 *
-0.09
0.24
0.04
A SDS -0.46 0.06
      Adjusted model:
      A SDS
      HC dose
-0.23 *
-0.09
0.33
0.04
All results represent the amount of change in final height (FHSDS-THSDS) associated with one mg/m2/day 
increase in HC dose or one unit change in steroid level (averaged over the time period). The adjusted 
models always included both the steroid levels and hydrocortisone (HC) dose, while the adjusted models 
for A also included: * CAH subtype and age at start puberty.
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Discussion
This study describes longitudinal data on glucocorticoid use, hormonal control, 
and height outcome in a unique single centre cohort of uniformly treated pediatric 
classic CAH patients regularly monitored by salivary steroid measurements. 
Although several studies previously reported reduced final height in CAH patients, 
[14-18] we report final height data corrected for both target height and secular 
trend in a homogenously treated cohort of CAH patients. When secular trend is not 
accounted for, height outcomes will be overestimated. Therefore, we consider our 
results to be a reliable representation of actual final height outcomes. Furthermore, 
we were able to define specific patterns related to age and CAH subtype. We 
showed that evaluating growth by using height measurement only is insufficient: by 
correction of the height for bone age as an additional method to describe growth 
and maturation, we unmasked a striking loss of growth potential in early childhood 
not visible in the regular growth charts. During puberty, no further loss of HSDS 
occurred. 
 As described in previous studies, FH was more reduced in SV-CAH patients 
compared to SW-CAH patients. [14, 16] This is most likely due to delayed diagnosis 
and treatment, resulting in more prolonged exposure to elevated androgen levels 
and consequently an advanced BA. The neonatal screening program that has been 
implemented widely, primarily to reduce salt wasting crises in SW-CAH patients, 
also detects SV-CAH patients. This may be beneficial for the long term height 
outcome in SV-CAH by shortening the period of elevated androgen exposure. [16] 
In SV-CAH patients, higher HC doses were needed to adequately suppress the 
androgen overproduction compared to SW-CAH patients, which also contributed 
to the more reduced FH. In the SW-CAH patients in our study however, FH was still 
slightly reduced despite early diagnosis and moderate HC doses. Current guidelines 
recommend HC doses between 10 and 17 mg/m2/day in growing CAH patients. [2, 
4] Our results show that even in these moderate supraphysiological doses a growth 
suppressing effect may occur. [14, 19-22] It seems that especially in puberty the 
growth suppressing effect of HC may outweigh the negative effect of increased 
androgen levels. 
 In childhood however, the A levels and the variability in these levels showed 
strong negative associations with FH. In our initial analyses, FH was also negatively 
associated with the salivary 17OHP, but these effects disappeared when 
glucocorticoid doses were taken into account. Therefore, in childhood the most 
important risk factor for reduced final height was elevated A levels, in contrast to 
puberty where the amount of glucocorticoids was more influential. 
 Based on these results, we suggest that treatment goals should be more 
specified according to age to find the optimal balance in growth and maturation. 
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During childhood, the main focus should be on adequately suppressing A levels 
without completely suppressing 17OHP, thereby preventing an advancement of 
bone maturation. During puberty, the main aim should be to avoid higher doses of 
glucocorticoids even when the A levels are not completely suppressed. 
 Previously, it has been argued that glucocorticoid doses need to be increased 
during puberty in CAH patients because of the alterations in glucocorticoid 
metabolism. [4, 23]  Our results do not support this hypothesis. In pubertal patients, 
salivary A levels remained mostly within the age appropriate reference ranges 
without routinely increasing the HC dose. Moreover, our results suggest that the 
currently advised doses of glucocorticoids may already have negative effects on 
final height. Therefore, we suggest being cautious with increasing the dose of 
glucocorticoid medication in puberty, since the detrimental effects may outweigh 
the benefits. 
In this study, we did not describe growth patterns in infants with CAH. We previously 
showed that growth velocity and bone maturation were not increased in the first 
year of life in untreated CAH patients, implying that the growth in the first year is less 
sensitive to androgens. [24] However, the negative effects of supraphysiological 
doses of HC may already occur at this age, since it seems likely that these effects 
are most pronounced when growth velocity is highest. [25, 26] This would lead to 
a cautious attitude towards glucocorticoid dosing in this age group as well. 
Besides the above mentioned strengths of this study, there are some limitations. 
The study was retrospective in nature and the number of patients was relatively 
small. Also, the number of available measurements per patients differed considerably. 
However, by performing mixed model analyses and weighing the linear regression 
analyses for the square root of the number of measurements, we were able to 
account for these differences and make full use of all longitudinal data.  
In conclusion, the glucocorticoid treatment in pediatric CAH patients should be 
tailored to the specific phase of growth and development. Salivary steroid measurements 
in combination with regular measurements of height and BA should be used as 
tools to optimize treatment. In childhood, the main focus should be on preventing 
exposure to increased androgens to prevent bone age advancement. In puberty, 
the attention should be shifted to preventing overtreatment with glucocorticoids.  
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Supplemental table
Supplemental table 1   Mutation analysis of the patients included in this study.
Patients  
per subtype
Mutation allele 1 Mutation 
group
Mutation allele 2 Mutation 
group
Salt wasting
1 Deletion 0 p.Arg356Trp 0
2 Deletion 0 p.Arg356Trp 0
3 Deletion 0 Δ8bp 0
4 Deletion 0 Δ8bp 0
5 Deletion 0 p.Gln318X 0
6 p.Gln318X 0 p.Val281Leu, p.Gln318X, 
p.Arg356Trp
0
7 p.Gln318X 0 p.Val281Leu, p.Gln318X, 
p.Arg356Trp
0
8 Deletion 0 Intron splice A
9 Deletion 0 p.Arg356Trp 0
10 Deletion 0 Δ8bp 0
11 Deletion 0 p.Arg356Trp 0
12 Deletion 0 E6 cluster 0
13 E6 cluster 0 p.Val281Leu, p.Gln318X, 
p.Arg356Trp
0
14 Intron splice 0 p.Arg356Trp 0
15 p.Arg356Trp 0 p.Ile172Asn, p.Gln318X, 
p.Val281Leu, 
p.Leu307PhefsX6 
0
16 p.Arg356Trp 0 p.Arg356Trp 0
17 p.Arg356Trp 0 E6 cluster 0
18 Deletion 0 p.Arg483Pro A
19 Δ8bp 0 E6 cluster 0
20 Deletion 0 Deletion 0
21 Deletion 0 Deletion 0
22 p.Arg356Trp 0 p.Arg356Trp 0
23a Deletion 0 p.Ile172Asn B
24 Deletion 0 Intron splice A
25 Marker analysis prenatally Marker analysis prenatally
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Supplemental table 1   Continued.
Patients  
per subtype
Mutation allele 1 Mutation 
group
Mutation allele 2 Mutation 
group
Simple virilizing
26 p.Ile172Asn B p.Ile172Asn B
27 p.Ile172Asn B p.Gln318X 0
28 p.Ile172Asn B p.Val237Glu, 
p.Met239Lys
0
29 Deletion 0 p.Ile172Asn B
30 p.Ile172Asn B Intron splice A
31 p.Ile172Asn B p.Ile172Asn B
32 p.Ile172Asn B p.Ile172Asn B
33 Deletion 0 p.Ile172Asn B
34 p.Ile172Asn B Δ8bp 0
35 Deletion 0 p.Ile172Asn B
36 Deletion 0 p.Ile172Asn B
37a Deletion 0 Deletion 0
38 Deletion 0 p.Ile172Asn B
39a p.Arg483Pro A Intron splice A
E6 cluster refers to the p.Ile236Asn, p.Val237Glu, and p.Met239Leu mutation cluster at exon 6. Intron splice 
refers to the c.293–13A/C>G mutation. Δ8bp refers to the p.Gly110ValfsX21 mutation.
a In three patients, genotype and phenotype were not consistent. These patients were classified according 
to their phenotype.

Part II
Glucocorticoid and 
mineralocorticoid effects of adrenal 
steroid hormone precursors

Chapter 5
A delayed diagnosis of salt wasting 
congenital adrenal hyperplasia
Pijnenburg-Kleizen KJ, Noordam C, Otten BJ, Claahsen-van der Grinten HL.
Clin Endocrinol. 2016; 85(3): 497-9

81
5
A DELAYED DIAGNOSIS OF SALT WASTING CAH
In patients with salt wasting congenital adrenal hyperplasia (SW-CAH) due to 
21-hydroxylase deficiency synthesis of cortisol and aldosterone is severely impaired. 
Untreated patients have a high morbidity and mortality due to salt wasting crises 
neonatally. The lack of cortisol may lead to life-threatening Addisonian crises later 
in life. We describe a SW-CAH  case where the diagnosis and treatment were 
delayed for several years.  
The patient was born before the introduction of neonatal screening for CAH in the 
Netherlands. He was admitted to the children’s department of our hospital at the 
age of two weeks because of poor feeding, irritability and weight loss. Biochemical 
analysis showed hyperkalemia (7.5 mmol/l; normal values 3.5-4.7 mmol/l), 
hyponatremia (132 mmol/l; normal values 135-145 mmol/l) and inadequately high 
urinary sodium excretion (46 mmol/l; normal values <20 mmol/l). There was no 
hypoglycemia. Initial treatment consisted of salbutamol, sodium polystyrene sulfonate 
and intravenous sodium chloride and glucose.  Urine analysis showed no signs of a 
urinary tract infection. Abdominal  ultrasound and a voiding cystourethrogram 
confirmed the presence of posterior urethral valves.  The electrolyte abnormalities 
were explained by secondary pseudohypoaldosteronism (PHA)  due to obstructive 
uropathy. Additional laboratory studies showed an ACTH of 36.0 pmol/l (normal 
values <11 pmol/l), plasma renin activity of 85 nmol/l/24 h (normal values 1.1 – 20.0 
nmol/l/24 h), 17-hydroxyprogesterone (17OHP) of 520.5 nmol/l (normal values 
0.2-7.4 nmol/l) and androstenedione of 14.0 nmol/l (normal values 0.21-2.79 
nmol/l). The increased concentrations of ACTH, 17OHP and androstenedione were 
(inappropriately) attributed to adrenal stimulation due to physical stress. 
 The urethral valves were surgically resected. No glucocorticoids were prescribed 
during surgery. Afterwards he was discharged home with sodium chloride suppletion 
orally 30 mmol/day. 
 During follow-up the sodium chloride dosage was repeatedly increased 
because of low serum sodium values. At the age of 16 months the patient was 
readmitted because of an acute otitis media. Serum sodium was 126 mmol/l and 
serum potassium was 5.9 mmol/l. No measurements of blood glucose or acid/
base balance were performed. The hyponatremia was attributed to a decreased 
intake of sodium and he received extra sodium chloride orally. 
 At the age of two years he still required sodium chloride supplementation 
to prevent hyponatremia. Additional laboratory studies were performed: ACTH 13 
pmol/l; aldosterone 1.10 nmol/l (normal values 0.1 – 1.7 nmol/l); plasma renin 
activity 20.20 nmol/l/24 h (normal values 1.0 – 6.4 nmol/l/24 h); cortisol 0.09 
umol/l (normal values 0.19-0.55 umol/l); 17OHP 309.80 nmol/l (normal values 
0.2-7.4 nmol/l); androstenedione 4.7 nmol/l (normal values 0.03-1.05 nmol/l). 
He was diagnosed with SW-CAH. The diagnosis was confirmed by mutaton analysis 
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(homozygous R356W mutation in the CYP21A2 gene). There were no clinical signs 
of androgen excess such as an increased growth velocity. He started treatment 
with hydrocortisone and fludrocortisone. The salt supplementation could be 
stopped .
It is well known that the clinical presentation of SW-CAH and PHA in the neonatal 
period overlaps. [1]  In both conditions patients develop hyponatremia, hyperkalemia, 
metabolic acidosis and dehydration due to renal salt wasting. However, the 
underlying mechanisms of renal salt loss differ. PHA is caused by aldosterone 
resistance, secondary to urinary tract pathology or due to mutations in the mineral-
ocorticoid receptor or the epithelial sodium channel. [1] In SW-CAH the 
hyponatremia is caused by a deficiency of aldosterone due to a lack of 21-
hydroxylase, an enzyme involved in the synthesis of aldosterone and cortisol. [2] 
The hyponatremia in our patient was attributed to aldosterone resistance due to his 
obstructive uropathy, although in hindsight the levels of 17OHP and androstenedi-
one were strongly suggestive of SW-CAH. The normal aldosterone level found in 
our patient seems to contradict this, however this is most likely the result of 
cross-reactivity with other, elevated steroids in the laboratory measurement. The 
patient showed persistent hyponatremia but no clinical signs of cortisol deficiency 
even during episodes of surgery and acute illness despite a severe CYP21A2 
mutation resulting in no residual enzymatic activity. [3] 
We hypothesize that this lack of signs of glucocorticoid deficiency  may be partially 
explained by the presence of elevated concentrations of adrenal steroid hormone 
precursors that are characteristic in CAH patients . It has previously been shown 
in vitro that 17OHP and progesterone have agonistic effects on the human 
glucocorticoid receptor and therefore might have glucocorticoid activity. [4] 
We have recently shown that increased levels of 21-deoxycortisol (21DF) can also 
transactivate the human glucocorticoid receptor in vitro at concentrations of only 
approximately six times the concentrations of cortisol, which is lower than the 
concentrations needed for 17OHP and progesterone. [5] Thus 21DF might have 
glucocorticoid properties closer to the potency of cortisol. 21DF is elevated in 
21-hydroxylase deficient CAH patients since it is formed from 17OHP by 
11-hydroxylase exclusively in the adrenal cortex in these patients. In contrast to 
other forms of primary adrenal insufficiency, in CAH patients elevated steroid 
precursors may partially compensate cortisol deficiency. 
Our hypothesis is based on in vitro data of which the clinical relevance has not yet 
been confirmed. There are alternative possible explanations for the lack of signs of 
cortisol deficiency in some CAH patients. For example, in neonates with CAH a 
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shift of the balance of cortisol – cortisone interconversion towards cortisol has 
been demonstrated. [6] This could result in the presence of more active cortisol, 
if the enzyme deficiency is not complete and there is residual cortisol production. 
Further studies are necessary to evaluate the role of adrenal steroid precursors in 
more detail and to determine the clinical relevance. 
In conclusion, we present a patient suffering from posterior urethral valves and 
SW-CAH with a salt wasting crisis but without evident clinical signs of cortisol 
deficiency. The diagnosis SW-CAH was delayed for two years due to an initial 
diagnosis of secondary PHA. We hypothesize that increased concentrations of 
adrenal steroid hormone precursors such as 21DF and 17OHP with agonistic effects 
on the human glucocorticoid receptor may partially compensate for cortisol 
deficiency. 
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Abstract
Background Congenital adrenal hyperplasia (CAH) patients are clinically often less 
severely affected by cortisol deficiency than anticipated from their enzymatic 
defect. We hypothesize that adrenal steroid hormone precursors that accumulate 
in untreated or poorly controlled CAH have glucocorticoid activity and partially 
compensate for cortisol deficiency. We studied the in vitro effects of 17-hydroxy-
progesterone (17OHP), progesterone (P), 21-deoxycortisol (21DF) and androstene-
dione (A) on the human glucocorticoid receptor (hGR).
Methods Competitive binding assays were performed in HeLa cells. Nuclear 
translocation of the hGR was studied by transfection of COS-7 cells with a 
GFP-tagged hGR and fluorescence microscopy. Transactivation assays were 
performed in COS-7 cells and in HEK 293 cells after co-transfection with hGR and 
luciferase reporter vectors using a dual luciferase assay. 
Results 17OHP, P and 21DF are able to bind to the hGR with binding affinities of 24 
– 43% compared to cortisol. A has a low binding affinity. Incubation with 21DF led 
to complete nuclear translocation of the hGR, whereas treatment with 17OHP or P 
resulted in partial nuclear translocation. 21DF transactivated the hGR with an EC50 
approximately 6-fold the EC50 of cortisol. 17OHP and P transactivated the hGR 
with EC50s of more than 100 times the EC50 of cortisol. No hGR transactivation 
was detected after incubation with A. 
Conclusions 21DF, 17OHP and P are able to bind, translocate and transactivate the 
hGR in vitro and thus may have glucocorticoid activity. Mainly 21DF might have a 
clinically relevant agonistic effect on the hGR and could potentially partially 
compensate the cortisol deficiency in CAH patients. 
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Introduction 
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder caused by 
a deficiency of one of the enzymes involved in adrenal steroid synthesis. 95% of 
cases are caused by 21-hydroxylase deficiency. This results in impaired synthesis of 
cortisol and in 75% of cases also in clinically relevant aldosterone deficiency. [1] 
Due to the reduced negative feedback to the hypothalamus and pituitary gland, 
cortisol deficiency leads to increased pituitary secretion of ACTH. Consequently, 
the steroid hormone precursors prior to the enzymatic block accumulate and 
are shunted into the androgen-synthesis pathway. The presence of increased 
concentrations of adrenal steroid hormone precursors  is a hallmark feature of 
patients with CAH and these precursors can be used as diagnostic markers.[2] CAH 
caused by 21-hydroxylase deficiency represents a spectrum of disease depending 
on the severity of the enzymatic defect. The most severe, classic CAH is subdivided 
in a salt wasting form (SW-CAH) and a simple virilizing form (SV-CAH) without 
aldosterone deficiency. Nonclassic CAH (NC-CAH) is less severe with generally 
only mild symptoms of hyperandrogenism. [1] The treatment of classic CAH consists of 
lifelong replacement of glucocorticoids and if necessary also of mineralocorticoids. 
The goal of treatment is to prevent adrenal and salt wasting crises and to suppress 
abnormal secretion of adrenal androgens by suppression of the pituitary gland. 
Treatment of NC-CAH is only indicated when there are severe symptoms of 
androgen excess and/or glucocorticoid deficiency. [2]
CAH patients are clinically often less severely affected by cortisol deficiency than 
anticipated from their enzymatic defect. For example, SW-CAH patients have a 
severe cortisol and aldosterone deficiency due to a residual enzymatic activity of 
<1%. [1] They develop salt-wasting crises neonatally but only a minority presents 
with hypoglycemia or conjugated jaundice, a classic symptom of infantile 
glucocorticoid deficiency. [3] SV-CAH patients have a residual enzymatic activity of 
1-2% and a suboptimal increase of cortisol after stimulation with ACTH. In areas 
where neonatal screening is not implemented, male SV-CAH patients often present 
with signs of androgen excess in (early) childhood, without a history of Addisonian 
crises during illness or surgery prior to their diagnosis. [1] Furthermore, many adult 
patients with classic CAH who are lost to endocrine follow-up and are not adherent 
to treatment with glucocorticoids do not develop adrenal crises for long periods of 
time. [4] Finally, between 30 and 40% of patients with NC-CAH diagnosed in 
adolescence or adulthood show a suboptimal cortisol response to synacthen 
stimulation suggesting a potential risk of adrenal insufficiency during illness or 
surgery. [5-7] However, these patients usually do not report a history of signs or 
symptoms consistent with adrenal insufficiency during surgery or illness. [5,7]
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These observations could hypothetically be explained by the presence of adrenal 
steroid hormone precursors that accumulate in untreated and poorly controlled 
CAH patients. These precursors, such as 17-hydroxyprogesterone (17OHP), 
progesterone (P), 21-deoxycortisol (21DF) and androstenedione (A), [2] have 
structural similarities to cortisol. [8] We hypothesizes that they may have clinically 
significant glucocorticoid activity and partially substitute for cortisol. To analyze 
their glucocorticoid properties, we studied their effects on binding, nuclear 
translocation and transactivation of the human glucocorticoid receptor (hGR). 
Materials and methods 
In vitro receptor binding assays
Competitive binding assays for the hGR were performed as described previously. 
[9] HeLa cells were cultured in Dulbecco’s minimal essential medium (DMEM) High 
Glucose (4.5 g/l) with L-Glutamine supplemented with 10% fetal bovine serum and 
1% Penicillin/Streptomycin (all PAA Laboratories GmbH, Pasching, Austria). Whole 
cells (0.2 – 1.0 x 106) were incubated in serum and phenol red free RPMI medium 
(final volume 150 μl) for 1.5 – 2 hours at 37°C in a series of 0.5 ml microcentrifuge 
tubes containing 30 nM 3H-cortisol (PerkinElmer Inc, Waltham, MA, USA) and an 
increasing amount of unlabeled competitor: cortisol, 17OHP, 21DF, A (all Steraloids, 
Newport, RI, USA) or P (Sigma Aldrich, Gillingham, United Kingdom). Nonspecific 
binding was assessed by means of 500 fold excess of dexamethasone (Steraloids). 
Radioactivity was counted in a β counter. Specific binding was expressed as the 
percentage of specific binding (Bs) over binding of radioligand only (B0), corrected 
for nonspecific binding. 
In vitro nuclear translocation assays
For the intracellular localization assays, hGR DNA (pRShGRα) was PCR amplified 
using primers with BamHI and EcoRV restriction sites (Sigma Aldrich). It was cloned 
into a pcDNA6-V5/HisB-EGFP vector (Invitrogen Corp., Carlsbad, CA, USA). The 
correct insertion of the hGR construct as well as the integrity of the cDNA was 
checked by direct DNA sequencing. 
The assays were carried out in COS-7 cells, which is a cell-line that does not contain 
endogenous glucocorticoid receptor. The COS-7 cells were cultured in DMEM 
High Glucose (4.5 g/l) with L-Glutamine supplemented with 10% fetal bovine serum 
and 1% Penicillin/Streptomycin. 1.5 x 105 COS-7 cells were grown in 6-well plates on 
glass coverslips. After 24 hours the cells were transiently transfected with 2 μg of 
GFP-hGR using the TransIT-LT 1 DNA transfection reagent (Mirus Bio, Madison, WI, 
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USA). 48 hours after transfection the cells were treated for 60 minutes with one of 
the steroids (cortisol, 17OHP, P, 21DF, A) in a concentration of 10-6 M. Afterwards the 
cells were fixated on the coverslips in 100% methanol at -20°C for 15 minutes and 
mounted with Vectashield with DAPI (Vector Laboratories, Peterborough, UK) on 
microscope slides. The cells were studied under the Zeiss Apotome Fluorescence 
microscope with Zeiss Axiovision imaging software (4.7.2) at a magnification of 
200x for the localization of the hGR. Representative images were taken. The 
experiment was performed in duplicate.
In vitro transactivation assays 
For the transactivation assays, the hGR DNA was cloned into a pcDNA6-V5/HisB 
vector (Invitrogen Corp.) using the same restriction enzymes as described above. 
The luciferase reporter vectors used for the transactivation assays were MMTV-luc 
and pRL-TK (Promega, Madison, WI, USA). MMTV-luc is a firefly luciferase reporter 
construct. Transcription is controlled by glucocorticoid response elements 
immediately upstream from the luciferase sequence. pRL-TK contains a renilla 
luciferase. It serves as an internal standard to normalize firefly luciferase light 
emission measurements with regard to transfection efficiency and the number of 
cells in each well. 
The COS-7 cells were cultured in DMEM High Glucose (4.5 g/l) with L-Glutamine 
supplemented with 10% fetal bovine serum and 1% Penicillin/Streptomycin and 
seeded in 24-well plates in a density of 2 x 104 cells per well. Twenty-four hours 
after seeding, the COS-7 cells were transiently co-transfected using the TransIT-LT 
1 DNA transfection reagent with 0.2 μg pcDNA6-V5/HisB-hGR, 0.3 μg MMTV-luc 
and 0.01 μg pRL-TK per well. Two days after transfection the cells were treated with 
one of the steroids (cortisol, 17OHP, P, 21DF, A). Steroid solutions in ethanol were 
made in concentrations of 200x the final desired concentration (10-9 – 10-4 M ) and 
diluted 1:200 with DMEM prior to adding them to the transfected cells. Twenty-four 
hours after adding the steroid, firefly and renilla luciferase activity were measured 
using the Dual-Luciferase Reporter Assay System (Promega) on a Fluoroskan FL 
luminometer (Thermo Scientific, Franklin, MA, USA). Firefly luciferase/renilla 
luciferase ratios were calculated to normalize for transfection efficiency. Each 
experiment was performed in triplicate. 
To ensure that the COS-7 cell line did not contain relevant amounts of endogenous 
steroid receptors, the transactivation activities of the different steroids were also 
measured in COS-7 cells that had not been transfected with steroid receptor 
expression vectors. Likewise, the system was tested for the presence of endogenous 
steroids by measuring the transactivation activity after transfection with the hGR 
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vectors but without addition of steroids. In neither approach relevant transactivation 
was measured. 
The transactivation assay was repeated in HEK293 cells using the methods described 
above. These experiments were performed in duplicate. 
Statistical analysis
Analyses were performed using GraphPad Prism software version 5.0 for Windows 
(GraphPad Software, San Diego, CA, USA). Steroid concentrations were expressed 
on a log scale and dose-response curves were calculated using non-linear 
regression. For the receptor binding assays, the concentration of unlabeled steroid 
that reduces binding of the radioligand by half (IC50) was determined. The relative 
binding affinity of the study steroids compared to cortisol was calculated by 
IC50cortisol / IC50test steroid x 100%.  For the transactivation assays, the estimated 
concentration for 50% transactivation (EC50) was determined. For calculation of the 
relative functional sensitivity of the hGR to the different steroids, the transactivation 
potential of cortisol was set at 100%. The sensitivity of the hGR to the other test 
compounds was calculated as EC50cortisol / EC50test steroid x 100%. 
Results 
Receptor binding assay
The receptor binding curves for the studied steroids are shown in Figure 1. The IC50 
and the relative binding affinity of cortisol, 17OHP, P, 21DF and A were calculated 
(Table 1). The results demonstrate that 17OHP, P and 21DF bind to the hGR with 
relative binding affinities of 27%, 43% and 24%, respectively. The binding affinity for 
A is dramatically less than that of cortisol, 0.4%. 
Nuclear translocation assay
Incubation with cortisol in a concentration of 10-6 M resulted in complete nuclear 
translocation of the hGR within 60 minutes (Figure 2b). Adding 17OHP, P and 21DF 
to the transfected cells in a concentration of 10-6 M resulted in respectively almost 
complete, partial and complete transport to the nucleus (Figure 2c-e). After 
treatment of the cells with A, the location of the hGR was still predominantly 
cytoplasmic (Figure 2f). 
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hGR transactivation assay in COS-7 cells
Cortisol activated the hGR with an EC50 of 1.7 x 10-8 M (Figure 3a-d, Table 1). 
Exposure of the hGR to increasing concentrations of 17OHP, P and 21DF resulted in 
increasing hGR transactivation, up to a maximum. A dose-response curve was 
fitted (Figure 3a-c) and the EC50 values for these steroids were calculated. The 
EC50 value was 2.2 x 10-6 M for 17OHP, 3.0 x 10-6 M for P and 1.0 x 10-7 M for 21DF 
(Table 1). A did not transactivate the hGR at the concentrations tested (Figure 3d).
hGR transactivation assay in HEK293 cells
The results for the transactivation assay in HEK293 cells are shown in Supplementary 
Figure 1 and Table 1. In these experiments, the EC50 for cortisol was 3,5 x 10-9 M. 
17OHP, P and 21DF activated the hGR with EC50 values of 1.2 x 10-6 M, 2.3 x 10-6 M 
and 4.1 x 10-8 M respectively. 
Figure 1  Binding assays. Competition of various steroids for binding of 3H cortisol 
to the hGR in HeLa cells. 
Binding data are expressed as the percentage of specific binding (Bs) remaining after adding increasing 
amounts of competitor.
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Figure 2  Localization of the human glucocorticoïd receptor (hGR) in COS-7 cells 
transfected with the hGR, without steroids (A) and after incubation with various 
steroids in a concentration of 10-6 M (B-F). 
The nucleus is stained blue, the hGR is tagged with a Green Fluorescent Protein. B cortisol. C 17-hydroxy-
progesterone. D progesterone. E 21-deoxycortisol. F androstenedione.
A. B.
C. D.
E. F.
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Discussion 
We here describe the binding of 17OHP, P, 21DF and A to the hGR and their effects 
on the nuclear translocation and transactivation of the hGR, in comparison to the 
effects of cortisol. We found that 21DF and to a lesser extent 17OHP and P can 
transactivate the hGR. This is consistent with the receptor binding and nuclear 
translocation of the hGR we found after incubation with these steroids. It has 
previously been described that 17OHP and P bind to the hGR [10-12], but to the best 
of our knowledge this has not been shown for 21DF previously. These agonistic 
properties on the hGR might explain the clinical observation that CAH patients 
are often less severely affected by cortisol deficiency than anticipated from their 
enzymatic defect.
Figure 3  Transactivation of the human glucocorticoid receptor (hGR) by 17-hydroxy-
progesterone, progesterone, 21-deoxycortisol and androstenedione, in comparison 
with the transactivation of the hGR by cortisol.
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Steroid hormone cross-reactivity to receptors is a well-known phenomenon. For 
example, cortisol is known to have an agonistic effect on the mineralocorticoid 
receptor. [13] Additionally, in a previous study of our group we have demonstrated 
that 17OHP and P can influence the transactivation of the human mineralocorti-
coid receptor (hMR): both have anti-mineralocorticoid effects in vitro. [14] The 
occurrence of cross-reactivity of these steroids at both the hGR and the hMR can 
be explained by the high degree of homology at the DNA-binding domains of 
these receptors. [15] 
The EC50 of cortisol in our model is comparable to the EC50 previously described 
[16],  demonstrating the reliability of our in vitro model. Under the experimental 
conditions 21DF, 17OHP and P have the capacity to transactivate the hGR. With the 
concentrations used in our experiments we were able to reconstruct complete 
dose response curves, up to the point where maximum transactivation was 
reached. In the two cell lines studied, a comparable profile was found: 21DF has 
the greatest transactivational capacity, 17OHP and progesterone are also able 
to transactivate the hGR but only at much higher concentrations. A does not 
transactivate the hGR at the concentrations tested. Since there was no transactivation 
detectable for A even in concentrations at least 100 times higher than the concentrations 
found in untreated CAH, we do not expect relevant transactivation will occur with 
higher concentrations. [17] The fact that A has no agonistic effect on the hGR might 
be explained by the greater structural dissimilarity between A and cortisol compared 
to that of the other test compounds and cortisol. [8] 
As illustrated by the EC50 values more than a hundred times higher than the EC50 
of cortisol, 17OHP and progesterone are less potent agonists of the hGR than 
cortisol. In healthy volunteers the 17OHP concentration is substantially lower than 
that of cortisol: reference values for serum 17OHP are 2.0-10.8 nmol/L for males 
and 0.45 – 12.7 nmol/L for females, 9 AM reference values for serum cortisol are 
190 – 550 nmol/L. In this situation cross-reactivity on the hGR will be negligible. 
However, in classic CAH patients 17OHP concentrations can increase to very high 
concentrations of more than 1500 nmol/l. [18,19] Based on the dose-response 
curve we constructed, these concentrations might be high enough to result in 
relevant hGR transactivation.
Interestingly, the EC50 of 21DF is much closer to the EC50 of cortisol (approximately 
six-fold in the transactivation assays in COS7 cells, approximately twelve-fold in the 
HEK293 cells). The serum concentrations of 21DF in untreated or poorly controlled 
patients with classic CAH can exceed 400 nmol/l. [18,19] Based on our results we 
hypothesize that these concentrations may lead to a clinically relevant transactivation 
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of the hGR. Less transactivation can be expected in NC-CAH patients, since in 
these patients the 21DF concentrations are lower and reach up to approximately 
40 nmol/l [6]. We suggest that high serum 21DF concentrations in untreated or 
poorly controlled CAH patients may partially compensate for their cortisol deficiency. 
In contrast, overtreatment with complete suppression of adrenal precursors including 
17OHP and 21DF might lead to an increased risk of adrenal crises and hypoglycemia. 
Therefore, adequate stress dosing is crucial once glucocorticoid treatment is 
initiated in CAH patients.
Considering that we have studied several elements of the hGR transactivation 
cascade with consistent results, we are confident that our results represent actual 
glucocorticoid properties of 21DF, 17OHP and P. However, since this is an in vitro 
model, our findings need to be confirmed in further studies. We have studied the 
transactivating properties of several steroids, and not the other mechanisms by which 
the glucocorticoid receptor exerts its actions: transrepression and nongenomic 
effects. [13,20,21] It might also be relevant to study other steroid precursors. In spite 
of these limitations, we consider our results promising and potentially relevant for 
a significant group of CAH patients. 
In conclusion, 21DF and to a lesser extent 17OHP and P are able to transactivate the 
hGR in vitro and thus may have glucocorticoid activity. 21DF, which can be strongly 
elevated in untreated or poorly controlled CAH patients, has the strongest agonistic 
effect on the hGR and may partially compensate for the cortisol deficiency in CAH 
patients.
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Supplementary Figure
Supplementary figure 1  Transactivation of the human glucocorticoid receptor 
(hGR) in HEK293 cells by 17-hydroxyprogesterone, progesterone, 21-deoxycortisol 
and androstenedione, in comparison with the transactivation of the hGR by cortisol.
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Abstract
Background Cortisol deficiency can cause adrenal crises, which can be life-threatening. 
Cortisol production is impaired in patients with congenital adrenal hyperplasia 
(CAH). Here, we describe a unique population of severely affected untreated CAH 
patients, with proven cortisol deficiency but without clinical signs of cortisol 
deficiency even in severe stress-situations. The lack of clinical signs of cortisol 
deficiency in untreated CAH patients might be explained by the glucocorticoid 
activity of increased concentrations of adrenal steroid precursors. 
Methods Adrenal steroid precursor concentrations before and 60 minutes after 
ACTH administration of 22 untreated Indonesian CAH patients (3-46 years) with 
proven cortisol deficiency (< 500nmol/l post-ACTH) measured by liquid chromatography 
tandem-mass spectrometry (LC-MS/MS) were compared to 6 control patients 
(Mann-Whitney U test). Glucocorticoid activity was determined by dual-luciferase 
assays in human embryonic kidney cells transfected with the glucocorticoid receptor 
and exposed to increasing amounts of adrenal steroid precursors for 24 hours.  
Results Blood concentrations of the steroid precursors 11-deoxycortisol (457nmol/l, 
p=0.003), 11-deoxycorticosterone (55nmol/l, p=0.003), 17-hydroxyprogesterone 
(610nmol/l , p<0.001), progesterone (29nmol/l, p<0.001), and 21-deoxycortisol (73 
nmol/l) were strongly elevated compared to controls. The hGR was activated with 
comparable potency to cortisol by corticosterone and 21-deoxycortisol, and with 
4-100x lower potency by 11-hydroxyprogesterone, 11-deoxycortisol, aldosterone, 
11-deoxycorticosterone, progesterone, and 17-hydroxyprogesterone. 
Conclusions We identified strongly elevated adrenal steroid precursor concentrations 
in blood from untreated CAH patients and demonstrated glucocorticoid activity of 
these adrenal precursors in vitro – implicating these precursors might be able to 
compensate for cortisol deficiency in untreated CAH patients, thereby potentially 
protecting against life-threatening adrenal crises.
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Introduction
An adrenal crisis due to cortisol deficiency, also known as Addisonian crisis, is a 
life-threatening condition when not properly treated with glucocorticoids. It is 
often described by its main symptoms: vomiting, diarrhea, and abdominal pain. 
Whereas the main cause of an adrenal crisis is cortisol deficiency, additional 
aldosterone deficiency can lead to the development of a salt wasting crisis, which 
is treated by supplementation of mineralocorticoids and sodium chloride. 
 Cortisol deficiency is one of the main findings in patients with congenital 
adrenal hyperplasia (CAH). CAH is an autosomal recessive disorder with impaired 
steroidogenesis in the adrenal cortex. Adrenal steroidogenesis involves the synthesis 
of cortisol, aldosterone, and androgens from the common precursor cholesterol 
via several enzymatic steps. More than 90% of CAH cases are caused by a mutation 
in the CYP21A2 gene resulting in 21-hydroxylase deficiency (21OHD). In 21OHD, 
conversion of the steroid precursors 17-hydroxyprogesterone (17OHP) and progesterone 
to 11-deoxycortisol and 11-deoxycorticosterone respectively is impaired (Figure 1). 
Consequently, cortisol production is inadequate, leading to elevated ACTH 
concentrations due to a lack of negative feedback to the hypothalamus and pituitary 
gland. Increased ACTH concentrations will stimulate the adrenal gland, eventually 
causing hyperplasia. Furthermore, adrenal steroid precursors before the enzymatic 
defect accumulate, and are shunted into the androgen synthesis pathway. [1] 
Increased concentrations of adrenal steroid precursors 17OHP and 21-deoxycortisol 
(21DF) are currently used as diagnostic markers for CAH. [1-3] The severity of the 
disease depends on the residual enzymatic activity with a strong phenotype-geno-
type relationship: Mutations that are classified as group null (0) or A are usually 
associated with <1% residual enzyme activity with additional aldosterone deficiency 
(salt wasting type), group B with 1-5% residual enzyme activity without aldosterone 
deficiency (simple virilizing type), and group C with a residual enzymatic activity of 
20-50% and a less severe phenotype with usually normal cortisol and aldosterone 
levels (non classic type). [4] 
 Approximately 5% of CAH cases are caused by mutations in the CYP11B1 gene 
resulting in 11-hydroxylase deficiency (11OHD). 11OHD results in decreased conversion 
of the precursors 11-deoxycorticosterone and 11-deoxycortisol to corticosterone 
and cortisol, respectively (Figure 1). As in 21OHD, cortisol production is deficient 
and adrenal androgen concentrations are increased. However, in contrast to 
21OHD, signs of mineralocorticoid excess occur with hypertension and hypokalemia 
due to the mineralocorticoid potency of 11-deoxycorticosterone. [5] 
 Patients with cortisol deficiency are generally treated with glucocorticoids to 
substitute for cortisol deficiency in order to prevent life-threatening adrenal crises 
and to suppress the elevated androgens. In our clinical experience however, there 
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are cases of untreated or noncompliant severely affected CAH patients known to 
have less clinical signs of cortisol deficiency than expected based on their enzyme 
deficiency, and compared to patients with other forms of adrenal insufficiency. For 
example, only a minority of neonates with the most severe form of 21OHD present 
with typical features of cortisol deficiency (hypoglycemia or conjugated jaundice). 
[6] We have previously described a patient with salt wasting CAH, who was only 
treated with sodium chloride for the first two years of life, without apparent 
complications from cortisol deficiency. [7] Moreover, in countries without neonatal 
screening programs for CAH, CAH patients from group B (simple virilizing) usually 
only present with signs of androgen excess during childhood, without reporting a 
history of adrenal crises. 
 The aim of our study was to determine if this lack of signs of cortisol deficiency 
might be explained by the glucocorticoid activity of increased concentrations of 
adrenal steroid precursors that accumulate before the enzymatic defect. Here, we 
describe the clinical phenotype and the biochemical profile of adrenal steroid 
precursors in a unique cohort of untreated 21OHD and 11OHD CAH patients, 
before and after ACTH administration using liquid chromatography tandem-mass 
spectrometry (LC-MS/MS). The glucocorticoid activity of these precursor steroids 
was assessed by in vitro human glucocorticoid receptor (hGR) transactivation 
studies.
Patients and methods
Study design
Within this translational study we had the objective to describe the phenotype and 
steroid profile of a cohort of untreated Indonesian CAH patients. No sample size 
calculation was performed in this descriptive study. We added 6 control patients, 
and 2 untreated CAH patients from the Netherlands in comparative biochemical 
analyses. Our inclusion criteria were untreated patients with a severe type of 
genetically confirmed CAH in which an ACTH stimulation test was performed. To 
understand the potential of different steroid hormones, we also performed cell 
culture experiments. We determined the potency to activate the hGR for each 
steroid, in which each concentration was measured in triplicate. No rules for 
stopping data collections were defined. We reported all data and did not find 
outliers in our data. Main outcomes in our study were defined as the number of 
stress-full events, biochemical evaluation of the ACTH stimulations tests by LC-MS/
MS and activation of hGR. 
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Patients 
Untreated CAH patients (n=22) were recruited from the local CAH database and 
included as a part of a cohort study on hormonal analysis and compliance in the 
Center for Biomedical Research, Faculty of Medicine Diponegoro University, 
Semarang, Indonesia (in compliance with relevant laws, institutional guidelines and 
the declaration of Helsinki). The study was approved by the local ethical committee 
of the Diponegoro University. Oral and written informed consent was obtained 
after full explanation of the purpose and nature of all procedures.  Data were 
collected on the type of CAH, karyotype, gender, mutation analysis, signs of salt 
wasting, and episodes of severe stress in their medical history (critical illness, 
trauma, surgery) by the local pediatric endocrinologist (AU). For all 21OHD patients, 
the severity of CAH was classified based on their mutation analysis into genotype 
groups 0, A, B, or C (4). 
Figure 1  Adrenal steroidogenesis. Cholesterol is converted to aldosterone, cortisol 
and androgens in the adrenal cortex via several enzymatic steps. 
Abbreviations: 11OHD, 11-hydroxylase deficiency; 17β-HSD, 17β-hydroxysteroid dehydrogenase; 21OHD, 
21-hydroxylase deficiency; 3β-HSD, 3β-hydroxysteroid dehydrogenase.
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In addition, the biochemical results of patients in whom an ACTH test was 
performed at Radboud university medical center in Nijmegen, the Netherlands in 
2017 were included (n=8). Oral informed consent was obtained by the treating 
physician as additional measurements were performed on coded stored blood 
samples in accordance with the Code of Conduct of the Federation of Medical 
Scientific Societies in the Netherlands (http://www.federa.org/codes-conduct). 
Two patients had a CAH diagnosis, the other 6 were non-CAH patients, falsely 
suspected of an adrenal disorder and were used as control group. Three of these 
patients were females with polycystic ovarian syndrome. One male patient 
presented with an abnormal result in the neonatal screening program for CAH, 
which turned out to be false positive, and the 2 other patients were 46XY neonates 
with ambiguous genitalia. In one of them, no final diagnosis could be made. In the 
other patient, a mutation with unknown pathogenicity was found in the NR5A1 
gene. Additionally, 1 healthy adult female underwent an ACTH stimulation test in 
the Center for Biomedical Research, Faculty of Medicine Diponegoro University, 
Semarang, Indonesia to serve as a control patient. 
Biochemical analysis
The standard ACTH stimulation test was performed in all patients to determine 
adrenal functioning by measuring steroid concentrations before and after ACTH 
administration. Synacthen (0.25 mg; Sigma Tau BV) was injected intravenously, 
with blood draws for steroid analysis before and 60 minutes after the injection. 
In the Indonesian patients all tests were performed before 9.00 am. Dutch patients 
had their ACTH stimulation test during their clinical appointment, which mostly 
took place in the morning. None of the patients received glucocorticoids at the 
time of biochemical analysis. Serum before and after ACTH administration were 
analyzed with LC-MS/MS to determine cortisol, corticosterone, 11-deoxycortisol, 
11-deoxycorticosterone, 17OHP, progesterone, and 21DF concentrations. The LC-MS/
MS protocol has been provided in the Supplemental Material. 
In vitro transactivation study
Cell culture
Human embryonic kidney cells (HEK293) were grown as a monolayer culture in 
DMEM with 4.5 g/L glucose with l-glutamine (Lonza; Leusden, the Netherlands) 
supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific; 
Landsmeer, the Netherlands) and 1% antibiotics (penicillin-streptomycin 10,000 U/
mL; Gibco). Cells were cultured at 37 °C in a humidified 95% air / 5% CO2 
atmosphere, and passaged when confluent. 
109
7
GLUCOCORTICOID EFFECTS OF ADRENAL STEROID PRECURSORS (2)
In vitro dual luciferase transactivation assays
Human hGR transactivation was measured using dual-luciferase transactivation assays 
(Promega; Leiden, the Netherlands) in which pcDNA6-V5/Hisb-hGR, MMTV-luc, 
and pRL-TK vectors were used as described earlier. [8]
 HEK293 cells were seeded at 40,000 cells/well in 24-well plates. Transient 
transfection was performed after 24 hours, using 0.2 μg pcDNA6-V5/Hisb-hGR, 0.3 
μg MMTV-luc, and 0.01 μg pRL-TK per well and 1 μL TransIT-LT1 transfection reagent 
(Mirus; Ochten, the Netherlands) according to manufacturer’s protocol. Cells were 
treated for 24 hours with one of the steroids (progesterone, 17-hydroxypregnenolone, 
pregnenolone (Sigma-Aldrich, Zwijndrecht, the Netherlands) or cortisol, aldosterone, 
corticosterone, 11-deoxycortisol, 11-deoxycorticosterone, 17OHP, 11β-hydroxypro-
gesterone, 16-hydroxyprogesterone, 21DF, (Steraloids, Newport, USA)) 2 days after 
transfection. Steroid solutions were prepared in ethanol (200X concentrated) and 
diluted 1:200 in culture medium prior to treatment. Thereafter, firefly and renilla 
luciferase activity was measured on a Fluoroskan FL luminometer (Thermo 
Scientific) according to manufacturer’s protocol (Promega) and firefly/renilla ratios 
were calculated. Each concentration was measured in triplicate.
 As controls, HEK293 cells were transfected with the MMTV-luc and pRL-TK 
vector, but not the hGR and treated with 10-4 M cortisol. Secondly, HEK293 cells 
were transfected with all the vectors, but not treated with any steroid (medium with 
0.5% ethanol). Neither of these approached resulted in transactivation activity. 
Statistical analyses
GraphPad Prism software version 5.0 for Windows and SPSS Statistics 22 (SPSS Inc., 
Chicago, IL, USA) were used to analyze adrenal steroid concentrations. Normality 
was assessed and median steroid concentration and interquartile range (IQR: 
Q1-Q3) were calculated. 21OHD and 11OHD patients were compared to the control 
group and distributions were compared using the Mann-Whitney U (MWU) test. 
P<0.05 was considered significant. GraphPad Prism was also used to calculate 
dose-response curves using nonlinear regression. The estimated concentration 
that causes 50% of the maximum transactivation (EC50) and its 95% confidence 
interval (95%CI) were also determined. Relative functional sensitivity of the hGR to 
the different steroids was calculated as EC50 cortisol / EC50 test steroid x 100% in 
which cortisol was set as 100%. 
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Results
Clinical characteristics of untreated CAH patients
Clinical characteristics of the included CAH patients are shown in Table 1. 
Twenty-two (long-time) untreated CAH patients were identified in the Indonesian 
CAH database, age 3-46 years, of which 17 had 21OHD and 5 had 11OHD. Most 
patients (n=15) were never treated with glucocorticoids, and 7 patients were treated 
in the past, but had been off treatment for at least 2 years at the time of biochemical 
analysis and were therefore considered as untreated. Additionally, we included the 
biochemical results of 2 Dutch male CAH neonates, who were identified from the 
national CAH neonatal screening program, and started glucocorticoid treatment 
only after the biochemical analysis of the ACTH stimulation test. All patients were 
diagnosed with a severe type of CAH based on mutation analysis. Episodes of 
severe stress in their medical history has been reported in 13/22 patients. In none 
of these episodes patients were treated with stress dosages of glucocorticoids. 
In the 11OHD group, 1 patient underwent genital surgery. In the 21OHD group, 
5 patients underwent genital surgery (genotype group 0 (n=3), A (n=1), B (n=1)) and 
2 patients underwent tonsillectomy (genotype group 0 (n=1), unclassifiable (n=1)). 
There were 5 reports of dengue hemorrhagic fever (genotype group 0 (n=2), 
unclassifiable (n=1)) or typhoid fever (genotype group 0 (n=1), B (n=1). Also, 5 
patients reported hospital admissions because of salt wasting crisis (genotype 
group A (n=2)) or because of episodes of vomiting and/or seizures (genotype group 
0 (n=3)). 
Biochemical evaluation of serum adrenal steroid precursors
In control patients, cortisol concentration increased adequately after ACTH 
administration (>500 nmol/l (9-11)), and all other measured steroids remained low 
with a 2-5 fold increase. In contrast, in our study population cortisol concentrations 
remained low after ACTH administration with a median concentration of 73 (IQR 
64-129) nmol/l in the 21OHD patients and 180 (IQR 159-214) nmol/l in the 11OHD 
patients, confirming severe cortisol deficiency in our cohort (Table 1, Figure 2). 
Adrenal steroid precursor concentrations were also measured in serum from CAH 
patients before and after ACTH administration (Figure 2). As we did not find 
differences in steroid concentrations before and after ACTH administration, we 
further only report on the steroid concentrations in serum after ACTH administration. 
Corticosterone concentrations were significantly lower in untreated CAH patients 
(median 21OHD: 7.1 (IQR 5.9-8.2) nmol/l, MWU p<0.001; median 11OHD: 4.3 (IQR 
3.7-8.4) nmol/l, MWU p=0.003) compared to controls (median 72 (IQR 55-78) 
nmol/l). Blood 11-deoxycortisol and 11-deoxycorticosterone concentrations were 
significantly elevated in 11OHD patients with respectively a median concentration 
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of 457 nmol/l (IQR 364-612, MWU p=0.003) and 55 nmol/l (IQR 25-119, MWU 
p=0.003) compared to control (median 3.2 (IQR 1.9-5.9), and 0.5 (IQR 0.2-0.8) 
nmol/l, respectively), but not in 21OHD patients (median 1.9 (IQR 1.5-3.8, MWU 
p=0.083) and 0.4 (IQR 0.3-0.6, MWU p=0.395) nmol/l, respectively). Blood 17OHP 
and progesterone concentrations were elevated in 21OHD patients (median 610 
(IQR 509-762, MWU p<0.001) and 29 (IQR 20-43, MWU p<0.001) nmol/l, 
respectively) and 11OHD patients (median 20 (IQR 16-21, MWU p=0.003), and 3.6 
(IQR 2.6-5.8, MWU p=0.003) nmol/l, respectively) compared to controls (median 
4.8 (IQR 2.7-5.6) nmol/l and 1.0 (IQR 0.5-1.1) nmol/l, respectively). 21DF 
concentrations were only measurable (>1 nmol/l) in blood from untreated 21OHD 
patients (median 73 (IQR 46-112) nmol/l). 
hGR transactivation in human embryonic kidney cells
To determine the potency of steroid precursors for hGR transactivation, we performed 
dual luciferase assays, which allows for the quantification of hGR-induced gene 
expression (Table 2, Figure 3). We found an EC50 of 11 nM (95%CI: 5.9-20) for 
cortisol, which is used as reference steroid. Similar potencies were found for 
corticosterone (EC50 of 17 nM, 95%CI: 8.9-32) and 21DF (EC50 of 22 nM, 95%CI: 
12-42) as confidence intervals overlap. 
 11-hydroxyprogesterone, 11-deoxycortisol, and aldosterone exhibited somewhat 
higher EC50 values: 47, 71, and 111 nM, respectively. Exposure to 11-deoxycortico-
sterone (EC50 of 725 nM), progesterone (EC50 of 1,147 nM), and 17OHP (EC50 of 
1,668 nM) also resulted in hGR transactivation, although these EC50 values were at 
least 65 times higher than that of cortisol. hGR transactivation was only observed 
at a very high concentration (100,000 nM) of 16-hydroxyprogesterone, while no 
hGR transactivation was found for pregnenolone, and 17-hydroxypregnenolone.
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Table 1   Clinical characteristics of untreated CAH patients.
Patient Age CAH type Karyotype Gender Mutations in CYP11B1  
(#I1-I5) and CYP21A2 (#I6-D2)
Geno-type 
group ^
Treatment with  
glucocorticoids
History of 
salt wasting
History of severe stress 
while untreated
cortisol 
before ACTH
cortisol  
after ACTH
I1 28 11OHD 46XX F c.799G>A 
c.799G>A
NA never no genital surgery 164 163
I2 19 11OHD 46XX F c.799G>A 
c.799G>A
NA never no no 218 225
I3 5 11OHD 46XX M c.799G>A
c.799G>A
NA never no no 150 155
I4 13 11OHD 46XX M c.799G>A 
c.799G>A
NA never no no 179 180
I5 3 11OHD 46XX U c.799G>A 
c.799G>A
NA never no no 202 202
I6 19 21OHD 46XX F p.Ile172Asn 
p.Ile172Asn
B treated at age 8-16 yr
stopped >3 yrs
no no 110 125
I7 23 21OHD 46XX F p.Ile172Asn 
p.Ile172Asn
B treated at age 13-20 yr
stopped >3 yrs
no no 233 238
I8 21 21OHD 46XX F p.Arg356Trp
p.Arg356Trp
0 treated at age 10-19 yr
stopped >2 yrs
yes genital surgery 68 66
I9 9 21OHD 46XX F intron splice
p.Arg356Trp
A treated at age 5-7 yr
stopped >2 yrs
yes repeated hospital 
admissions for salt 
wasting crises
82 73
I10 4 21OHD 46XX F intron splice
p.Arg356Trp
A treated at age 0-2 yr
stopped >2 yrs
yes repeated hospital 
admissions for salt 
wasting crises
35 33
I11 13 21OHD 46XX F p.Arg356Trp
p.Arg356Trp
0 treated since childhood
stopped > 4 years
no genital surgery 115 119
I12 46 21OHD 46XX M p.Trp20*
p.Ile172Asn
B never no severe gastritis (2x), 
typhoid fever
159 159
I13 15 21OHD 46XX M intron splice
intron splice
A never no no 89 79
I14 32 21OHD 46XX M intron splice
intron splice
A never no genital surgery 61 65
I15 13 21OHD 46XX F p.Arg356Trp
p.Arg356Trp
0 treated for one year at age 5 yr
stopped > 8 yrs
no genital surgery, 
tonsillectomy, dengue 
hemorrhagic fever, 
typhoid fever
75 68
I16 15 21OHD 46XX M p.Arg356Trp
deletion of exon 1-3
0 never yes repeated hospital 
admissions for vomiting 
and seizures 
57 58
I17 14 21OHD 46XX M p.Ile386del 
p.Arg356Trp
0 never yes repeated hospital 
admissions for seizures 
53 50
I18 14 21OHD 46XX F p.Pro30Leu
p.Pro30Leu
B treated at age 4-10 yr
stopped > 4 yrs
no genital surgery 210 187
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Table 1   Clinical characteristics of untreated CAH patients.
Patient Age CAH type Karyotype Gender Mutations in CYP11B1  
(#I1-I5) and CYP21A2 (#I6-D2)
Geno-type 
group ^
Treatment with  
glucocorticoids
History of 
salt wasting
History of severe stress 
while untreated
cortisol 
before ACTH
cortisol  
after ACTH
I1 28 11OHD 46XX F c.799G>A 
c.799G>A
NA never no genital surgery 164 163
I2 19 11OHD 46XX F c.799G>A 
c.799G>A
NA never no no 218 225
I3 5 11OHD 46XX M c.799G>A
c.799G>A
NA never no no 150 155
I4 13 11OHD 46XX M c.799G>A 
c.799G>A
NA never no no 179 180
I5 3 11OHD 46XX U c.799G>A 
c.799G>A
NA never no no 202 202
I6 19 21OHD 46XX F p.Ile172Asn 
p.Ile172Asn
B treated at age 8-16 yr
stopped >3 yrs
no no 110 125
I7 23 21OHD 46XX F p.Ile172Asn 
p.Ile172Asn
B treated at age 13-20 yr
stopped >3 yrs
no no 233 238
I8 21 21OHD 46XX F p.Arg356Trp
p.Arg356Trp
0 treated at age 10-19 yr
stopped >2 yrs
yes genital surgery 68 66
I9 9 21OHD 46XX F intron splice
p.Arg356Trp
A treated at age 5-7 yr
stopped >2 yrs
yes repeated hospital 
admissions for salt 
wasting crises
82 73
I10 4 21OHD 46XX F intron splice
p.Arg356Trp
A treated at age 0-2 yr
stopped >2 yrs
yes repeated hospital 
admissions for salt 
wasting crises
35 33
I11 13 21OHD 46XX F p.Arg356Trp
p.Arg356Trp
0 treated since childhood
stopped > 4 years
no genital surgery 115 119
I12 46 21OHD 46XX M p.Trp20*
p.Ile172Asn
B never no severe gastritis (2x), 
typhoid fever
159 159
I13 15 21OHD 46XX M intron splice
intron splice
A never no no 89 79
I14 32 21OHD 46XX M intron splice
intron splice
A never no genital surgery 61 65
I15 13 21OHD 46XX F p.Arg356Trp
p.Arg356Trp
0 treated for one year at age 5 yr
stopped > 8 yrs
no genital surgery, 
tonsillectomy, dengue 
hemorrhagic fever, 
typhoid fever
75 68
I16 15 21OHD 46XX M p.Arg356Trp
deletion of exon 1-3
0 never yes repeated hospital 
admissions for vomiting 
and seizures 
57 58
I17 14 21OHD 46XX M p.Ile386del 
p.Arg356Trp
0 never yes repeated hospital 
admissions for seizures 
53 50
I18 14 21OHD 46XX F p.Pro30Leu
p.Pro30Leu
B treated at age 4-10 yr
stopped > 4 yrs
no genital surgery 210 187
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Table 1   Continued.
Patient Age CAH type Karyotype Gender Mutations in CYP11B1  
(#I1-I5) and CYP21A2 (#I6-D2)
Geno-type 
group ^
Treatment with  
glucocorticoids
History of 
salt wasting
History of severe stress 
while untreated
cortisol 
before ACTH
cortisol  
after ACTH
I19 10 21OHD 46XX M p.Gln196*
p.Arg356Trp
0 never yes hospital admission 
for vomiting, dengue 
hemorrhagic fever
61 60
I20 19 21OHD 46XX F p.Ile172Asn
deletion of exon 1-6
B never no no 139 129
I21 3 21OHD 46XX F p.Ile172Asn
p.Arg356Trp
B never no no 101 64
I22 21 21OHD 46XX F deletion of exon 1-6
no second mutation # 
NC never no tonsillectomy, dengue 
hemorrhagic fever
146 149
D1 0 21OHD 46XY M deletion of exon 1-3 
p.Ile172Asn 
B treatment started after ACTH 
stimulation test
NA 30 70
D2 0 21OHD 46XY M deletion of exon 1-7
p.Pro30Leu
B treatment started after ACTH 
stimulation test
NA 30 90
^Genotype classification is based on mutation analysis. Mutations in genotype group 0 and A usually have 
<1% residual enzyme activity, genotype B has 1-5% residual enzyme activity, while genotype C has a residual 
enzyme activity of 20-50% (4). We classified the p.Pro30Leu mutation in genotype group B. * This patients 
also had a cluster of mutations in the CYP21A2 promotor region in one allele, possibly resulting in a more 
severe phenotype. # This patient had very high 17OHP levels (>400 nmol/l), and although no second 
mutation has been found it is very likely that this patient belongs to the same genotype group (B) as her 
sister (#I20). Abbreviations: 11OHD, 11-hydroxylase deficiency; 21OHD, 21-hydroxylase deficiency; F, female;  
M, male; NA, not applicable; NC, not classifiable; U, undefined; yr, year; yrs, years.
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Table 1   Continued.
Patient Age CAH type Karyotype Gender Mutations in CYP11B1  
(#I1-I5) and CYP21A2 (#I6-D2)
Geno-type 
group ^
Treatment with  
glucocorticoids
History of 
salt wasting
History of severe stress 
while untreated
cortisol 
before ACTH
cortisol  
after ACTH
I19 10 21OHD 46XX M p.Gln196*
p.Arg356Trp
0 never yes hospital admission 
for vomiting, dengue 
hemorrhagic fever
61 60
I20 19 21OHD 46XX F p.Ile172Asn
deletion of exon 1-6
B never no no 139 129
I21 3 21OHD 46XX F p.Ile172Asn
p.Arg356Trp
B never no no 101 64
I22 21 21OHD 46XX F deletion of exon 1-6
no second mutation # 
NC never no tonsillectomy, dengue 
hemorrhagic fever
146 149
D1 0 21OHD 46XY M deletion of exon 1-3 
p.Ile172Asn 
B treatment started after ACTH 
stimulation test
NA 30 70
D2 0 21OHD 46XY M deletion of exon 1-7
p.Pro30Leu
B treatment started after ACTH 
stimulation test
NA 30 90
^Genotype classification is based on mutation analysis. Mutations in genotype group 0 and A usually have 
<1% residual enzyme activity, genotype B has 1-5% residual enzyme activity, while genotype C has a residual 
enzyme activity of 20-50% (4). We classified the p.Pro30Leu mutation in genotype group B. * This patients 
also had a cluster of mutations in the CYP21A2 promotor region in one allele, possibly resulting in a more 
severe phenotype. # This patient had very high 17OHP levels (>400 nmol/l), and although no second 
mutation has been found it is very likely that this patient belongs to the same genotype group (B) as her 
sister (#I20). Abbreviations: 11OHD, 11-hydroxylase deficiency; 21OHD, 21-hydroxylase deficiency; F, female;  
M, male; NA, not applicable; NC, not classifiable; U, undefined; yr, year; yrs, years.
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Figure 2  Steroid concentrations in untreated CAH patients. 
Blood adrenal steroid concentrations were determined before and 60 minutes after ACTH administration. 
Black indicates 21-hydroxylase deficient patients, pink indicates 11-hydroxylase deficient patients, and blue 
indicates control.
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Figure 2  Continued. 
cortisol
n
m
o
l/
L
corticosterone
n
m
o
l/
L
11-deoxycortisol
n
m
o
l/
L
11-deoxycorticosterone
n
m
o
l/
L
17-hydroxyprogesterone
n
m
o
l/
L
progesterone
n
m
o
l/
L
21-deoxycortisol
be
fo
re
 A
CT
H
af
te
r A
CT
H
be
fo
re
 A
CT
H
af
te
r A
CT
H
be
fo
re
 A
CT
H
af
te
r A
CT
H
be
fo
re
 A
CT
H
af
te
r A
CT
H
be
fo
re
 A
CT
H
af
te
r A
CT
H
be
fo
re
 A
CT
H
af
te
r A
CT
H
be
fo
re
 A
CT
H
af
te
r A
CT
H
0.01
0.1
0
0
10
100
1000
0.01
0.1
10
100
1000
0
0.01
0.1
10
100
1000
0
0.01
0.1
10
100
1000
0
0.01
0.1
10
100
1000
0
0.01
0.1
10
100
1000
0
0.01
0.1
10
100
1000
n
m
o
l/
L
Table 2   (Relative) potency of steroids to activate the human glucocorticoid 
 receptor (hGR).
EC50 (95% CI) Relative potency to hGR
cortisol 11 (5.9-20) nM 100%
corticosterone 17 (8.9-32) nM 64 %
21DF 22 (12-42) nM 49%
11-hydroxyprogesterone 47 (30-73) nM 23%
11-deoxycortisol 71 (56-92) nM 15%
aldosterone 111 (72-171) nM 9.8%
11-deoxycorticosterone 725 (422-1246) nM 1.5%
progesterone 1147 (664-1981) nM 0.95%
17OHP 1668 (1300-2140) nM 0.65%
16-hydroxyprogesterone NC * 
pregnenolone NA
17OHpregnenolone NA
Data of the transactivation assays in human embryonic kidney cells were used to calculate dose-response 
curves using nonlinear regression. EC50 values could be calculated when a complete dose-response 
curves was available, including a concentration in which maximum transactivation was reached (plateau 
phase). * some transactivation at 100,000 nM, but no maximum transactivation was reached with the 
concentrations tested. Abbreviations: CI, confidence interval; EC50, estimated concentration that causes 
50% of the maximum transactivation; hGR, glucocorticoid receptor; NA, not applicable; NC, not calculable.
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Figure 3  Glucocorticoid receptor transactivation by adrenal steroids. 
RLU is a measure for glucocorticoid receptor transactivation as measured by a dual-luciferase assay in 
human embryonic kidney cells that were exposed to increasing amount of steroids (depicted in black) for 
24 hours. Cortisol was used as a reference steroid (depicted in grey). All concentrations were measured in 
triplicate and mean and range are depicted. Abbreviations: RLU, relative light units.
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Discussion
Here, we describe a unique group of untreated CAH patients with biochemically 
confirmed severe cortisol deficiency. None of these patients had clinical signs of 
cortisol deficiency and more than half of these patients report a history of severe 
stress-situations, such as surgery or severe infectious diseases, and recovered 
without glucocorticoid stress dosing. We show here that this might be explained by 
the glucocorticoid activity of significantly increased steroid precursor concentrations, 
that at least partially compensate the cortisol deficiency.
 To the best of our knowledge we are the first to report on measurement of 
multiple adrenal steroid precursors in an unique cohort of untreated CAH patients. 
As expected from their enzymatic defect, in untreated 21OHD patients 17OHP (127x 
higher), progesterone (29x higher), and 21DF (only measurable in 21OHD) concentrations 
were significantly increased compared to controls. Remarkably, this corresponds 
to the measured concentrations of adrenal steroid precursors in blood of treated 
21OHD patients. [12] Furthermore, in untreated 11OHD patients, we found 11-deoxy - 
cortisol (457x higher) and 11-deoxycorticosterone (55x higher) to be the most 
important accumulating steroid precursors. We hypothesized that these strongly 
elevated adrenal precursor concentrations may have a stimulating effect on the hGR.
Figure 3  Continued.
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Steroid hormone action is initiated by binding of the hormone to its receptor. 
The hormone-receptor complex subsequently will translocate to the nucleus were 
it binds to hormone response elements in the regulatory region of target gene 
promoters, initiating transactivation. [13] Several studies have been performed 
evaluating the binding of steroids to the hGR and mineralocorticoid receptor (hMR) 
and/or the nuclear translocation of the receptor-complex, but only a few studies 
report on hGR transactivation [8, 14-18], mainly focusing on aldosterone and 
cortisol, showing that cortisol has higher potency for hGR transactivation than 
aldosterone. [14, 15, 17, 18] It is nowadays well established that adrenal steroids have 
steroid hormone cross-reactivity explained by the high degree of homology of the 
DNA binding domain of the hGR and the hMR. [19] Only one study showed that 
21DF, 17OHP and progesterone are able to activate the hGR. [8] To the best of our 
knowledge, we are the first to describe the potency to activate the hGR for more 
than 10 adrenal steroid precursors relative to cortisol. We found that 21DF and 
corticosterone had similar potency to activate the hGR, while the potency of 
 11-hydroxyprogesterone, 11-deoxycortisol and aldosterone was 4-10x lower, and 
the potency of 11-deoxycorticosterone, progesterone and 17OHP more than 65x 
lower compared to cortisol. 
 Comparison of the transactivation data with the molecular structure of the 
adrenal steroid precursors shows that dehydrogenation of the steroid precursors 
by 3β-hydroxysteroid dehydrogenase is a prerequisite to enable a steroid to activate 
the hGR, as pregnenolone and 17-hydroxypregnenolone, which are not dehydrogenated, 
were not able to cause hGR transactivation in vitro. We also observed that dehydro-
genation alone (progesterone) or combined with 21-hydroxylation (11-deoxycortico-
sterone) or 17-hydroxylation (17OHP) resulted in relatively low potency to activate 
the hGR. Combination of dehydrogenation and hydroxylation of position 11 and 21 
(corticosterone), or position 11 and 17 (21DF), or position 17 and 21 (11-deoxycortisol), 
increased the potency to activate the hGR as EC50 values were similar or 7 times 
higher than of cortisol. Strikingly, the most potent hGR activation precursor steroids 
are 11β-hydroxylated steroids. This confirms the hypothesis of Hellal-Levy et al.[15] 
and Rousseau et al. [20] that hydroxylation at position 11 enhances glucocorticoid 
activity. 
 The strongly increased concentrations of the 11-hydroxylated steroid precursors 
21DF and 11-hydroxyprogesterone in untreated 21OHD patients, that are able to 
activate the hGR, might at least partially compensate for their cortisol deficiency. 
17OHP and progesterone might also contribute as we found increased concentrations 
in 21OHD and 11OHD patients, although the potential to activate the hGR is lower. 
Furthermore, in 11OHD patients, 11-deoxycortisol and 11-deoxycorticosterone also 
might compensate for the cortisol deficiency as these steroids had good hGR 
activation potency.
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A clinical threshold of 500 nmol cortisol/L blood after ACTH administration is 
widely used to define adrenal insufficiency, and although lower thresholds also have 
been proposed [9-11, 21], all of our patients had cortisol concentrations far below 
this threshold. Previously, it has been suggested to include serum corticosterone, 
11-deoxycorticosterone and 11-deoxycortisol in addition to serum cortisol to 
evaluate adrenal function. [22]. Based on our finding of glucocorticoid receptor 
activation we emphasize the importance to use multiple adrenal steroid precursors, 
such as 11-deoxycortisol, 11-deoxycorticosterone, 11-hydroxyprogesterone, 21DF, 
17OHP, progesterone, and cortisol to evaluate glucocorticoid action. More studies 
are necessary to study the clinical significance of our findings in more detail. 
 Although our data suggest that CAH patients may survive without glucocorticoid 
treatment, it has to be pointed out that based on our results we do not advocate to 
withhold treatment in severely affected CAH patients. However, it has to be noted that 
in treated CAH patients blood concentrations of the elevated adrenal steroid precursors 
are generally suppressed and consequently patients become more dependent on 
glucocorticoid treatment and additional glucocorticoid stress dosing in case of severe 
illness. As knowledge and infrastructure are far from perfect in developing countries 
such as Indonesia, treated CAH patients may have an increased risk to develop 
adrenal crises as the compensatory effect of steroid precursors is absent. Also, acute 
discontinuation of glucocorticoid treatment, which is likely in developing countries as 
medication is not always available, can increase the risk to develop adrenal crises as 
the compensatory steroid precursors will be suppressed for some time. Patients and 
clinicians should be aware of the importance of daily glucocorticoid supplementation 
without discontinuation in order to prevent adrenal crises. For the same reason, the 
importance of an appropriate stress dosing regimen has to be emphasized.
 Despite this being the first study in a relatively large cohort of untreated CAH 
patients, our study has some limitations. In some of the reported stress-situations, 
there may have been an underlying adrenal crisis as some episodes were reported 
as salt wasting crises or severe vomiting and/or seizures. Still, it is remarkable that all 
patients recovered from these episodes without administration of glucocorticoid 
medication. Furthermore, none of our patients had the most severe type of CAH, a 
homozygous deletion of CYP21A2, although several patients were classified as 
genotype group 0, with an expected enzyme activity of <1%. As neonatal screening 
is not implemented in Indonesia, the prevalence of CAH patients is probably higher 
than the current number of patients diagnosed with CAH, which might have led to 
selection of our patient group. Especially male CAH patients are expected to be 
underdiagnosed, either because they have no complaints or because they have 
died within the first weeks of life due to a salt wasting crisis. Education programs in 
these countries should therefore also focus on salt requirements in neonates to 
prevent salt wasting crises. 
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In conclusion, our results show that severely affected untreated CAH patients with 
proven cortisol deficiency might survive due to accumulated adrenal steroid 
precursors which can activate the hGR, and might at least partially compensate for 
the cortisol deficiency. Especially 21DF, 11-hydroxyprogesterone, 11-deoxycortisol 
and 17OHP can contribute to this compensation. Therefore, we suggest to measure 
all relevant hGR activating steroids in the evaluation of adrenal function, especially 
in CAH patients. Further research should focus on establishing cut-off values for 
the combined adrenal steroid concentrations and to personalize treatment 
necessities according to the total panel.
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Supplemental material – LC-MS/MS protocol
Cortisol, 21DF, 11-deoxycortisol, 17OHP, and progesterone were analyzed by 
LC-MS/MS after protein precipitation and solid-phase extraction. Internal standard 
[2H4]-cortisol, [2H4]-21-deoxycortisol, [2H5]-11-deoxycortisol, [13C3]-17-hydroxypro-
gesterone (Isoscience, King of russia, PA) and [2H9]-progesterone (CDN isotopes) 
was added to 100 μL serum. Subsequently 300 μL Acetonitrile + 0.1% formic acid 
was added for protein precipitation. 300 μL H2O was added to 200 μL supernatant 
followed by solid phase extraction (Oasis HLB 1cc, Waters). The eluate (methanol/
isopropanol 95:5) was dried under a stream of N2 gas, reconstituted in methanol: 
water (3:7) and injected (10 μL) into an Agilent Technologies 1290 Infinity 
UHPLC-system (Agilent Technologies, Santa Clara, CA) equipped with a BEH C18 
(1.7μm 2.1 X 50mm) analytical column (Waters Corp.) at 60°C. Mobile phase A 
(methanol:water 20:80 + 2 mM NH4CH3COO + 0.1% formic acid) and B 
(methanol:water 98:2 + 2 mM NH4CH3COO + 0.1% formic acid) were run in a 
gradient (0.4 mL/min). Start gradient 70:30 A:B for 2.5 min; then to 40:60 A:B in 3.5 
min; followed by a gradient in 0.5 min to 2:98 to remain such for 0.5 min and 
thereafter to 70:30 A:B in 0.5 min and remain such for 0.5 min. Retention time was 
1.41 min, 2.13 min, 2.56 min, 4.66 min and 6.04 min for cortisol, 21DF, 11-
deoxycortisol, 17OHP and progesterone respectively. Total run time was 8 minutes. 
An 9-point calibration curve was used (cortisol, 21DF, 11-deoxycortisol, 17OHP 
(Steraloids), progesterone (Sigma). An Agilent 6490 tandem mass spectrometer 
(Agilent Technologies) was operated in the electrospray positive ion mode, with a 
capillary voltage 3.5 kV, fragmentor voltage 380 V, sheath gas temperature 350°C 
and gas temperature 150 °C with N2 collision gas. Two transitions (qualitative and 
quantitative) were monitored. Transitions (Q1>Q3) were m/z 363.4 > 97.1 (34 V) and 
m/z 363.4 > 121.1 (25 V) for cortisol; m/z 367.4 > 97.1 (34 V) and m/z 367.4 > 121.1 
(25 V) for [2H4]-cortisol. m/z 347.2 > 121.1 (27 V) and m/z 347.2 > 269.0 (18 V) for 
21DF; m/z 351.2 > 121.0 (29 V) and m/z 351.2 > 273.0 (18 V) for [2H4]-21-deoxycor-
tisol. m/z 347.2 > 109.1 (31 V) and m/z 347.2 > 97.1 (29 V) for 11-deoxycortisol; m/z 
352.3 > 113.1 (29 V) and m/z 352.3 > 100.1 (31 V) for [2H5]-11-deoxycortisol. m/z 
331.3 > 109.1 (31 V) and m/z 331.3 > 97.1 (31 V) for 17OHP; m/z 334.3 > 112.1 (33 V) 
and m/z 334.3 > 100.1 (30 V) for [13C3]-17-hydroxyprogesterone. m/z 315.3 > 109.1 
(29 V) and m/z 315.3 > 97.1 (29 V) for progesterone; m/z 324.3 > 113.1 (29 V) and 
m/z 324.3 > 100.1 (29 V) for [2H9]-progesterone. Dwell time was 100 ms, 20 ms, 20 
ms, 60 ms and 100 ms for cortisol, 21DF, 11-deoxycortisol, 17OHP, and progesterone 
respectively. The method was linear assessed by CLSI EP6 protocol. For cortisol 
total CV is 3.6% at 300 nmol/l and 3.1% at 1080 nmol/l. For 21DF total CV is 9.6% at 
1.1 nmol/l and 8.6% at 15.2 nmol/l. For 11-deoxycortisol total CV is 5.9% at 2.1 nmol/l 
and 5.2% at 26.9 nmol/l. For 17OHP total CV is 5.6% at 2.6 nmol/l and 5.1% at 94.3 
nmol/l. For progesterone total CV is 5.9% at 5.1 nmol/l and 3.9% at 30.4 nmol/l. 
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Corticosterone and 11-deoxycorticosterone were analyzed by LC-MS/MS after 
protein precipitation and solid-phase extraction. Internal standard [2H4]-corticoste-
rone and [13C3]-11-deoxycorticosterone (Isoscience, King of Prussia, PA) was added 
to 100 μL serum. Subsequently 300 μL Acetonitrile + 0.1% formic acid was added 
for protein precipitation. 500 μL H2O was added to 200 μL supernatant followed by 
solid phase extraction (Oasis HLB 1cc, Waters). The eluate (methanol/water 90:10) 
was dried under a stream of N2 gas, reconstituted in methanol: water (3:7) and 
injected (10 μL) into an Agilent Technologies 1290 Infinity UHPLC-system (Agilent 
Technologies, Santa Clara, CA) equipped with a HSS T3 (1.8μm 2.1 X 100mm) 
analytical column (Waters Corp.) at 40°C. Mobile phase A (methanol:water 20:80 + 
2 mM NH4CH3COO + 0.1% formic acid) and B (methanol:water 98:2 + 2 mM 
NH4CH3COO + 0.1% formic acid) were run in a gradient (0.4 mL/min). Start gradient 
60:40 A:B for 3.5 min; then to 48:52 A:B in 1 min and 38:62 A:B in 3 min; followed 
by a gradient in 0.01 min to 5:95 A:B to remain such for 1 min and thereafter to 
60:40 A:B in 0.5 min and remain such for 2 min. Retention time was 5.6 min and 7.2 
min for corticosterone and 11-deoxycorticosterone, respectively. Total run time 
was 11 minutes. A 9-point calibration curve was used (corticosterone and 11-deoxy-
corticosterone (Sigma)). An Agilent 6490 tandem mass spectrometer (Agilent 
Technologies) was operated in the electrospray positive ion mode, with a capillary 
voltage 3.0 kV, fragmentor voltage 380 V, sheath gas temperature 350°C and gas 
temperature 150 °C with N2 collision gas. Two transitions (qualitative and 
quantitative) were monitored. Transitions (Q1>Q3) were m/z 347.2 > 97.0 (31 V) and 
m/z 347.2 > 121.1 (29 V) for corticosterone; m/z 351.3 > 97.1 (31 V) and m/z 351.3 > 
121.1 (29 V) for [2H4]-corticosterone; m/z 331.3 > 109.1 (31 V) and m/z 331.3 > 97.1 
(29 V) for 11-deoxycorticosterone; m/z 334.3 > 112.2 (29 V) and m/z 334.3 > 100.2 
(27 V) for [13C3]-11-deoxycorticosterone. Dwell time was 100 ms for both 
corticosterone and 11-deoxycorticosterone. The method was linear assessed by 
CLSI EP6 protocol. For corticosterone total CV is 3.2% at 26.8 nmol/l and 3.6% at 
59.4 nmol/l. For 11-deoxycorticosterone total CV is 3.7% at 0.2 nmol/l and 2.7% at 
2.0 nmol/l.
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Abstract
Background Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency 
leads to accumulation of steroid precursors and adrenal androgens. These steroids 
may have a biological effect on the steroid receptor with clinical consequences 
on diagnostics and treatment in CAH patients. Therefore, we analysed the effect 
of accumulated steroids [17-hydroxyprogesterone (17OHP), progesterone, andro-
stenedione and testosterone] on aldosterone-mediated transactivation of the 
human mineralocorticoid receptor (hMR). 
Methods A transactivation assay using transiently transfected COS7 cells was employed. 
Cells were co-transfected with hMR-cDNA, MMTV-luciferase and renilla-luciferase 
expression vectors. Transfected cells were incubated with six different steroid 
concentrations in addition to aldosterone (10-10M). Luciferase and renilla activities 
were measured to quantify hMR transactivation. 
Results Linear regression analysis showed statistically significant linear inhibition of 
transactivation of the hMR by 10-10M aldosterone in the presence of increasing 
17OHP [F(1,5) = 11.34, p = 0.019] and progesterone [F(1,5) = 11.08, p = 0.021] 
concentrations. In contrast, neither androstenedione nor testosterone affected 
hMR transactivation by aldosterone at a concentration of 10-10M. 
Conclusions Our study shows for the first time that neither androstenedione nor 
testosterone has a biological effect on aldosterone-mediated transactivation of the 
hMR. 17OHP and progesterone have an anti-mineralocorticoid effect in vitro that 
may clinically lead to an increased requirement of mineralocorticoids in poorly 
controlled CAH patients.
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Introduction
Congenital adrenal hyperplasia (CAH) is a group of disorders affecting adrenal ste-
roidogenesis. The incidence of classic CAH varies between 1 in 10,000 and 1 in 
15,000 live births in most Caucasian populations. [1] In about 95% of the cases, 
CAH is caused by 21-hydroxylase deficiency [2], resulting in impaired adrenal 
synthesis of cortisol. Cortisol deficiency triggers a counter-regulatory increase in 
pituitary ACTH secretion leading to accumulation of adrenal steroid precursors 
before the deficient enzymatic step and increased adrenal androgen production. 
21-hydroxylase converts 17-hydroxyprogesterone (17OHP) to 11-deoxycortisol, the 
penultimate step in cortisol synthesis. Hence, 17OHP accumulates and is used as a 
marker for 21-hydroxylase deficiency.
 Classic CAH is commonly subdivided in the salt wasting (SW) and simple 
virilizing (SV) forms depending on the residual enzymatic activity. SW patients have 
no residual 21-hydroxylase activity leading to severe salt loss, typically after the first 
week of life, and prenatal virilization of the female external genitalia. Patients with 
the SV form of CAH have a residual enzyme activity of 1-2% and usually have 
sufficient aldosterone production to prevent severe salt loss, whereas glucocorticoid 
synthesis is severely impaired. In both SW and SV forms, elevated adrenal androgens 
cause prenatal virilization of the female external genitalia and postnatal androgen 
excess in both sexes. [2,3] Current treatment of CAH consists of lifelong glucocorticoid 
and, if necessary, mineralocorticoid treatment. [4] Treatment with glucocorticoids 
restores feedback within the hypothalamus-pituitary-adrenal axis, consequently 
achieving downregulation of adrenal androgen production. In many patients, 
however, supraphysiological doses of glucocorticoids are needed to normalize 
androgen levels.
 Untreated and poorly controlled CAH patients are characterized by elevated 
levels of steroid hormone precursors, including progesterone and 17OHP, and 
androgens such as androstenedione and testosterone. [3,5,6,7,8] It has been shown 
that progesterone and 17OHP have antagonistic properties on the human miner-
alocorticoid receptor (hMR), and therefore may contribute to mineralocorticoid 
deficiency in classic CAH patients. [9] The aim of our study was to evaluate the 
effects of 17OHP, progesterone, androstenedione and testosterone on aldoste-
rone-mediated transactivation and translocalization of the hMR. Furthermore, we 
studied the effect of the frequent mineralocorticoid receptor p.Ile180Val single 
nucleotide polymorphism (SNP) on transactivation of the hMR.
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Material and methods
Construction of plasmids
The hMR cDNA was PCR amplified from the previously used pcDNA3.1-NR3C2 
construct [10] using specific primers with HindIII and EcoRV restriction sites for directional 
cloning into pcDNA6/V5-His-B vector (Invitrogen Corp., Carlsbad, Calif., USA). The p.
Ile180Val SNP was recreated in the pcDNA6-hMR construct by site-directed mutagenesis 
using the QuikChange XL Site-Directed Mutagenesis Kit according to the manufacturer’s 
protocol (Stratagene, Amsterdam, The Netherlands). The correct insertion of the hMR 
construct and the p.Ile180Val SNP as well as the integrity of the cDNA was checked by 
direct DNA sequencing. For intracellular localization assays, Green Fluorescent Protein 
(GFP), an autofluorescent genetic reporter, was cloned into pcDNA6. The hMR cDNA 
and the hMR p.Ile180Val (hMR-I180V) construct were cloned into the pcDNA6-GFP 
vector using the same restriction enzymes as described above.
In vitro transactivation assays
Transactivation of hMR and hMR-I180V by different concentrations of aldosterone 
was investigated using a MMTV-luciferase assay. Approximately 2.5 × 104 COS-7 
cells were grown in 500 ml of Dulbecco’s minimal essential medium (DMEM) high 
glucose (4.5 g/l) with L-glutamine (PAA Laboratories GmbH, Pasching, Austria) 
supplemented with 10% fetal bovine serum (PAA Laboratories GmbH) and penicillin/
streptomycin (PAA Laboratories GmbH) in 24-well plates, and transiently transfected 
24 h after seeding using FuGene® HD transfection reagent (Roche Applied 
Sciences, Burgess Hill, UK). Cells were transfected with 300 ng of pcDNA6-V5/
HisB-hMR or pcDNA6-V5/HisB-hMR variant (p.Ile180Val) in the presence of 300 ng 
of a mouse mammary tumour virus (MMTV)-luciferase reporter construct 
(MMTV-luc) driving the firefly luciferase gene. Co-transfection with 50 ng of pRL-TK 
(Promega, Madison, Wisc., USA), a renilla luciferase vector, was performed to 
normalize data for transfection efficiency. In each set of experiments, 3 wells with 
COS-7 cells were co-transfected with 300 ng of pcDNA-hMR and 300 ng of 
pGL3-Basic (Promega) for data normalization and interassay comparison purposes 
as pGL3-Basic contains a coding region for firefly luciferase for monitoring tran-
scriptional activity in transfected cells. Two days after transfection, cells were 
treated with aldosterone (Sigma Aldrich, Gillingham, UK) for 24 h in different 
concentrations (final concentrations made up in total of 500 μl full DMEM media: 
10-6, 10-8, 10-10, 10-12 and 10-14M), or in a 10-10M concentration in addition to 
different concentrations of 17OHP (range 5-1,000 nM), progesterone (2.5-100 nM), 
androstenedione (1-250 nM) or testosterone (0.5-60 nM) (Sigma Aldrich). 
Concentrations of 17OHP, progesterone, androstenedione and testosterone used 
in the assays were based on biochemical findings in CAH patients [5,6,7,8].
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To evaluate the transactivational potential of 17OHP, progesterone, androstenedi-
one and testosterone on the hMR in the absence of aldosterone, transfected cells 
were also incubated in 500 μl of full DMEM supplemented with different 
concentrations of these steroids.
 Cells were lysed in 100 μl of passive lysis buffer (Promega). Consequently, 30 μl 
of cell lysate was used for the measurement of firefly and renilla luciferase activity, 
with a luminometer (Berthold, Bad Wildbad, Germany), using the Dual-Luciferase® 
Reporter Assay System (Promega) according to manufacturer’s standard protocol. 
The hMR transactivation was calculated by the ratio of the steroid-dependent 
(firefly) luciferase and the steroid independent renilla (luciferase). Luciferase/renilla 
ratios were normalized for luciferase activity driven by pGL3-Basic. Data were 
normalized for the transactivation by a 10-10M aldosterone concentration and are 
presented as fold transactivation compared to the transactivation by 10-10M 
aldosterone (transactivation by 10-10M aldosterone was set as 1.0-fold transactiva-
tion). All assays were performed in triplicate (n = 9). Statistical analysis was performed 
using GraphPad Prism software version 5.0 (GraphPad Software, San Diego, Calif., 
USA). Results were analysed by both linear regression analyses and ANOVA with 
Bonferroni adjustment for multiple comparisons (all possible comparisons were 
analysed). Differences between the hMR wild type and the p.Ile180Val construct 
were analysed using a t-test. p < 0.05 was considered significant.
Intracellular localization
The transactivation potential of the hMR-GFP construct was evaluated to ensure 
comparable transactivation potential to the hMR construct in the presence of 
10-10M concentrations of aldosterone. The hMR-GFP construct was used for an 
intracellular localization assay. Approximately 2 × 105 COS-7 cells were grown on 
glass coverslips in 6-well plates containing 2 ml of DMEM high glucose (4.5 g/l) with 
L-glutamine (PAA Laboratories GmbH) supplemented with charcoal stripped fetal 
bovine serum (Sigma Aldrich) and penicillin/streptomycin (PAA Laboratories GmbH). 
Twenty-four hours after seeding, the cells were transiently transfected using 
FuGene® HD transfection reagent (Roche Applied Sciences) with 2 μg of hMR-GFP 
or 2 μg of hMR-I180V-GFP. Forty-eight hours after transfection, cells were treated 
for 120 min with a combination of 10-10M aldosterone and different concentrations 
of other steroids (17OHP, progesterone, androstenedione and testosterone) to 
study the effect of these steroids on the intracellular localization of the receptor. 
Cells were washed three times in 1× phosphate buffered saline (PBS) and fixed in 
1 ml 100% methanol at -20°C for 15 min. Fixed cells were further washed three 
more times in 1× PBS and mounted on Vectorshield with 4’, 6-diamidino-2-phenylindole 
(DAPI; exclusively nuclear staining). Results were obtained from three independent 
transfection experiments in which 150 transfected cells were classified in 4 categories: 
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(1) nuclear, (2) mainly nuclear, (3) equal nuclear and cytoplasmic, and (4) mainly 
cytoplasmic. Representative images were taken using confocal microscopy (Nikon 
Instruments Inc., Melville, N.Y., USA). To evaluate if treatment causes a difference in 
the number of cells counted as nuclear, mainly nuclear, equal nuclear or mainly 
cytoplasmic, respectively, one-way ANOVA was performed. Statistical analysis was 
performed using GraphPad Prism software version 5.0.
Results
Transactivation of the mineralocorticoid receptor by aldosterone
Increasing concentrations of aldosterone caused an increase in potent transactivation 
of both the hMR and hMR-I180V. The dose-dependent effects on the transactivation 
are shown in a dose-response curve (Figure 1). An estimated concentration for 50% 
transactivation (EC50) of the hMR of around 10-10M aldosterone was calculated for 
both the wild type (2.4 × 10-11M) and the p.Ile180Val SNP (1.2 × 10-11M).
Figure 1   Dose-response curves showing the transactivation of the hMR  
(wild type) and the hMR-I180V SNP by different concentrations of 
aldosterone using a luciferase assay.
The results are expressed as the ratio of (firefly) luciferase and renilla (luciferase) activity. Data are means ± 
SEM for each concentration (n = 9). MR = Mineralocorticoid receptor.
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Effect of 17OHP, progesterone, androstenedione and testosterone 
on hMR transactivation
Increasing concentrations of 17OHP and progesterone inhibited aldosterone- 
mediated transactivation of the hMR in a dose-dependent fashion (Figure 2). 
Linear regression analyses showed a linear inhibition of transactivation of the hMR 
by 10-10M aldosterone in the presence of increasing concentrations of 17OHP 
[F(1,5) = 11.34, p = 0.019] and progesterone [F(1,5) = 11.08, p = 0.021]. Variable 
concentrations of 17OHP [F(6,48) = 111.9, p < 0.0001] and progesterone [F(6,48) = 
62.11, p < 0.0001] have a significant effect on transactivation of the hMR by 
aldosterone in the presence of 10-10M aldosterone, as shown by ANOVA 
(Supplemental Tables 1, 2).
Figure 2   The effect of different concentrations of 17OHP (a), progesterone (b), 
testosterone (c) and androstenedione (d) on the transactivation of hMR 
by 10-10M aldosterone concentration.
The transactivation activity of 10-10M aldosterone was set as 1.0. Results are expressed as x-fold transacti-
vation of MMTV (firefly) luciferase (MMTV-luc). Data are means ± SEM for each concentration (n = 9). 
Significant differences in transactivation between two concentrations closest to each other are indicated 
by an asterisk (p < 0.05).
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In contrast, treatment with increasing concentrations of androstenedione and 
testosterone did not have any measureable effect on hMR transactivation (Figure 2). 
No linear effect of increasing concentrations of androstenedione [F(1,5) = 0.709, p 
= 0.438] or testosterone [F(1,5) = 1.57, p = 0.265]on transactivation of the hMR by 
aldosterone was found. In addition, ANOVA showed that different concentrations 
of androstenedione or testosterone did not affect transactivation of the hMR by 
aldosterone (Supplemental Tables 3, 4).
 The effect of three different concentrations of 17OHP on the aldosterone- 
mediated transactivation of the hMR was also evaluated in the p.Ile180Val SNP 
construct (Figure 3). The inhibitory effect of 17OHP on hMR-I180V was found to be 
similar to its effect on the wild-type hMR (p > 0.05).
Figure 3   The effect of different concentrations of 17OHP on the transactivation of 
hMR by 10-10M aldosterone concentration compared to the effect of different 
concentrations of 17OHP on the transactivation of the hMR-I180V SNP.
The transactivation activity of 10-10M aldosterone on the hMR (wild type) was set as 1.0. Results are 
expressed as x-fold transactivation of MMTV (firefly) luciferase (MMTV-luc). Data are means ± SEM for each 
concentration (n = 9).
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Figure 4   a Cellular localization of the hMR without the presence of  
aldosterone and in the presence of aldosterone with or without  
different concentrations of 17OHP and progesterone.
Cells were localized using confocal microscopy as (1) nuclear (black bars), (2) mainly nuclear (dark grey 
bars), (3) equal nuclear-cytoplasmic (light grey bars) and (4) mainly cytoplasmic (white bars). b Images 
showing the four possible cellular localizations of the hMR: (1) nuclear, (2) mainly nuclear, (3) equal nuclear 
and cytoplasmic, (4) mainly cytoplasmic. Images were taken with a confocal microscope. Different images 
were taken showing DAPI staining, GFP and a merged image. c Cellular localization of the hMR-I180V 
without the presence of steroids and in the presence of aldosterone with or without different concentrations 
of 17OHP. Cells were localized using confocal microscopy as (1) nuclear (black bars), (2) mainly nuclear 
(dark grey bars), (3) equal nuclear - cytoplasmic (light grey bars) and (4) mainly cytoplasmic (white bars).
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Intracellular localization of the hMR
The transactivation potential of both the hMR-GFP and the hMR construct were 
compared to assess whether the GFP had altered transactivation properties of 
the construct prior to performing an intracellular localization assay. The hMR-GFP 
construct was shown to have equal transactivational properties as the hMR 
construct (Supplemental Figure 1).
 In untreated cells, the hMR was localized only in the cytoplasm or equally 
distributed in nucleus and cytoplasm (Figure 4a). Treatment with aldosterone for 
120 min resulted in a clear translocation of the hMR with a predominantly nuclear 
localization.
 17OHP and progesterone did not influence the translocation of the hMR to the 
nucleus in the presence of aldosterone (Figure 4b). Treatment with 17OHP, progesterone, 
androstenedione or testosterone did not result in significant differences in the 
intracellular localization of the hMR.
 In the presence of aldosterone, the hMR-I180V-GFP was also mainly localized 
in the nucleus. 17OHP did not inhibit the translocation of the hMR-I180V-GFP to the 
nucleus in the presence of aldosterone (Figure 4c).
Discussion
We studied the effects of different adrenal steroid hormone precursors and androgens 
on the transactivation potential and localization of the hMR. Our study shows for 
the first time that excess concentrations of androstenedione and testosterone do 
not have a biological effect on the aldosterone-mediated transactivation of the 
hMR in vitro. Furthermore, 17OHP and progesterone have a strong anti-mineralo-
corticoid effect in vitro, which confirms previous findings. [9] This study highlights 
the anti-mineralocorticoid effect of elevated 17OHP concentrations as found in 
poorly controlled CAH patients.
 These findings may have important implications for clinical care. Based on our 
results, it can be suggested that elevated 17OHP and progesterone concentrations 
are likely to have an adverse effect on the mineralocorticoid effect in untreated and 
poorly treated CAH. This may potentially lead to increased requirement of mineralo-
corticoids and suboptimal control. In contrast, elevated androgens did not influence the 
mineralocorticoid transactivation in vitro. We therefore hypothesize that elevated 
androgens per se do not have a clinically relevant effect on mineralocorticoid treatment 
of CAH.
 The current treatment strategy is based on normalizing adrenal androgens to 
prevent adverse effects of hyperandrogenism. Slightly elevated 17OHP concentrations 
are generally accepted because of the possible side effects of high dosages of 
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 glucocorticoids needed to achieve physiological 17OHP concentrations. Based on 
our results it can be suggested that lowering of highly elevated 17OHP concentrations 
may also have an additional positive effect on the dose of mineralocorticoid 
treatment and consequently decrease the potential risk of adverse effects of 
 mineralocorticoid treatment such as hypertension. Unfortunately, supraphysiological 
doses of glucocorticoids are generally necessary to lower 17OHP levels, that may 
lead to adverse effects and long-term complications. Therefore, the treatment goal 
in CAH patients is normalization of adrenal androgens with slightly elevated 17OHP 
levels [4]. Elevated renin levels may indicate the need for higher mineralocorticoid 
doses. However, based on our data, elevated renin concentrations may also reflect 
the anti-mineralocorticoid effect of elevated 17OHP concentrations. A fine balance 
between the use of supraphysiological dosages of glucocorticoids, mineralocorticoid 
treatment and normalizing 17OHP levels has to be achieved to prevent long-term 
complications of overtreatment with glucocorticoids on one hand and overtreatment 
with mineralocorticoids on the other hand.
 The antagonistic properties of progesterone on the human, rat and sheep 
 mineralocorticoid receptor have been previously described. [9,11,12,13,14,15] 50% 
inhibition of the maximum transactivation of the mineralocorticoid receptor is 
caused by progesterone concentrations between 2 and 11 nM. [9,16,17,18] The 
inhibitory effect of progesterone described in our study is in line with those 
described in the studies mentioned above. Minor differences between the results 
of those studies may be explained by different cells and different luciferase 
constructs used.
 The effect of slightly elevated 17OHP concentrations on the hMR have been 
studied previously. [9] The previously reported concentration of 135 nM, causing a 
50% inhibition of transactivation of the hMR by a 10-9M aldosterone, is in line with the 
antagonistic effect of 17OHP on aldosterone-mediated transactivation described in our 
study. In our study we evaluated the effect of even higher 17OHP concentrations, 
as found in untreated or poorly controlled CAH patients.
 In contrast to the effect on transactivation, the translocation to the nucleus 
seems not to be affected by 17OHP or progesterone. The physiological human 
ligand of the hMR is aldosterone. After binding to aldosterone, the hMR undergoes 
a conformational change and partial dissociation of the ligand binding complex 
occurs, leading to translocation of the hMR to the nucleus. Within the nucleus, 
the activated receptors regulate transcription by different pathways including 
 transactivation of target genes. [19,20,21,22,23] Intracellular localization studies 
on the hMR have shown that in the absence of steroids the hMR is localized in 
the cytoplasm and in the nucleus, while aldosterone causes a rapid nuclear 
accumulation of the hMR. [19,24,25,26,27] Binding of aldosterone to the hMR 
causes dissociation of several associated proteins from the receptor, followed by 
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dimerization and finally nuclear translocation of the activated receptor. The 
translocation assay performed in this study showed a similar subcellular localization 
with a predominant localization of the hMR in the cytoplasm in the absence of 
steroids. Treatment of the COS-7 cells expressing the hMR-GFP construct with 
aldosterone causes a quick translocation of the hMR to the nucleus of the cells. 
However, different concentrations of 17OHP and progesterone in addition to an 
aldosterone concentration of 10-10M do not have an impact on the translocation of 
the hMR to the nucleus. This finding is in contrast to the described effects of hMR 
antagonists, such as spironolactone and eplerenone, which inhibit the translocation 
of the hMR to the nucleus. [19]
 The mechanism of the inhibition of aldosterone-mediated transactivation of 
the hMR by progesterone and 17OHP remains unclear. It has been shown that 
17OHP has a relatively high binding affinity for the hMR. [9] Therefore, competitive 
binding of the hMR between 17OHP and aldosterone, such as in patients with 
poorly controlled CAH, is very likely. We showed that 17OHP does not inhibit the 
translocation of the hMR to the nucleus. Therefore, we hypothesize that the anti- 
mineralocorticoid effect of 17OHP on the hMR is not due to an effect on the 
translocation of the hMR, but might be caused by effects on the transcription after 
translocation to the nucleus. It has been suggested by Hellal-Levy et al. [20] that 
binding of an antagonist to the hMR leads to an inactive conformation of the hMR. 
Due to instability, this complex of the mineralocorticoid receptor and its antagonist 
will not be converted into a transcriptionally active conformation. [20] This 
hypothesis may explain the antagonistic properties of 17OHP and progesterone on 
the hMR.
 The mineralocorticoid receptor p.Ile180Val SNP (rs5522) is one of the most 
frequent SNPs in the hMR with a frequency of 10.2% of the G allele in a European 
population (HapMap project, www.hapmap.org). The mineralocorticoid receptor 
p.Ile180Val SNP has been associated with an increased hypertension risk [28]. 
As CAH patients have a tendency to develop elevated blood pressure [29,30], 
the role of this SNP in CAH patients might be important with respect to their 
cardiovascular risk profile. We showed that the hMR p.Ile180Val SNP does not affect 
transactivation of the hMR by aldosterone. These findings are in line with the results 
by DeRijk et al. [31] In addition, 17OHP has the same antagonistic effect on the 
hMR-I180V SNP as on the wild-type hMR. Thus, the results of this study do not 
explain the increased hypertension risk in p.Ile180Val.
 In conclusion, our study shows for the first time that neither androstenedione 
nor testosterone have a significant biological effect on the aldosterone-mediated 
transactivation of the hMR. In contrast, increased 17OHP and progesterone 
concentrations have an anti-mineralocorticoid effect due to an inhibition of 
aldosterone- mediated transactivation of the hMR. However, unlike hMR blockers, 
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neither 17OHP nor progesterone inhibits the translocation of the hMR to the 
nucleus. Further studies are needed to explain the mechanism of this inhibition of 
transactivation by 17OHP and progesterone.
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Supplementary material
Supplementary Figure 1  Transactivation potential of the hMR construct versus the 
hMR-GFP construct evaluated by a luciferase assay. 
The results are expressed as the ratio of (firefly) luciferase to renilla (luciferase) activity corrected for pGL3 
(transfection efficiency). Data are means ± S.E.M. (n=9).
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Table 1   Results of Bonferroni’s Multiple Comparison Test for all comparisons  
in the experiment evaluating the effect of different concentrations of 
17OHP on the aldosterone mediated transactivation of the hMR
Comparison Mean 
difference.
t P < 0.05?
1000 nmol/l vs 500 nmol/l -0,09818 2,176 No
1000 nmol/l vs 250 nmol/l -0,1691 3,748 Yes
1000 nmol/l vs 100 nmol/l -0,3538 7,841 Yes
1000 nmol/l vs 20 nmol/l -0,6562 14,54 Yes
1000 nmol/l vs 5 nmol/l -0,7723 17,12 Yes
1000 nmol/l vs 0 nmol/l -0,8160 18,09 Yes
500 nmol/l vs 250 nmol/l -0,07093 1,572 No
500 nmol/l vs 100 nmol/l -0,2556 5,664 Yes
500 nmol/l vs 20 nmol/l -0,5581 12,37 Yes
500 nmol/l vs 5 nmol/l -0,6741 14,94 Yes
500 nmol/l vs 0 nmol/l -0,7179 15,91 Yes
250 nmol/l vs 100 nmol/l -0,1846 4,092 Yes
250 nmol/l vs 20 nmol/l -0,4871 10,80 Yes
250 nmol/l vs 5 nmol/l -0,6032 13,37 Yes
250 nmol/l vs 0 nmol/l -0,6469 14,34 Yes
100 nmol/l vs 20 nmol/l -0,3025 6,704 Yes
100 nmol/l vs 5 nmol/l -0,4186 9,277 Yes
100 nmol/l vs 0 nmol/l -0,4623 10,25 Yes
20 nmol/l vs 5 nmol/l -0,1161 2,573 No
20 nmol/l vs 0 nmol/l -0,1598 3,542 Yes
5 nmol/l vs 0 nmol/l -0,04373 0,9692 No
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Table 2   Results of Bonferroni’s Multiple Comparison Test for all comparisons  
in the experiment evaluating the effect of different concentrations of 
progesterone on the aldosterone mediated transactivation of the hMR.
Comparison Mean 
difference
t P < 0.05?
100 nmol/l vs 75 nmol/l -0,04790 0,9424 No
100 nmol/l vs 50 nmol/l -0,1382 2,719 No
100 nmol/l vs 25 nmol/l -0,09753 1,919 No
100 nmol/l vs 10 nmol/l -0,3455 6,797 Yes
100 nmol/l vs 2.5 nmol/l -0,5654 11,12 Yes
100 nmol/l vs 0 nmol/l -0,7384 14,53 Yes
75 nmol/l vs 50 nmol/l -0,09030 1,776 No
75 nmol/l vs 25 nmol/l -0,04963 0,9763 No
75 nmol/l vs 10 nmol/l -0,2976 5,855 Yes
75 nmol/l vs 2.5 nmol/l -0,5175 10,18 Yes
75 nmol/l vs 0 nmol/l -0,6905 13,58 Yes
50 nmol/l vs 25 nmol/l 0,04067 0,8001 No
50 nmol/l vs 10 nmol/l -0,2073 4,078 Yes
50 nmol/l vs 2.5 nmol/l -0,4272 8,405 Yes
50 nmol/l vs 0 nmol/l -0,6002 11,81 Yes
25 nmol/l vs 10 nmol/l -0,2480 4,878 Yes
25 nmol/l vs 2.5 nmol/l -0,4679 9,205 Yes
25 nmol/l vs 0 nmol/l -0,6408 12,61 Yes
10 nmol/l vs 2.5 nmol/l -0,2199 4,327 Yes
10 nmol/l vs 0 nmol/l -0,3929 7,729 Yes
2.5 nmol/l vs 0 nmol/l -0,1729 3,402 Yes
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Table 3   Results of Bonferroni’s Multiple Comparison Test for all comparisons in 
the experiment evaluating the effect of different concentrations of 
 testosterone on the aldosterone mediated transactivation of the hMR.
Comparison Mean 
difference
t P < 0.05?
60 nmol/l vs 30 nmol/l -0,3613 2,501 No
60 nmol/l vs 15 nmol/l -0,3361 2,326 No
60 nmol/l vs 7.5 nmol/l -0,3316 2,295 No
60 nmol/l vs 2.5 nmol/l -0,1137 0,7870 No
60 nmol/l vs 0.5 nmol/l -0,3324 2,301 No
60 nmol/l vs 0 nmol/l -0,2067 1,431 No
30 nmol/l vs 15 nmol/l 0,02527 0,1749 No
30 nmol/l vs 7.5 nmol/l 0,02973 0,2058 No
30 nmol/l vs 2.5 nmol/l 0,2476 1,714 No
30 nmol/l vs 0.5 nmol/l 0,02890 0,2001 No
30 nmol/l vs 0 nmol/l 0,1546 1,070 No
15 nmol/l vs 7.5 nmol/l 0,004459 0,03086 No
15 nmol/l vs 2.5 nmol/l 0,2224 1,539 No
15 nmol/l vs 0.5 nmol/l 0,003627 0,02511 No
15 nmol/l vs 0 nmol/l 0,1294 0,8955 No
7.5 nmol/l vs 2.5 nmol/l 0,2179 1,508 No
7.5 nmol/l vs 0.5 nmol/l -0,0008315 0,005755 No
7.5 nmol/l vs 0 nmol/l 0,1249 0,8646 No
2.5 nmol/l vs 0.5 nmol/l -0,2187 1,514 No
2.5 nmol/l vs 0 nmol/l -0,09299 0,6436 No
0.5 nmol/l vs 0 nmol/l 0,1257 0,8704 No
146
CHAPTER 8
Table 4   Results of Bonferroni’s Multiple Comparison Test for all comparisons  
in the experiment evaluating the effect of different concentrations of 
androstenedione on the aldosterone mediated transactivation of the hMR.
Comparison Mean 
difference
t P < 0.05?
250 nmol/l vs 100 nmol/l -0,1522 1,264 No
250 nmol/l vs 50 nmol/l -0,3702 3,073 No
250 nmol/l vs 25 nmol/l -0,2441 2,027 No
250 nmol/l vs 10 nmol/l -0,1788 1,484 No
250 nmol/l vs 1 nmol/l -0,1100 0,9129 No
250 nmol/l vs 0 nmol/l -0,01177 0,09770 No
100 nmol/l vs 50 nmol/l -0,2180 1,810 No
100 nmol/l vs 25 nmol/l -0,09192 0,7631 No
100 nmol/l vs 10 nmol/l -0,02654 0,2204 No
100 nmol/l vs 1 nmol/l 0,04224 0,3507 No
100 nmol/l vs 0 nmol/l 0,1404 1,166 No
50 nmol/l vs 25 nmol/l 0,1261 1,047 No
50 nmol/l vs 10 nmol/l 0,1915 1,589 No
50 nmol/l vs 1 nmol/l 0,2602 2,160 No
50 nmol/l vs 0 nmol/l 0,3584 2,976 No
25 nmol/l vs 10 nmol/l 0,06538 0,5427 No
25 nmol/l vs 1 nmol/l 0,1342 1,114 No
25 nmol/l vs 0 nmol/l 0,2324 1,929 No
10 nmol/l vs 1 nmol/l 0,06878 0,5710 No
10 nmol/l vs 0 nmol/l 0,1670 1,386 No
1 nmol/l vs 0 nmol/l 0,09820 0,8152 No
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Since the first case of congenital adrenal hyperplasia (CAH) was described in 1865 
[1], a vast amount of knowledge on the pathophysiology, clinical features and 
treatment of CAH has been gathered. However, there are still gaps in our knowledge 
and new questions have emerged. This thesis aims to add new insights to the 
existing knowledge on CAH. In the first part of the thesis, we describe patterns of 
linear growth and bone maturation in untreated nonclassic (NC) CAH patients and 
treated classic CAH patients, as well as salivary steroid patterns in treated classic 
CAH patients. In the second part of the thesis, we focus on the effect of adrenal 
steroid precursors that aberrantly accumulate in CAH patients on the glucocorticoid 
and mineralocorticoid receptor. In this concluding chapter, the results described in 
this thesis are discussed in view of current literature. The clinical implications of our 
findings are discussed and recommendations for future research are made. 
Patterns of growth and salivary steroid levels
in CAH patients
Growth patterns in CAH 
It has been well established that monitoring of linear growth is an important aspect 
of the clinical care of pediatric CAH patients. [2] Untreated or poorly treated patients 
are exposed to increased levels of adrenal androgens, resulting in an increased 
growth velocity, an advanced bone age with early epiphyseal maturation, and 
eventually a decreased final height. However, treatment with (supraphysiological 
doses of) glucocorticoids can also result in a diminished final height due to a 
reduction of growth hormone secretion and action, disturbances of the calcium 
metabolism and direct effects on the growth plate. [2-4] Therefore, keeping the 
balance between overtreatment and undertreatment is the main challenge for 
pediatric endocrinologists taking care of CAH children. 
Final height in CAH patients has been studied previously, and two meta-analyses 
have been published. [5, 6] Both report a decreased final height compared to the 
general population and compared to midparental height. However, the studies 
included in the meta-analyses suffer from serious methodological issues and there 
is a large inconsistency of results across included studies, resulting in a low level of 
evidence. Among these studies, there is large variability in severity of CAH, in 
monitoring regimen, in glucocorticoid treatment and in the patient categories that 
are included. Incidentally, predicted final height is used instead of actual final height 
and in a number of studies parental height is not available. Secular trend is usually 
not considered, which may result in an underestimation of the expected final 
height. [5, 6] Studies on the determining factors of final height are further 
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complicated by the long term follow-up that needs to be evaluated, by the influence 
of both the disease and the treatment on growth, and by the low incidence of CAH. 
The final height that we have found in classic CAH patients seems more decreased 
than reported in the two meta-analyses, -1.63 SDS versus -1,21 SD and -1,02 SD. 
This might partially be explained by the fact that we do take secular trend into 
account and thus do not underestimate target height. Also, we made a strict 
selection of patients to ensure the study group is a homogenous group of severe 
CAH patients. 
Both studies on growth patterns in CAH included in this thesis illustrate that merely 
describing linear growth is not sufficient. The final height is determined by the 
balance between growth velocity and bone maturation. When growth velocity is 
increased, but the advancement of bone maturation is more severe, final height will 
be reduced. When the increased growth velocity and advanced bone maturation 
keep equal pace, final height may not be reduced. Most NC-CAH children seem to 
reach a final height within their target range [7] and glucocorticoid treatment is not 
necessarily indicated in NC-CAH children to improve their final height. [2, 7-10] 
However, we have shown that in NC-CAH patients an increased growth velocity 
can be absent while bone maturation is advanced. Both height velocity and bone 
age should be taken into account by clinicians considering treatment, weighing the 
risk of not treating and the risk of growth suppression due to glucocorticoid 
treatment. 
Previously it has been concluded that in classic CAH children mainly the pubertal 
growth is reduced, resulting in a decreased final height. [11-13] However, our 
evaluation of linear growth as well as bone maturation in classic CAH patients 
reveals that the loss of growth potential already occurs in early childhood (see 
further). Establishing the diagnosis of CAH as early as possible is crucial to lower the 
exposure to adrenal androgens by early glucocorticoid treatment, to improve final 
height outcome. [5, 14] Since the patients in our study – as well as the patients 
reported in other studies – were diagnosed before the introduction of national 
neonatal screening programs and were therefore not all treated from a young age, 
we expect that final height outcomes in currently treated pediatric CAH patients will 
improve. Neonatal screening for CAH was implemented in the Netherlands in 
2002, so the first patients diagnosed in the screening program are now reaching 
their final height. This creates opportunities for new evaluations of growth patterns 
in CAH children. Longitudinal, multi-center registries could be of great value to 
overcome some of the difficulties in studying long term outcomes mentioned 
previously.   
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Age-specific treatment of CAH 
Nowadays, almost all CAH patients reach adulthood with a good quality of life. 
However, both undertreatment with exposure to increased levels of androgens, 
and overtreatment with exposure to supraphysiological amounts of glucocorticoids 
are common. The reduced final height in which this may result is a reliable long 
term outcome measure for adequate treatment. Although the effect of a decreased 
final height on the quality of life is not clear [6], there are other potential long term 
complications from both under- and overtreatment that are worth avoiding. 
For example, prolonged exposure to increased levels of androgens can result in 
gonadal dysfunction and fertility problems in both male and female CAH patients. 
[15-17] Long term treatment with supraphysiological doses of glucocorticoids can 
result in side effects such as hypertension, obesity and a reduced bone mineral 
density. [16, 18] Therefore, studies on growth patterns in CAH patients can yield 
recommendations on CAH treatment that are relevant for more than height alone. 
Although not all previous studies have found a correlation between glucocorticoid 
treatment and height outcomes, our results and those of other groups do, yielding 
age-specific treatment suggestions. [6, 14] Infancy, childhood and puberty should 
be regarded as distinct periods, each with their own treatment goals and approaches 
(Figure 1).
In infancy (0 – 1 year), patients are relatively insensitive to the effects of androgens 
on growth. [14, 19] However, higher doses of glucocorticoids may already have 
Figure 1   Growth velocity during infancy, childhood and puberty. 
Treatment and treatment goals of CAH patients may be different in these periods, as growth velocity, 
sensitivity to androgens and sensitivity to glucocorticoids may change.
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deleterious effects on growth because of the high growth velocity in infants. 
Therefore, it can be advised that in infancy glucocorticoid overtreatment should 
be especially avoided and patients should be treated with physiological doses of 
gluco corticoids. However, as yet longitudinal studies confirming an improved 
outcome with this treatment strategy are lacking. Hopefully, longitudinal registries 
will provide us with these data in the future. 
 In childhood (age 1 year until the onset of puberty), patients seem to become 
more sensitive to the androgen-related effects on growth and maturation. Strict 
monitoring of androgen levels and appropriate hydrocortisone dose adjustments 
are indicated to avoid exposure to increased androgen levels and accelerated bone 
maturation. Supraphysiological doses of hydrocortisone may be necessary in this 
period, but the dose should be as low as possible, adequately suppressing androgen 
production while avoiding overtreatment. [2, 9] Adequate monitoring of treatment 
is crucial to detect signs of under- or overtreatment at an early stage. 
 Puberty might be the most challenging phase in the treatment of CAH patients. 
The growth velocity increases again, due to the effect of the sex steroids. Gluco-
corticoid metabolism changes, with an increased cortisol clearance due to decreased 
activity of 11β-hydroxysteroid dehydrogenase type 1. [20, 21] Also, decreased insulin 
sensitivity can result in increased adrenal and ovarian androgen synthesis. [14, 22] 
Furthermore, adherence to medical treatment may be more complicated due to 
psychosocial issues. [22] Based on our studies, showing that in puberty increased 
doses of glucocorticoids were associated with a decreased final height, we suggest 
that glucocorticoid doses should not be routinely increased in puberty despite the 
increased cortisol clearance, to avoid overtreatment. The patients should be treated 
with the lowest possible glucocorticoid dose, possibly allowing adrenal androgen 
levels to be slightly increased. [2, 12, 22]  
Besides these age-specific aspects, individual patient characteristics can influence 
the effect of glucocorticoid treatment. Individual variation in absorption from the 
gastro-intestinal tract, corticosteroid binding globulin concentrations and cortisol 
half-life in the circulation influence optimal dosing. [23] Glucocorticoid receptor 
polymorphisms might results in variations in individual glucocorticoid sensitivity. 
[24] Also, complications arising in CAH patients can make adaptations in treatment 
necessary. For example, when adolescent males develop testicular adrenal rest 
tumors, or when adolescent females suffer from menstrual irregularity due to 
slightly elevated adrenal progestins, it can be appropriate to increase the gluco-
corticoid dose. [17, 25, 26] The benefits and risks of adjusting the glucocorticoid 
dose should continuously be weighed, treatment should be monitored carefully, 
and the treatment should be individualized as much as possible. 
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It is questionable whether optimally individualized and age-specific treatment can 
be achieved with the currently common treatment modalities. Current recommen-
dations are to treat pediatric CAH patients with hydrocortisone, 10-15 mg/m2/day in 
three daily doses.[27] Long-acting glucocorticoids such as prednisolone and 
dexamethasone are generally avoided in children, because of the suspected higher 
risk of growth suppression. [2, 27] There is still controversy on whether the highest 
dose of hydrocortisone should be given in the evening, with the goal of optimally 
suppressing the hypothalamic-pituitary-adrenal axis at its peak activity, or in the 
morning, mimicking the normal diurnal rhythm. [28] 
 Several new treatment strategies are being explored, with the hopes of coming 
closer to achieve the much-needed balance between appropriate suppression of 
adrenal androgens and not exposing patients to supraphysiological amounts of 
 glucocorticoids. [27, 29] Improvements in the delivery and dosing schedule of gluco-
corticoids are investigated, for example using modified release oral glucocorticoids 
and continuous subcutaneous hydrocortisone pumps. [30-32] Also, attempts are 
made to find nonglucocorticoid strategies to diminish androgen excess, such as 
androgen biosynthesis inhibitors and corticotrophin releasing hormone receptor 
antagonists. [33, 34] Data on the long term effects and on the results in pediatric 
CAH patients are not yet available, but hopefully these attempts will provide new 
modalities for optimal and individualized treatment of CAH patients in the future. 
Salivary steroid measurements
Whichever treatment strategy is chosen, monitoring of the treatment is of utmost 
importance. Both clinical and biochemical parameters should be used in the long 
term monitoring of CAH patients. [2, 9, 22, 27] Unfortunately, current monitoring 
strategies are far from perfect. Growth velocity and bone age reflect androgen 
exposure, however the cumulative effect of exposure to androgens over time is 
difficult to estimate. Periodic measurements of 17-hydroxyprogesterone (17OHP) 
and androstenedione (A), the most commonly used biochemical parameters, only 
reflect short term hormonal control. Taking this into account, salivary steroid 
measurements can be of great value in clinical practice for the monitoring of 
adrenal steroid precursor levels. The salivary levels of 17OHP and A reliably represent 
serum levels. [35, 36] Collection of saliva is stress-free. Patients can collect multiple 
samples per day before taking their glucocorticoid medication, reflecting the 
diurnal rhythm of steroid synthesis and reliably representing endogenous steroid 
production. Saliva collection can be performed at home and the samples can be 
sent to the hospital by mail, ensuring accessibility of this monitoring method to all 
patients.  
 Unfortunately, saliva collection is difficult in young children, who are not able 
to collect the saliva on command. As described previously, in young children after 
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infancy adequate monitoring of adrenal androgen levels and adequate treatment 
are as important as in older children. Therefore, it would be desirable to develop 
novel methods for saliva collection in young children.
 Current treatment goals are to suppress the A levels to within age- and sex 
appropriate reference values and to not completely suppress 17OHP levels. [2, 27] 
It can be questioned whether these goals are specific enough, and whether they 
remain constant throughout childhood. It can even be debated whether 17OHP 
and A are the best markers for adequate disease control. 21-deoxycortisol (21DF) 
might prove to be a more reliable parameter in the future (see further). Potentially, 
measurement of cortisol and steroid precursors in scalp hair could be used to 
evaluate steroid levels over a longer period of time. [37, 38] Further studies are 
needed to determine its value in clinical practice.
It needs to be noticed that no single biochemical parameter can suffice to monitor 
the treatment of CAH patients. The entire clinical picture should always be taken 
into account.
Glucocorticoid and mineralocorticoid action of
steroid hormone precursors
Glucocorticoid activity of adrenal steroid hormone precursors
It has been well established that adrenal steroid hormones can cross-activate the 
human glucocorticoid receptor (hGR) and the human mineralocorticoid receptor 
(hMR). The adrenal steroid hormones and their precursors are structurally similar, 
and the DNA binding domain of the hGR and the hMR is highly homologous. [39] 
It has been shown previously that aldosterone and cortisol can each activate both 
receptors. [40-43]  Also, progesterone and 17OHP are known to activate the hGR. 
[43-45] We have further expanded this knowledge, by evaluating the ability of more 
than ten adrenal steroid precursors to transactivate the hGR and determine their 
relative glucocorticoid potency to cortisol. We have shown that mainly 21DF and 
corticosterone, and to a lesser extent 11-hydroxyprogesterone and 11-deoxycortisol, 
are able to transactivate the hGR. 
21-deoxycortisol
Of all steroid precursors, 21DF deserves special attention. It is formed when 17OHP 
is 11β-hydroxylated. In healthy subjects, 21-hydroxylation of 17OHP is the preferred 
pathway and 21DF levels are very low. However, in CAH patients 17OHP cannot be 
21-hydroxylated and the excess 17OHP is converted to 21DF. [46, 47]
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21DF has been shown to have relatively high glucocorticoid potency, close to 
cortisol itself. Furthermore, it is metabolized via the ‘backdoor’ pathway to steroids 
with potent androgenic activity. [48] 
 Because of the increased levels of 21DF specifically in CAH patients, there may 
be a role for it in clinical practice. 21DF can be of added value in the diagnostic 
process of CAH, for example in newborn screening, and may be more specific than 
17OHP. [9, 49-51] Also, in contrast to 17OHP, the levels of 21DF do not change with 
either puberty or the menstrual cycle since 11β-hydroxylation is restricted to the 
adrenal cortex. [46, 47, 52, 53] Thus, suppression of 21DF may be a more reliable 
target for glucocorticoid treatment than 17OHP. However, clinically relevant target 
levels need to be determined. 
Clinical implications of glucocorticoid activity of  
adrenal steroid precursors
As described previously, 21DF and several other steroid hormone precursors that 
are present in increased levels in CAH patients, have glucocorticoid potency in 
vitro. Besides increasing the understanding of pathophysiological mechanisms, 
there may be several clinical consequences relevant for CAH patients. It seems that 
the elevated levels of adrenal steroid precursors may at least partially compensate 
for cortisol deficiency. This protective mechanism could explain the lack of signs of 
cortisol deficiency we have encountered in the patients described in chapters 5 
and 7. Also, it might explain the rarity of signs of adrenal insufficiency in NC-CAH 
patients. [54] 
 It should be noted, that the possible protective effects of elevated adrenal 
steroid precursors disappear once glucocorticoid treatment is initiated. Due to the 
glucocorticoid treatment, ACTH and consequently the adrenal steroid precursors 
are suppressed. Thus, once maintenance-therapy is started, adequate stress-dosing 
is of utmost importance. Recent studies have shown, that almost all episodes of 
adrenal insufficiency and deaths in treated CAH patients have been preceded by a 
lack of applying adequate stress-dosing. [55, 56] 
The implications of the glucocorticoid activity of elevated levels of adrenal steroid 
precursors for clinical practice are still unclear. Based on current knowledge it 
cannot be determined to what extent individual patients are protected from 
developing clinical signs of adrenal insufficiency by elevated steroid precursors. We 
have shown that some untreated CAH patients with severe enzyme deficiencies 
can survive until adulthood, but we cannot predict which patients this will be. 
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Hypothetically, the glucocorticoid potency of elevated adrenal precursors may 
have treatment implications for two patient categories: classic CAH patients in 
areas with limited resources, and non-classic CAH patients. 
1. When local knowledge, education opportunities, resources and infrastructure 
are insufficient to guarantee access to adequate glucocorticoid medication 
and stress-dosing, it may be safer for a subset of CAH patients not to be treated 
with glucocorticoids at all, as treatment will suppress the levels of protective 
steroid precursors, especially when only long-acting steroids are available. 
When stress-dosing is not applied adequately, or when maintenance treatment 
is discontinued, the risk of developing adrenal crises might be increased 
compared to untreated patients. However, we are not yet able to predict which 
patients belong to this subset. Also, in untreated CAH patients there will be 
signs of hyperandrogenism and possible long term complications of exposure 
to increased levels of adrenal androgens that should be considered. Alternative 
strategies focusing on decreasing the androgen secretion and/or action might 
be of use in these patients. 
2. The discussion on the need of stress-dosing in untreated NC-CAH patients is 
ongoing. It has been reported that in 60% of NC-CAH patients, the response of 
cortisol to tetracosactide is suboptimal, suggesting a potential risk of adrenal 
crises. However, clinical signs of adrenal insufficiency seem uncommon. [54] 
When the adrenal precursors with glucocorticoid activity are sufficiently elevated, 
this could potentially be an additional argument to withhold stress-dosing in 
these untreated patients.
To determine whether untreated CAH patients are adequately protected from 
cortisol deficiency by the accumulated adrenal steroid precursors, the standard 
ACTH-stimulation test is not sufficient. Ideally, the ACTH-stimulated levels of all 
relevant adrenal steroid precursors should be considered, and weighed for their 
relative glucocorticoid potency. Additionally, adequate reference values need to be 
determined. Even for the routinely used ACTH stimulation test, no agreement exists 
on the appropriate cut-off levels for maximal serum cortisol response. [57, 58] For 
the combined glucocorticoid activity of all steroids and steroid precursors, clinically 
relevant cut-off levels will need to be established to be of use in daily practice.
 Thus, combined steroid profiling with adequately determined cut-off levels 
could be of great value in making treatment decisions. However, more translational 
research will be required to develop this glucocorticoid activity tool.   
Mineralocorticoid activity of adrenal steroid hormone precursors
In contrast to the glucocorticoid potency of several adrenal steroid hormone 
precursors, it has been shown that 17OHP and progesterone have anti-mineralo-
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corticoid potency in vitro. This can be of clinical relevance in CAH patients as well. 
In untreated CAH patients, salt wasting can be exaggerated, when the remaining 
aldosterone is counteracted by the elevated steroid precursors. Furthermore, 
neonates are relatively resistant to aldosterone. Thus, during the neonatal period 
higher doses of mineralocorticoids and sodium chloride may be required to relieve 
salt wasting. Once the glucocorticoid treatment adequately suppresses the adrenal 
steroid precursor levels, the need for mineralocorticoids may decrease and 
potentially the dose can be lowered to prevent overtreatment, which is associated 
with complications such as hypertension. Monitoring of renin levels and blood 
pressure can aid the clinician in adequately dosing mineralocorticoid treatment.   
General conclusion – one size does not fit all
In this thesis we have explored several consequences of the elevated levels of 
adrenal steroid precursors in CAH patients. We have described the patterns of 
salivary steroid levels in childhood and adolescence, and the consequences for 
linear growth and bone maturation. We have shown the potential glucocorticoid 
and anti-mineralocorticoid effects of adrenal steroid precursors, and the clinical 
consequences this may have for CAH patients. 
 Overall it can be concluded that the care of CAH patients cannot be based on 
a ‘one size fits all’ principle. Long term outcome is determined by many different 
factors (Figure 2). Monitoring and treatment decisions should be tailored to the 
individual patient’s needs and characteristics. Diverse aspects such as severity of 
the enzymatic defect, stage of life, but also local availability of medical resources 
should be considered. 
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Figure 2   Factors influencing long term outcome in pediatric CAH patients. 
Long term outcome is determined by the balance between exposure to adrenal androgens and exposure 
to glucocorticoids. This balance is influenced by multiple factors.
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SUMMARY
The studies described in this thesis aim to provide more insight in the pathophysio-
logical processes related to the elevated levels of adrenal steroid precursors in 
congenital adrenal hyperplasia (CAH) patients. In the first part of the thesis (chapter 
2-4), the perspective is mostly clinical and the focus lies on growth patterns and 
salivary steroid levels in CAH patients. The studies in the second part of the thesis 
(chapter 5-8) focus on the glucocorticoid and mineralocorticoid potency of 
accumulating adrenal steroid precursors. This chapter summarizes the studies and 
their most important outcomes. 
Chapter 2 describes growth patterns of nonclassic (NC) CAH children. In classic 
CAH, elevated concentrations of adrenal androgens lead to accelerated growth 
and bone maturation with compromised adult height. However, in children with 
NC-CAH, the concentrations of adrenal androgens are generally only slightly 
increased. We conducted a retrospective study to describe the growth and bone 
maturation in untreated NC-CAH children to determine the effect of these only 
slightly elevated adrenal androgen levels. 24 patients were included and divided in 
a symptomatic (n=17) and an asymptomatic (n=7) group. In the symptomatic 
patients, height SDS corrected for target height (HSDS-THSDS) only slightly 
increased with 0.06 SDS per year (95% CI 0.02 – 0.10). Mean bone age advancement 
(BAc) was 2.21 years (SDS 0.66, p< 0.0001). In asymptomatic patients no significant 
growth acceleration or BAc was found. Therefore we concluded that in untreated 
NC-CAH children growth acceleration is small and generally not visible in their 
growth charts. BAc can be more pronounced. Therefore, the absence of an increase 
in growth velocity does not exclude the diagnosis NC-CAH. When considering this 
diagnosis and when monitoring NC-CAH patients over time, bone age acceleration 
should be taken into account.   
In chapter 3, we describe the salivary levels of 17-hydroxyprogesterone (17OHP) 
and androstenedione (A) in classic CAH patients, both in childhood and in puberty. 
Monitoring of treatment by measurement of these adrenal steroid precursors in 
saliva is a patient friendly and reliable method. However, there are no objective 
criteria for setting relevant target values or data on changes of 17OHP and A during 
monitoring. Therefore, we evaluated A and 17OHP levels in nearly 2000 salivary 
samples collected during long term treatment of 84 pediatric patients with classic 
21-hydroxylase deficiency. 
 17OHP and A levels, and its ratio 17OHP/A, remained constant from the ages of 
4 to 11 years with no sex-related differences. During puberty, 17OHP and A levels 
both increased, starting at earlier age in girls than in boys reflecting the earlier start 
of puberty in girls. A normalised A level concomitant with an elevated 17OHP level 
could be obtained with moderate glucocorticoid dosages of 11 – 15 mg/m2/day. 
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A levels above the upper reference limit (URL), suggesting undertreatment, coincided 
with 17OHP levels ≥ 10 times URL. The percentage of A levels above URL increased 
in puberty, especially in boys. 
In chapter 4 we describe the final height (FH) of classic CAH children, and age- 
specific factors that contribute to the FH. FH is a relevant long term outcome measure 
in CAH patients, since both over- and undertreatment with glucocorticoids can 
negatively influence FH.   
 We retrospectively evaluated longitudinal data of 39 pediatric CAH patients. We 
analyzed height and bone age at diagnosis or at 4 years of age, at the start of 
puberty, and at FH. Height data were corrected for parental height and secular 
trend. Hydrocortisone use and salivary steroid levels were studied longitudinally 
throughout childhood and puberty. 
 We found that median FHSDS corrected for target height SDS (THSDS) was 
decreased, at -1.63 SDS. FH was most compromised in simple virilizing (SV) CAH 
patients (FHSDS–THSDS -1.92 in males, -1.93 in females), while FH in salt wasting 
(SW) CAH patients was closer to their predicted final height (FHSDS–THSDS -1.27 in 
males and -0.79 in females). Both in SV and in SW-CAH patients, median height SDS 
corrected for THSDS decreased from diagnosis or the age of four years to FH. 
However, when height was corrected for bone age, no height loss occurred from 
diagnosis or age 4 years to FH in any of the subgroups. Therefore, we conclude that 
although the height loss only becomes visible in the growth charts in the course of 
puberty, the loss of growth potential already occurs in early childhood.
 Hydrocortisone dose and FH were negatively associated throughout childhood 
and puberty. However, in the combined model with A, in childhood only A levels 
were negatively associated with FH. Thus, in prepubertal children, the most important 
factor contributing to a decreased final height is exposure to elevated androgen 
levels. In puberty, the growth suppressing effects of hydrocortisone outweigh the 
negative effects of elevated androgen levels. Therefore, we suggest that the treatment 
goals should be more specified according to age to find the optimal balance in 
growth and maturation.
Chapter 5 contains a case description of a patient with SW-CAH, in whom the 
diagnosis and treatment were delayed for several years. Due to the co-incidence of 
posterior urethral valves and an initial false diagnosis of secondary pseudohypoal-
dosteronism explaining his hyponatremia, he was not treated with glucocorticoids 
or mineralocorticoids for the first two years of life. He did not develop signs of cortisol 
deficiency despite undergoing surgery and suffering several illnesses. Based on 
these and other clinical observations, we hypothesize that in untreated CAH patients 
elevated levels of steroid precursors may partially compensate cortisol deficiency. 
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This hypothesis is further explored in chapter 6 by studying the in vitro effects of 
adrenal steroid precursors on the human glucocorticoid receptor (hGR): the 
binding, nuclear translocation and finally transactivation of the hGR when exposed 
to 17OHP, A, progesterone and 21-deoxycortisol (21DF). Competitive binding assays 
were performed in HeLa cells. 17OHP, progesterone and 21DF are able to bind to 
the hGR with binding affinities of 24 – 43% compared to cortisol. A has a low binding 
affinity. Nuclear translocation of the hGR was studied by transfection of COS-7 cells 
with a GFP-tagged hGR and fluorescence microscopy. Incubation with 21DF led to 
complete nuclear translocation of the hGR, whereas treatment with 17OHP or 
progesterone resulted in partial nuclear translocation. 
 Transactivation assays were performed in COS-7 cells and in HEK293 cells after 
co-transfection with hGR and luciferase reporter vectors using a dual luciferase 
assay. 21DF transactivated the hGR with an EC50 approximately 6-fold the EC50 of 
cortisol. 17OHP and progesterone transactivated the hGR with EC50s of more than 
100 times the EC50 of cortisol. No hGR transactivation was detected after 
incubation with A. In conclusion, 21DF, 17OHP and progesterone are able to bind, 
translocate and transactivate the hGR in vitro and thus may have glucocorticoid 
activity. Mainly 21DF might have a clinically relevant agonistic effect on the hGR and 
could potentially partially compensate the cortisol deficiency in CAH patients.
In chapter 7, the research on the glucocorticoid potency of adrenal steroid 
precursors is continued. Previous results are replicated, the transactivation of the 
hGR by previously not studied steroid precursors is evaluated, and clinical and 
biochemical data of untreated classic CAH patients are described. 
 We describe a unique population of 22 severely affected untreated CAH 
patients (age 0 - 46 years), with proven cortisol deficiency (<500nmol/L after ACTH 
stimulation)  but without clinical signs of cortisol deficiency even in situations of 
severe stress. 
 Blood concentrations of adrenal steroid precursors that aberrantly accumulate 
due to the enzymatic defect were assessed by LC-MS/MS. The levels of the steroid 
precursors 11-deoxycortisol, 11-deoxycorticosterone, 17OHP, 21DF and progesterone 
were significantly elevated compared to a control group. 
 The effect of progesterone, 17-hydroxypregnenolone, pregnenolone, aldosterone, 
corticosterone, 11-deoxycortisol, 11-deoxycorticosterone, 17OHP, 11β-hydroxy-
progesterone, 16-hydroxyprogesterone and 21DF on the hGR transactivation was 
evaluated in vitro. The hGR  was activated with comparable potency to cortisol by 
21DF, and 4-100x lower potency by the other measured adrenal steroid precursors. 
 In conclusion, we identified strongly elevated adrenal steroid precursor 
concentrations in blood from untreated CAH patients and demonstrated glucocorticoid 
activity of these adrenal precursors in vitro – implicating that these precursors 
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might be able to partially compensate for cortisol deficiency in untreated CAH 
patients.
 
In chapter 8, the effect of adrenal steroid precursors on the human mineralocorticoid 
receptor (hMR) is described. In vitro transactivation assays of COS7 cell transfected 
with the hMR were performed, to assess the mineralocorticoid potency of 17OHP, 
progesterone, A and testosterone. By exposure of the hMR to aldosterone in 
combination with the adrenal steroid precursors it was shown that transactivation 
of the receptor was inhibited by 17OHP and progesterone, with a linear increase of 
inhibition with increasing  concentrations of these steroids. A and testosterone did 
not affect transactivation of the hMR by aldosterone. In conclusion, while the 
glucocorticoid potency of accumulating steroid precursors in CAH patients may 
have a protective effect, elevated concentrations of 17OHP and progesterone have 
an anti-mineralocorticoid effect in vitro that may clinically contribute to an increase 
of salt wasting and a higher requirement of mineralocorticoids in poorly controlled 
CAH patients. 
Chapter 9 discusses the findings in our studies in view of current literature, and 
elaborates on possible clinical implications of our results. We provide a general 
conclusion and give suggestions for future research. 
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Samenvatting
De studies die opgenomen zijn in dit proefschrift hebben tot doel om meer inzicht 
te verkrijgen in enkele klinische en pathofysiologische processen bij patiënten 
met het adrenogenitaal syndroom (AGS). In het eerste deel van het proefschrift 
(hoofdstuk 2-4) ligt de nadruk op de lengtegroei van AGS patiënten, en op de rol 
van steroïdhormonen gemeten in het speeksel. De studies in het tweede deel van 
het proefschrift (hoofdstuk 5-8) richten zich op de glucocorticoïde en mineralo-
corticoïde effecten van de verhoogde concentraties steroïdvoorlopers, die karakteristiek 
zijn voor AGS. Dit hoofdstuk biedt een samenvatting van de studies en hun belangrijkste 
resultaten. 
Hoofdstuk 1 geeft een overzicht van de fysiologie van de bijnier, en van het ziektebeeld 
AGS. In de bijnierschors worden vanuit de gezamenlijke bron cholesterol verschillende 
steroïdhormonen gemaakt: glucocorticoïden (cortisol), mineralocorticoïden (aldosteron) 
en androgenen. De productie van cortisol wordt gereguleerd door de hypothalamus- 
hypofyse-bijnier as. CRH uit de hypothalamus stimuleert de afgifte van ACTH door 
de hypofyse. ACTH stimuleert op zijn beurt de bijnier om cortisol te produceren. 
Door middel van een nauwkeurig afgesteld terugkoppelingssysteem, waarbij cortisol 
de afgifte van CRH en ACTH remt, blijft het systeem in balans. 
 Om in de bijnier vanuit cholesterol de steroïdhormonen te vormen zijn 
verschillende enzymatische stappen nodig. Bij AGS is er een tekort aan één van de 
enzymen die nodig zijn voor de vorming van de bijniersteroïden, meestal 21-hydroxylase. 
Hierdoor is er een tekort aan cortisol en vaak ook aan aldosteron. Hierdoor ontbreekt 
de negatieve terugkoppeling naar de hypofyse en wordt er steeds meer ACTH 
geproduceerd om de bijnier te stimuleren. Daardoor worden verhoogde hoeveelheden 
van voorlopersteroïden (precursors) gevormd, die niet verder omgezet kunnen 
worden tot cortisol en aldosteron. De verhoging van deze precursors, met name 
17-hydroxyprogesteron (17OHP) en androsteendion (A), is karakteristiek voor AGS 
patiënten en kan gemeten worden in onder meer bloed en speeksel.  Deze voor-
lopersteroïden kunnen door het enzymtekort niet of slechts gedeeltelijk omgezet 
worden in cortisol en aldosteron, maar wel in bijnierandrogenen. Het tekort aan 
cortisol kan leiden tot een Addisonse crisis. Het gebrek aan aldosteron leidt tot 
renaal zoutverlies. Het overschot aan androgenen leidt tot virilisatie van het 
uitwendig genitaal bij meisjes, wat al antenataal kan optreden. 
 Er zijn verschillende vormen van AGS, afhankelijk van de ernst van het enzym - 
tekort: klassiek AGS, dat onderverdeeld kan worden in een zoutverliezende (salt 
wasting, SW) en een niet-zoutverliezende (simple virilizing, SV) vorm, en het mildere, 
niet klassieke AGS (nonclassic, NC).  
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Patiënten met klassiek AGS worden behandeld met glucocorticoïden (hydrocortison) 
en indien nodig ook mineralocorticoïden (fludrocortison). Hierdoor worden niet 
alleen de tekorten aangevuld, maar wordt ook de negatieve terugkoppeling naar de 
hypofyse hersteld. De stimulatie van de bijnier door ACTH neemt af, waardoor ook 
de overmatige productie van androgenen daalt. Patiënten met NC-AGS worden 
meestal alleen behandeld bij klinisch relevante tekenen van hyperandrogenisme.       
In hoofdstuk 2 worden de groeipatronen van kinderen met de NC vorm van AGS 
beschreven. Het is bekend dat de overmaat aan bijnierandrogenen bij kinderen met 
klassiek AGS leidt tot een versnelling van de lengtegroei, maar ook tot een versnelde 
botrijping. Hierdoor bereiken deze patiënten uiteindelijk een kleinere lengte. Bij 
kinderen met NC-AGS zijn de bijnierandrogenen echter slechts mild verhoogd. Wij 
beschrijven retrospectief de lengtegroei en botrijping van onbehandelde kinderen 
met NC-AGS, om het effect van deze mild verhoogde androgeenconcentraties te 
beoordelen. 
 Bij patiënten mét klinische verschijnselen van AGS (zoals vroegtijdige puber-
teitskenmerken) was er een minimale groeiversnelling. De botrijping was duidelijk 
versneld, met een gemiddelde voorsprong in de botleeftijd van ruim 2 jaar. Bij patiënten 
zonder klinische verschijnselen werd geen groeiversnelling of botleeftijdsvoorsprong 
gevonden. Wij concludeerden dat bij onbehandelde NC-AGS patiënten de groei-
versnelling zo gering is dat deze over het algemeen niet zichtbaar zal zijn in de 
groeicurve. Wel kan er een uitgesproken voorsprong in de botleeftijd zijn. De afwezigheid 
van een groeiversnelling sluit de diagnose NC-AGS niet uit. Als deze diagnose 
overwogen wordt, en wanneer deze patiënten vervolgd worden in de loop van de 
tijd, dient de ontwikkeling van de botleeftijd meegewogen te worden.   
In de studie beschreven in hoofdstuk 3 worden de concentraties van 17OHP en A 
in het speeksel van klassieke AGS patiënten geëvalueerd, zowel in de prepuberale 
fase als in de puberteitsleeftijd. Controle van de instelling van de behandeling door 
middel van het meten van deze steroïdprecursors is een patiëntvriendelijke en 
betrouwbare methode. De huidige richtlijnen adviseren om te streven naar 
concentraties van A in het normale bereik, en om het 17OHP niet volledig te onder- 
drukken. Er bestaan echter geen objectieve streefwaarden, en er is weinig bekend 
over de patronen van de concentraties van 17OHP en A gedurende de behandeling. 
Daarom hebben we de waarden van 17OHP en A geëvalueerd in bijna 2000 
speeksel monsters die verzameld zijn tijdens de behandeling van 84 kinderen met 
klassiek AGS. De waarden van 17OHP en A, en de ratio 17OHP/A bleven constant vanaf 
de leeftijd van 4 jaar tot de leeftijd van 11 jaar, zonder verschil tussen jongens en 
meisjes. Tijdens de puberteit stegen de waarden van zowel 17OHP als A. Met doseringen 
hydrocortison van 11-15 mg/m2/dag werden normale A-waarden bereikt, met een 
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niet volledig onderdrukt 17OHP. Het aantal speekselmonsters met A-waarden boven het 
referentie-interval, passend bij onvoldoende onderdrukking van de bijnierandrogenen, 
nam toe tijdens de puberteit, en dan met name bij jongens.  
Hoofdstuk 4 beschrijft eveneens een onderzoek bij klassieke AGS patiënten. Deze 
studie was gericht op het evalueren van de eindlengte, en het bepalen van leeftijds-
specifieke factoren die hierop van invloed zijn. De eindlengte is een relevante uit-
komstparameter in de behandeling van AGS patiënten, aangezien zowel over- als 
onderbehandeling met glucocorticoïden een negatieve invloed kan hebben op de 
eindlengte. Het vinden van een goede balans tussen over- en onderbehandeling is 
een grote uitdaging in de zorg voor patiënten met AGS.   
 Retrospectief werden longitudinale data van 39 AGS patiënten geëvalueerd. 
Lengte en botleeftijd bij diagnose, bij het begin van de puberteit en bij het bereiken 
van de eindlengte werden verzameld. De lengtes werden gecorrigeerd voor de 
ouderlengtes en voor de seculaire trend. De gebruikte doseringen hydrocortison en 
de concentraties van 17OHP en A in het speeksel werden longitudinaal geëvalueerd. 
 Voor de hele groep was de mediane eindlengte gecorrigeerd voor de streef - 
lengte verlaagd, namelijk -1.63 SDS. De eindlengte was het meest verlaagd bij 
jongens met SV-AGS. Zowel bij SV- als bij SW-AGS patiënten nam de mediane 
gecorrigeerde lengte af tussen het moment van diagnose en het bereiken van de 
eindlengte. Als de lengte echter ook werd gecorrigeerd voor de botleeftijd, trad 
geen verlies van lengte op tussen diagnose en eindlengte. Daaruit concludeerden 
wij dat hoewel de kleinere gestalte over het algemeen pas in de loop van de 
puberteit zichtbaar wordt in de groeicurve, het verlies van groeipotentieel al vroeg 
in de kinderleeftijd ontstaat. 
 De hydrocortisondosering gedurende de kinderleeftijd en de puberteit was 
negatief geassocieerd met de eindlengte. Dit gold ook voor de A-concentraties op 
de kinderleeftijd en de eindlengte, maar niet voor de A-waarden in de puberteit. 
Vóór de puberteit lijkt daarom de blootstelling aan de verhoogde concentraties van 
bijnierandrogenen het grootste negatieve effect op de eindlengte te hebben, terwijl 
in de puberteit het groeiremmende effect van glucocorticoïden de overhand lijkt te 
krijgen. Daarom adviseren wij om de behandelstrategie meer te specificeren op 
basis van de levensfase, om de optimale balans in de behandeling te bereiken. 
In Hoofdstuk 5 beschrijven we een patiënt met de zoutverliezende vorm van AGS, 
bij wie de diagnose pas op de leeftijd van 2 jaar werd gesteld. Neonataal was er 
sprake van ernstige hyponatriëmie, die werd geduid als passend bij secundair pseudo - 
hypoaldosteronisme ten gevolge van urethrakleppen. Hiervoor werd hij chirurgisch 
behandeld en kreeg hij orale zoutsuppletie. Hij werd gedurende zijn eerste twee 
levensjaren niet behandeld met glucocorticoïden of mineralocorticoïden. Desondanks 
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ontwikkelde hij geen klinische tekenen van cortisoltekort, terwijl hij wel meerdere 
episodes van stress doormaakte waarbij te verwachten zou zijn dat een cortisoltekort 
tot problemen zou leiden, zoals episodes van ziekte en de chirurgische behandeling 
van zijn urethrakleppen. De diagnose AGS werd pas gesteld toen hij op de leeftijd 
van 2 jaar nog steeds zoutsuppletie nodig had, en er uitgebreider aanvullend 
onderzoek werd gedaan.
 Naar aanleiding van deze klinische observatie werd de hypothese opgesteld 
dat de voorlopers van steroïdhormonen, die in verhoogde concentraties voorkomen 
bij AGS patiënten, mogelijk het cortisoltekort ten dele kunnen compenseren. 
Deze hypothese wordt uitgewerkt in hoofdstuk 6. Hier beschrijven wij een studie 
waarin de in vitro effecten van de steroïdprecursors op de glucocorticoïdreceptor 
werden onderzocht. De glucocorticoïdreceptor wordt geactiveerd via verschillende 
stappen: binding van het ligand, verplaatsing van de receptor naar de celkern 
(translocatie) en transactivatie. Van de steroïdprecursors 17OHP, A, progesteron en 
21-deoxycortisol (21DF) werd onderzocht in hoeverre zij kunnen binden aan de 
glucocorticoïdreceptor, en in welke mate translocatie en transactivatie van de 
receptor plaatsvinden. 
 17OHP, progesteron en 21DF bleken te binden aan de glucocorticoïdreceptor, 
met bindingsaffiniteiten van 24 – 43% in vergelijking met cortisol (100%). A had 
echter een lage affiniteit voor de glucocorticoïdreceptor. De nucleaire translocatie 
van de glucocorticoïdreceptor werd bestudeerd in een cellijn met een gluco-
corticoïdreceptor gekoppeld aan een fluorescerend eiwit. Blootstelling aan 21DF 
resulteerde in volledige nucleaire translocatie van de receptor, terwijl incubatie met 
17OHP of progesteron leidde tot partiële nucleaire translocatie. 
 In twee verschillende cellijnen werden transactivatiestudies verricht middels 
een luciferase assay. 21DF transactiveerde de glucocorticoïdreceptor met een 
EC50 (de concentratie waarbij 50% van de maximale activatie bereikt wordt) van 
circa zesmaal de EC50 van cortisol. 17OHP en progesteron transactiveerden de 
receptor met een EC50 van meer dan 100 keer de EC50 van cortisol. Na incubatie 
met A trad geen transactivatie op. 
 Concluderend kunnen 21DF, 17OHP en progesteron binden aan de gluco-
corticoïdreceptor, waarna nucleaire translocatie en transactivatie kunnen plaats- 
vinden. Van de onderzochte steroïden heeft 21DF het grootste effect op de gluco-
corticoïdreceptor. Dit zou klinisch relevant kunnen zijn, en zou mogelijk het 
cortisoltekort bij AGS patiënten ten dele kunnen compenseren.   
In de studie beschreven in hoofdstuk 7 werd het onderzoek naar de glucocortico-
ide activiteit van steroïdprecursors voortgezet. Resultaten uit het voorgaande 
onderzoek werden gerepliceerd, nieuwe steroïden werden toegevoegd en klinische 
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en biochemische gegevens van onbehandelde klassieke AGS patiënten werden 
geëvalueerd.  
 Wij beschreven een uniek cohort van 22 onbehandelde patiënten met ernstige 
vormen van AGS (leeftijd 0-46 jaar), met bewezen cortisoldeficiëntie maar zonder 
klinische tekenen van cortisoltekort, zelfs in ernstige stresssituaties. De concentraties 
van steroïdprecursors uit de bijnier die zich opstapelen als gevolg van de enzym-
deficiëntie werden gemeten. De concentraties van de steroïdprecursors 11-deoxy-
cortisol, 11-deoxycorticosteron, 17OHP, 21DF en progesteron waren significant 
verhoogd in vergelijking met een controlegroep. De concentraties van deze steroïden 
namen niet verder toe na blootstelling aan ACTH, wat aangeeft dat de bijnier al 
maximaal gestimuleerd was in een rustsituatie. 
 De effecten van progesteron, 17-hydroxypregnenolon, pregnenolon, aldosteron, 
corticosteron, 11-deoxycortisol, 11-deoxycorticosteron, 17OHP, 11β-hydroxyprogesteron, 
16-hydroxyprogesteron en 21DF op de transactivatie van de glucocorticoïdreceptor 
werden in vitro onderzocht. 21DF activeerde de glucocorticoïdreceptor in vergelijkbare 
mate als cortisol, de potentie van de overige gemeten steroïden was 4-100 maal lager. 
 Concluderend werd vastgesteld dat de concentraties van verschillende steroïd-
precursors sterk verhoogd zijn bij onbehandelde AGS patiënten. In vitro hebben 
meerdere steroïdprecursors glucocorticoïde eigenschappen, hoewel in mindere 
mate dan cortisol. Dit suggereert dat deze voorlopers mogelijk de cortisoldeficiëntie 
bij AGS patiënten ten dele zouden kunnen compenseren, en deze patiënten zouden 
kunnen beschermen tegen Addisonse crises.   
In hoofdstuk 8 wordt het in vitro effect van de steroïdprecursors op de mineralo-
corticoïdreceptor onderzocht. In vitro transactivatie studies werden verricht na 
blootstelling van de mineralocorticoïdreceptor aan aldosteron, in combinatie met 
17OHP, progesteron, A of testosteron. Transactivatie van de receptor bleek te worden 
geremd door 17OHP en progesteron. A en testosteron hadden geen invloed op de 
transactivatie van de glucocorticoïdreceptor.
 Concluderend hebben 17OHP en progesteron een antimineralocorticoïde 
effect in vitro, dat bij AGS patiënten zou kunnen leiden tot een toename van het 
zoutverlies en een hogere behoefte aan mineralocorticoïden.
In hoofdstuk 9 worden de bevindingen uit deze studies bediscussieerd in de 
context van de wetenschappelijke literatuur. De mogelijke klinische consequenties 
van onze resultaten worden besproken. Wij geven een overkoepelende conclusie 
en doen aanbevelingen voor toekomstig onderzoek.
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Eindelijk is het zover, mijn proefschrift is afgerond! Ik wil iedereen die de afgelopen 
jaren betrokken is geweest heel hartelijk bedanken. Zonder jullie hulp, steun, 
inspirerende en motiverende bijdragen had ik hier niet kunnen staan. Ik wil een 
aantal mensen in het bijzonder bedanken. 
Om te beginnen mijn promotoren en copromotoren. Prof. dr. C. Noordam, beste 
Kees. Ik heb zowel in het onderzoek als op klinisch vlak veel geleerd van je nuchtere 
en pragmatische aanpak. Ondanks je drukke agenda weet je altijd je humor en 
vriendelijkheid te bewaren. Prof. dr. F. Sweep, beste Fred. Je kritische en constructieve 
inbreng in het laboratoriumgedeelte van mijn proefschrift was zeer welkom. 
Dr. H. Claahsen-van der Grinten, beste Hedi. We werken inmiddels al lang samen, 
sinds mijn beginjaren als arts-assistent. Dankzij die vroege samenwerking is dit 
 promotietraject ontstaan, en onder jouw hoede heb ik mijn eerste stappen binnen 
de kinderen docrinologie gezet. En nu is niet alleen mijn promotie, maar ook mijn 
fellowship bijna afgerond! Je drive om het beste uit jezelf en uit anderen te halen 
heeft je ver gebracht. Ik ben blij dat ik deel mag uitmaken van je team. Dr. P. Span, 
beste Paul. Ondanks je andere achtergrond zijn je commentaren altijd raak. 
Je constructieve inbreng bij mijn artikelen en de onderzoeksbesprekingen heb ik 
als heel prettig ervaren.  
Ik wil graag de leden van de manuscriptcommissie, prof. dr. Jan Smit, prof. dr. 
Martine Cools en dr. Hetty van der Kamp, bedanken voor het kritisch lezen en 
beoordelen van mijn manuscript. 
In de loop van de jaren zijn veel mensen betrokken geweest bij de totstandkoming 
van de artikelen in dit proefschrift. Manon Engels, je bent zelf recent gepromoveerd, 
en staat vandaag naast me als paranimf. Ik denk met veel plezier terug aan onze 
samenwerking en de koppen koffie in het restaurant om ons onderzoek – en 
andere dingen – te bespreken. Christiaan Mooij, ook jij bent me niet lang geleden 
voorgegaan met je promotie. We zullen elkaar zeker nog vaak tegenkomen in 
 kinderendocrinologisch Nederland. Teun van Herwaarden, je kritische blik is zowel 
in het onderzoek als in onze patiëntenbesprekingen van grote waarde. Het is mooi 
om de klinische zorg en de laboratoriumwereld zo bij elkaar te kunnen brengen. 
Joop Heuvel, Chris Thomas, Nel Roeleveld en Monique de Groot: jullie hebben 
een belangrijke bijdrage geleverd aan één of meerdere artikelen. Veel dank voor 
jullie inbreng! In het bijzonder wil ik ook Barto Otten bedanken. In het begin van 
mijn loopbaan heb ik je nog mogen meemaken in de kliniek, daarna ben je betrokken 
gebleven bij meerdere onderzoeken in dit proefschrift. Je schat aan ervaring, 
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enthousiasme en originele blik hebben mij altijd geïnspireerd. Het laatste artikel 
heeft meer tijd gekost dan ooit gedacht, maar met mooi resultaat!
I would also like to thank our international collaborators. Specifically I would like to 
thank Nils Krone and Aliesha Griffin for welcoming me to the lab in Birmingham 
and patiently guiding me through my first experiments. Thanks to you we were able 
to get good results in a short period of time. Agustini Utari, it’s very valuable to 
collaborate with someone in a country so different from my own. Learning about 
the CAH patients in Indonesia has been a great addition to my clinical and research 
training.   
Ik heb het geluk om binnen een heel fijn kinderendocrinologisch team te mogen 
werken. Janielle van Alfen-van der Velden, het is een plezier om met je samen te 
werken. Je zet je vol in voor je werk en in het bijzonder voor het opleiden, en je 
hebt daarbij altijd oog voor je collega’s. Annelieke van der Linde, ik ben blij dat ik 
je heb mogen opvolgen als fellow en dat we de afgelopen jaren hebben kunnen 
blijven samen werken. Ik heb bewondering voor de manier waarop je twee banen 
weet te combineren. Cathelijne van de Sande, je levert vanuit jouw achtergrond een 
heel mooie bijdrage aan het team, en laat mij ook met een andere blik kijken. 
Ik ben blij om samen te mogen werken met de collega’s binnen het DSD-team. 
Het is mooi om te zien hoe iedereen zich vanuit zijn eigen achtergrond inzet voor 
de patiënten, allen  met evenveel hart voor het onderwerp. Ook de samenwerking 
met de kinderarts-endocrinologen en aandachtsvelders kinderendocrinologie 
in de regio Zuid-Oost Nederland is voor mij van grote waarde. Ik leer altijd veel van 
onze netwerkbesprekingen. De medewerkers van het KDCN wil ik bedanken voor 
de opleidingstijd die ik daar heb doorgebracht, en voor het delen van jullie kennis 
over de diabeteszorg.  
De kinderartsen en (oud)arts-assistenten in het Amalia kinderziekenhuis wil ik 
van harte bedanken voor de prettige samenwerking in de afgelopen jaren. Samen 
met jullie heb ik mij kunnen ontwikkelen van co-assistent, tot arts-assistent, tot 
kinderarts, en nu bijna kinderarts-endocrinoloog. Hier verdient Jos Draaisma een 
bijzondere vermelding. Je hebt je opleiderschap binnen de kindergeneeskunde in 
Nijmegen prachtig vormgegeven. Je was ook mijn opleider en hebt een belangrijke 
rol gespeeld in hoe ik mij heb ontwikkeld. Het secretariaat kindergeneeskunde, 
de polikliniekmedewerkers en verpleegkundigen wil ik ook bedanken voor de fijne 
omgeving waar ik mag werken. In het bijzonder wil ik Sandra Tiemissen bedanken, 
je bent een onmisbare schakel!
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De kinderartsen in het CWZ wil ik bedanken voor de samenwerking in de tijd dat ik 
als chef de clinique in het CWZ werkzaam was. In deze periode heb ik mij na mijn 
opleiding verder kunnen ontwikkelen als kinderarts, in een fijne werkomgeving.   
Lieve familie en vrienden. Jullie wil ik bedanken voor de grote rol die jullie spelen in 
mijn leven.
Papa en mama, jullie zijn nog altijd een veilige basis voor mij om naar terug te 
keren. Jullie hebben mij altijd gestimuleerd om het beste uit mezelf te halen, en om 
mijn eigen keuzes te maken. Ik deel alle momenten graag met jullie. Het is mooi 
om te zien hoe jullie elke fase meebeleven, trots op me zijn, genieten van de mooie 
momenten en me steunen in  moeilijke momenten. Annick en Marien, ik heb geluk 
met zulke fijne zussen. Annick, doordat we allebei een heel andere richting in zijn 
geslagen is jouw perspectief altijd een verrijking. Ik ben blij dat je vandaag naast me 
staat als paranimf. Marien, jij hebt me voor het eerst laten proeven van het 
studentenleven en was toen al een voorbeeld voor me. Samen met Leon heb je 
ervoor gezorgd dat Sophie en Julia prachtige meiden zijn geworden!
 Inez en Hans, ik had me geen fijnere schoonouders kunnen wensen. Jullie steun, 
interesse en trots is voor mij van grote waarde. Michael, Mirjam, Myrthe en Maurits, 
ik ben blij dat ik ook jullie familie mag noemen. 
Lieve vrienden, Hanneke, Klaas, Manon, Rick, Stefan, Lara, Bert, Ieke, Freek en 
Robine. Wat kennen we elkaar intussen al lang. Ik heb zoveel mooie herinneringen 
aan alle tijd die we samen hebben doorgebracht. Ik hoop dat er nog veel weekendjes 
weg zullen volgen, al hebben we met alle kleintjes die er de afgelopen jaren bij zijn 
gekomen inmiddels wel een heel groot huis nodig! Alette, ook al zien we elkaar 
niet vaak meer, een band die al zo lang bestaat blijft sterk. Alice, ook wij kennen 
elkaar intussen al lang, en ik ben blij dat we elkaar niet uit het oog verloren zijn. 
Je vriendschap is daarvoor te belangrijk voor me.    
Floris en Vera, uiteindelijke draait alles om jullie. Floris, je bent er altijd voor me, 
houdt me scherp en kan me altijd laten lachen. Jouw nuchterheid en relativerings-
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0-9
11OHD 11 hydroxylase deficiency
17β-HSD 17β-hydroxysteroid dehydrogenase
17OHP 17-hydroxyprogesterone
21DF 21-deoxycortisol
21OHD 21 hydroxylase deficiency
3β-HSD 3β-hydroxysteroid dehydrogenase
95%CI 95% confidence interval
A
A Androstenedione
ACTH Adrenocorticotropic hormone
B
BA Bone age
BAc Bone age corrected for chronological age
BMI Body mass index
BSA Body surface area
C
CA Chronological age
CAH Congenital adrenal hyperplasia
COS-7 Fibroblast-like cell line derived from monkey kidney tissue
CRH Corticotrophin releasing hormone
D
DHEA(S) Dehydroepiandrosterone(sulphate)
E
EC50 Estimated concentration for 50% transactivation
F
FH Final height
FHSDS Final height standard deviation score
G
GFP Green fluorescent protein
H
HC Hydrocortisone
HEK293 Human embryonic kidney cell line
HeLa Cell line derived from cervical cancer from Henrietta Lacks
hGR Human glucocorticoid receptor
hMR Human mineralocorticoid receptor
HPA Hypothalamus-pituitary-adrenal
HSDS Height standard deviation score
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I
IC50 Concentration that reduces binding of a radioligand by 50%
IQR Interquartile range 
L
LC-MS/MS Liquid chromatography – tandem mass spectrometry
M
MMTV-Luc Firefly luciferase reporter construct
MWU Mann Whitney U test
N
NC-CAH Non classic congenital adrenal hyperplasia
P
P Progesterone
PCR Polymerase chain reaction
PHA Pseudohypoaldosteronism
pRL-TK Renilla luciferase construct
R
RLU Relative light units
S
SNP Single nucleotide polymorphism
SV-CAH Simple virilizing congenital adrenal hyperplasia
SW-CAH Salt wasting congenital adrenal hyperplasia
T
TH Target height
THSDS Target height standard deviation score
U
URL Upper reference limit
193
A
LIST OF ABBREVIATIONS

